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LEK 2mg/kg was observed on 5
th 
day, and day by day it was more 
intensive till 9
th
 day when stereotype behavior was observed. 
Locomotor activity was decrease on account of stereotype behavior. 
On 13
th
 day (n = 3) with acute test dose of LEK 2mg/kg additional 
decrease in locomotor activity on account of more intensified 
stereotype behavior was observed. On 13
th
 day (n = 3) with acute test 
dose of BrEKT 2mg/kg the same rate of locomotor activity without 
stereotype behavior was observed. Slightly increased locomotor 
activity with LEK 0.2mg/kg was observed on 5
th 
day, with substantial 
increase on 9
th
 day. Stereotyped behavior was not observed. On 13
th
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day with acute test dose of LEK 2mg/kg and BrEKT 2mg/kg the same 
rate of locomotor activity was observed  
77 
Figure 41: Comparison of daily treatment with bromoergocriptine (BrEKT) 
2mg/kg and LEK -8829 2mg/kg + SCH 1mg/kg and acute test doses 
on 13th day. Increase of locomotor activity with BrEKT 2mg/kg was 
observed from 8
th 
day. On 13
th
 day (n = 3) with acute test dose of LEK 
2mg/kg the same rate of locomotor activity was observed. On 13
th
 day 
(n = 3) with acute test dose of BrEKT 2mg/kg decrease of locomotor 
activity was observed. Increase of locomotor activity with LEK 
2mg/kg + SCH 1mg/kg was observed on 5
th 
day, and day by day it was 
more intensive till 9
th
 day. This increase was on account of the first 
20min locomotor activity with LEK 2mg/kg. On 13
th
 day (n = 3) with 
acute test dose of LEK 2mg/kg increase of locomotor activity was 
observed. On 13
th
 day (n = 3) with acute test dose of BrEKT 2mg/kg 
decrease of locomotor activity was observed. 79 
Figure 42: D2 receptor isoforms in striatum: D2 long 52kDa, D2 short 47kDa. 
Housekeeping protein β-tubulin on 50kDa  80 
Figure 43: D2 receptor isoforms: D2 long and D2 short more separate. 
Housekeeping GAPHD on 37 kDa 80 
Figure 44: Nova 1 protein on 50kDa. Housekeeping GAPHD on 37 kDa 81 
Figure 45:     Membrane incubate only with secondary antibodies    81 
Figure 46: Black and with view of mRNA expression D2 receptors in striatum 82 
Figure 47: Expression mRNA D2 receptors after prolonged daily treatment with 
test compounds. Groups are not significantly different. One way 
ANOVA with Scheffe’s post hoc analysis, n = 4, p≤ 0.05 was 
considered to be statistically significant. The tendency is noticed that 
prolonged daily treatment causes a higher up-regulation of mRNA D2 
receptors in the group treated with haloperidole 2 mg/kg than in the 
group treated with LEK-8829 2 mg/kg. 83 
Figure 48: Black and white view of mRNA expression D2 receptors, D2L and 
D2S  in striatum 84 
Figure 49: Expression mRNA D2R, mRNA D2L and mRNA D2S isofoms. * 
Significantly different compare to lesion D2R. # Significantly 
different compare to lesion D2S. One way ANOVA with Scheffe’s 
post hoc analysis, n = 4, p≤ 0.05 was considered to be statistically 
significant. 85 
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CREB  cyclic AMP regulatory element-binding protein  
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1 INTRODUCTION AND  RESEARCH  HYPOTHESIS     
1.1 INTRODUCTION AND DEFINITION OF A SCIENTIFIC PROBLEM 
Schizophrenic patients exhibit positive, negative and cognitive symptoms arising from an 
imbalance between the brain dopamine (DA) pathways mediating D2 and D1 receptor 
signaling (Yeganeh-Doost et al., 2011; Lewis and Lieberman, 2000). Subcortical increase 
of DA, leading to hyperstimulation of D2 receptors, would give rise to the positive 
symptoms, while a concomitant cortical deficit of DA, leading to hypostimulation of D1 
receptors, would give rise to the negative and cognitive symptoms of shizophrenia.  
Blockade of dopamine D2 receptors (Wang et al., 2000) is a prerequisite characteristic of 
all clinically effective antipsychotic drugs. A major difference between typical and atypical 
antipsychotic drugs is in the increased incidence of extrapyramidal adverse effects (EPS) 
by the typical vs. atypical (Niznik and Van Tol, 1992; Strange, 2001; Carlsson and 
Carlsson, 2006; Tarazi et al., 1997; Kapur and Remington, 2001). Extrapyramidal adverse 
effects (EPS) (Niznik and Van Tol, 1992; Tarazi et al., 1997; Kapur and Remington, 2001; 
Strange, 2001, Carlsson and Carlsson, 2006), characterized by Parkinsonism, akathisia, 
catalepsy, and, after long-term treatment, tardive dyskinesia (Kapur and Remington, 2001; 
Strange 2001). One of the most striking and consistent consequences of chronic 
antipsychotic exposure is supersensitivity D2 receptor (Meshul and Casey., 1989; 
Kostrzewa, 1995; Samaha et al., 2007) and increase in striatal D2 receptor density 
(Sirinathsinghji et al., 1994; Laruelle et al., 1992; Tarazi et al., 1997; Buckland et al., 1993; 
Hu et al., 1990; Meshul and Casey, 1989). This D2 receptor up-regulation is thought to be 
responsible for loss of efficacy of antipsychotics and the development of tardive dyskinesia 
(TD) in humans (Strange, 2001; Xu et al., 2002; Ginovart et al., 2009; Lewis and 
Lieberman, 2000; Hess et al., 1986; Jorgensen et al., 1994). 
Parkinsonian patients exhibit deficits in motor function, which are attributed to the 
degeneration of dopaminergic neurons in the substantia nigra compacta (SNc) (Wang et al., 
2000; Sirinathsinghji et al., 1994). 
Treatment for Parkinson’s disease is with the dopamine precursor L-DOPA and remains 
the most effective treatment. Unfortunately, L-DOPA, upon long-term administration, 
gradually loses its efficacy and eventually leads to severe motor complications, including 
dyskinesia (Gurevich and Gurevich, 2010). Dopamine depletion with reserpine also 
increases striatal D2 receptor density in the rat brain (Tarazi et al., 1997, Hu et al., 1990). 
Long-term treatment with antipsychotic drugs arise striatal D2 receptor supersensitivity as 
well depletion with reserpine produces denervation hypersensitivity (increase 
responsiveness of D2 receptors) in the rat brain (Hu et al., 1990; LaHoste and Marshall, 
1992).   
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It has already been described in the literature that striatal D2 receptor up-regulation and 
development of behavioral supersensetivity can be prevented by simultaneous stimulation 
of D1 receptors in the rat brain (Braun et al., 1997). A similar effect of D1 agonist 
treatment on behavioral supersensitivity and D2 receptor up-regulation induced by 
subchronic (21 day) haloperidol exposure has been reported by (Marin et al., 1993). 
Previous observations suggest that combined D1 agonist, D2 antagonist treatment of 
psychotic disorders might be less likely to induce chronic extrapyramidal adverse effects, 
without significantly altering antipsychotic potential. This D1 agonist, D2 antagonist 
combination make it possible to selectively modify activity in direct and indirect striatal 
motor circuits, or to differentially regulate outflow through striatonigral and striatopallidal 
pathways. It would be a rationale design for pharmacotherapy for Parkinson’s disease 
(Braun et al., 1997). 
Research on the ergoline derivative LEK-8829 demonstrated an antagonist effects on 
dopamine D2 receptors and on serotonin 5-HT2 and 5-HT1A receptor subtypes.  LEK-8829 
was designed as a potential atypical antipsychotic drug (Krisch et al., 1994, 1996) and have 
additional D1 agonist properties (Zivin et al., 1996). Dopaminergic profile of the substance 
LEK-8829 was discovered by examining the short-term effects of LEK-8829 on behavior 
and gene expression in the striatum of experimental rats with normosensitive and 
hypersensitive dopamine receptors in the rat animal models for schizophrenia, 
parkinsonism, Huntington's disease and addiction with psychomotor stimulants (Zivin, 
2010). Long-term effects of LEK-8829 on the animals’ behavior and gene expression have 
not yet been investigated. 
Recent studies have revealed that alternative D2 receptor pre-mRNA splicing is controlled 
by two splicing regulators, hnRNP M and Nova 1. HnRNP M directly binds to D2 receptor 
exon 6, and inhibits its inclusion thus favoring D2S mRNA production in a dose-dependent 
manner. Nova 1 blocks the effect of hnRNP M on D2S mRNA production via exon 6 
binding. Nova 1 is known as a splicing factor which regulates the inclusion or exclusion of 
exons depending on the position of Nova binding relative to splice site (Ule et al., 2006). 
When Nova binds to the 3' region of the cassette exon, it promotes inclusion of this exon 
(Ule et al., 2006). Consistent with this, overexpression of Nova 1 dose-dependently 
increases D2 receptor exon 6 inclusion likely by blocking hnRNP M function (Park et al., 
2011). On the other hand, in the literature importance expression of both dopamine 
receptors splicing forms in striatal neurons of the indirect pathway, as well as in the 
nigrostriatal dopamine neurons are many unknowns. There is also no data on the possible 
functional significance of the mechanisms regulating alternative splicing in 
pathophysiological conditions. 
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1.2 RESEARCH OBJECTIVES AND HYPOTHESES 
The objectives of the research are to:  
1) determine the impact on behavioral and neurochemical effect of subchronic treatment of 
LEK-8829; 
2) establish whether D1 agonist reduce dopaminergic supersensitivity;   
3) establish the  D2 up-regulation-mediated influence on D2L and D2S isoforms;  
4) establish whether D1 agonist properties of LEK-8829 may change expression levels of 
Nova 1. 
Hypotheses: 
 Subchronic treatment of experimental rats with LEK-8829 would cause less 
dopaminergic supersensitivity and up-regulation of dopamine D2 receptors in the 
striatum than chronic treatment with D2 antagonist haloperidol. 
 Subchronic treatment and up-regulation of dopamine D2 receptors in the striatum 
would result in changes in relative splicing forms of D2S and D2L. 
 Subchronic stimulation of dopamine D1 receptors (i.e. LEK-8829) in the striatum 
have resulted in a decreased expression of splicing factor Nova 1.  
 
1.3 THE CONTRIBUTIONS TO SCIENCE 
Results of the doctoral thesis will contribute to the understanding of the interaction 
between dopamine D1 and D2 receptors in the regulation of motor function. The results 
will contribute to a better understanding of regulation of gene expression of dopamine D2 
receptors and their alternative splicing forms of D2S and D2L. I expect that research will 
show that the use of a dopamine D1 receptor agonist can reduce the negative effects of 
dopaminergic denervation hypersensitivity and supersensitisation of D2 receptors. This 
would allow the planning of new medicines and improve treatment strategies for 
schizophrenia and Parkinson's disease. 
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2 REVIEW OF THE LITERATURE 
2.1 ERGOLINE DERIVATE LEK-8829 
The ergoline derivative LEK-8829 (9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-
aminomethylergoline bimaleinate) is an antagonist on dopamine D2 receptors and on 
serotonin 5-HT2A and 5-HT1A receptors and was designed as a potential atypical 
antipsychotic drug (Krisch et al., 1994, 1996). In vitro experiments have shown that LEK-
8829 stimulates adenylate cyclase and binds to dopamine D1 receptors with moderate 
affinity (Krisch et al., 1994). On the other hand, the drug has been tested in vivo for its 
effects on dopamine D1 receptors only in dopamine-depleted animals, using the rats with 
unilateral lesions of striatonigral neurons with 6-hydroxydopamine (6-OHDA). In this 
turning model, LEK-8829 induced a dose-dependent contralateral turning and the 
expression of c-fos mRNA in dopamine-depleted striatum that were both blocked by SCH-
23390, a dopamine D1 receptor antagonist, but not by haloperidol (dopamine D2 receptor 
antagonist). It was therefore proposed that LEK-8829 may be an agonist on dopamine D1 
receptors (Zivin et al., 1996). The interaction of LEK-8829 and bromocriptine has also 
been analyzed in a 6-OHDA model (Zivin et al., 1998). It was found that contralateral 
turning that was initiated with bromocriptine was not inhibited by the treatment with either 
LEK-8829 or SCH-23390, whereas the combined treatment with both drugs inhibited the 
turning. It was concluded that LEK-8829 has a dual action on the dopamine receptors in 
dopamine depleted striatum, as an agonist on dopamine D1 receptors and as an antagonist 
on dopamine D2 receptors (Zivin et al., 1998).  
Further results have shown that LEK-8829 may be an agonist of dopamine D1 receptors 
and an antagonist at dopamine D2 receptors in dopamine-innervated striatum (Sprah et al., 
1999).  Glavan (2002) in their study clearly demonstrates that in hemi-parkinsonian rats D1 
agonistic activity of LEK-8829 confers its anti-parkinsonian drug-like properties and 
modulates its neuroleptic drug-like properties, which are dependent on the blockade of 
dopamine D2 receptors. These findings imply that atypical antipsychotics with D1 intrinsic 
activity might have a reduced propensity for the induction of extrapyramidal syndrome 
(Glavan et al., 2002).  
Although many questions regarding the beneficial mechanisms of LEK-8829 in 
parkinsonism, schizophrenia and drug-addiction remain to be addressed, it appears that 
agents with dual actions toward dopamine receptors may represent a new and potent drug 
class for the treatment of these disorders. LEK-8829 may be particularly useful whenever 
the treatment of Parkinson disease with D2 agonist drugs, is complicated by psychosis. 
Antiparkinsonic properties of LEK-8829 also suggest a lower propensity of this drug for 
the induction of EPS in the treatment of positive symptoms of schizophrenia. (Zivin, 2010) 
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2.2 BRAINSTEM AND RETICULAR FORMATION       
Brainstem intrinsic systems are interconnected with virtually all parts of the central 
nervous system (CNS). The most important of these intrinsic systems is the reticular 
formation (Fig.1).  The reticular formation consists of network of neurons deep in the 
tegmentum of the brainstem that extends thought the brainstem as well as the central core 
of the entire spinal cord. The vast majority of neurons in this network are inteneurons that 
have multiple efferent projections, resulting in literally trillions of synaptic contacts. The 
reticular formation can be subdivided into three functional components: a lateral zone, a 
medial zone and the sum of neurotransmitter systems that project to widespread areas of 
the CNS. In our focus will be dopaminergic (DA) systems beside norepinephrine (NE) and 
serotonin (5-HT) system (Krebs et al., 2012).  
 
 
Figure 1: Overview of the reticular formation in the brainstem (Krebs et al., 2012). 
Slika 1: Pregled mreže retikularnih nevronov v možganskem deblu (Krebs in sod., 2012). 
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Dopaminergic systems (Fig.2) Dopaminergic neurons in the brainstem are located in two 
anatomically and functionally distinct areas: the substantia nigra and the ventral 
tegmental area (VTA).  
Dopaminergic systems are (Vallone et al., 2000): 
Nigrostriatal system – dopaminergic cell bodies in the substantia nigra project to the 
caudate nucleus and putamen and play an important role in the control of movement. 
Mesolimbic system - dopaminergic cell bodies in the ventral tegmental area project to the 
limbic system via the nucleus accumbens (NAcc).  
Mesocortical system – dopaminergic cell bodies in the ventral tegmental area project to 
the frontal cortex. 
Tuberoinfundibular system - transmits dopamine from the hypothalamus to the pituitary 
gland.  This pathway influences the secretion of certain hormones, including prolactin.  
 
 
Figure 2: Dopaminergic projections from the ventral tegmental area and substantia nigra. (Krebs et al., 2012). 
Slika 2: Dopaminergična pot iz ventralno-tegmentalnega področja in črne substance (Krebs in sod., 2012). 
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2.2.1 The basal ganglia    
The basal ganglia are a group of interconnected subcortical structures involved in the 
control of motor, cognitive and limbic functions (Smith et al., 2009). They form a side loop 
to the descending motor pathways, and diseases affecting the basal ganglia lead to 
characteristic disturbances of voluntary movements and of muscle tone. The basal ganglia 
process information from large parts of the cerebral cortex before “answers” are sent back 
to the cortex (Brodal, 2010).  
2.2.2 Striatum 
The striatum is divided into dorsal (caudate nucleus and putamen, separated by the internal 
capsule) and ventral regions (nucleus accumbens and olfactory tubercle). Globus pallidus 
(external GPe and internal GPi), the subthalamic nucleus (STN), and the substantia nigra 
with its pars reticulata (SNr) and pars compacta (SNc) (Goole and Amighi, 2009). In most 
mammals, including rats, the homologue of GPi is entopeduncular nucleus (EP) (Albin et 
al., 1989). 
Information from the cortex passes through the basal ganglia to the thalamus and then 
returns to the supplementary motor area of the cortex through the dopaminergic pathway. 
Under normal conditions, the striatum and the STN receive glutamatergic afferents from 
specific areas of the cerebral cortex or thalamus and transfer the information to the basal 
ganglia output nuclei, GPi and SNr (Fig.3). The projections between the striatum and 
GPi/SNr are divided into two separate pathways – direct connection and indirect projection 
– via the intercalated GPe and STN. Output from GPi/SNr goes to the motor thalamus 
which, in turn, projects back to the cerebral cortex and then to the striatum via the direct 
pathway (Gerfen, 1992).The striatum also receives a non negligible dopaminergic input 
directly from the SNc. This anatomic arrangement places the dopaminergic input in a 
position to regulate or gate the corticostriatal transmission. The D1 receptors are involved 
in the direct pathway, while the indirect pathway is mediated by the D2 receptors (Goole 
and Amighi, 2009; Gerfen et al., 1990; Alexander and Crutcher, 1990). 
These pathways are thought to provide modulating antagonistic effects: direct pathway 
(Fig.4) activation may inhibit GPi/SNr activity, thereby disinhibiting thalamocortical 
interactions and stimulate movement. The indirect pathway (Fig.5) activation inhibits GPe 
which sends less inhibition to STN. STN became more active and they are able to stimulate 
GPi (via glutamate). Normal role of GPi is to inhibit the thalamus (via GABA). STN is 
more activate and stimulate GPi which became more active and inhibit thalamus better 
than they normally would.  Therefore, it will be decrease excitatory flow from thalamus to 
motor cortex and as a result we have inhibition of unvoluntary movement (Galvan and 
Wichmann, 2008; Goole and Amighi, 2009). 
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Figure 3: Direct and indirect pathways and the anatomical names of their connecting fibers. GPe - globus 
pallidus, external segment; GPi - globus pallidus, internal segment; C/P – caudate/putamen; STN – 
subthalamic nucleus; SNc – supstantia nigra pars compacta (Krebs et al., 2012). 
Slika 3: Neposredna in posredna pot ter anatomska imena njihovih povezovalnih vlaken. GPe - globus 
pallidus, zunanji segment; GPi - globus pallidus, notranji segment; C/P – caudatus/putamen; STN – 
subtalamično jedro; SNc – črna substanca  - pars compacta (Krebs in sod., 2012). 
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Figure 4: Wiring diagram for the direct pathway. GPe - globus pallidus, external segment; GPi – globus 
pallidus, internal segment; C/P – caudate/putamen; D1 – dopamine receptor type; SN – substantia nigra; SNc 
– supstantia nigra pars compacta (Krebs et al., 2012). 
Slika 4: Načrt povezav za neposredno pot. GPe - globus pallidus, zunanji segment; GPi - globus  pallidus, 
notranji segment; C/P – caudatus/putamen; D1 – tip dopaminskega receptorja;  SN – črna substanca; SNc –
črna substanca - pars compacta (Krebs in sod., 2012). 
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Figure 5: Wiring diagram for the indirect pathway  GPe - globus pallidus, external segment; C/P –
caudate/putamen; SNc – supstantia nigra pars compacta (Krebs et al., 2012). 
Slika 5: Načrt povezav za posredno pot. GPe - globus pallidus, zunanji segment;  C/P – caudatus/putamen; 
SNc – črna substanca  pars compacta (Krebs in sod., 2012). 
 
2.2.3 The substantia nigra 
The substantia nigra and some of its connections have been mentioned several times, and 
we will also return to it when dealing with Parkinson’s disease, in which the nigra plays a 
crucial role. A collective treatment of the main features of the substantia nigra may 
therefore be pertinent at this stage.  
The substantia nigra can be divided anatomically into two parts, the pars compacta and 
the pars reticulate. The compacta is richer in cells than the reticulate and compacta 
neurons contain pigment (neuromelanin), which makes the nigra visible as a dark band in 
the cut human mesencephalon. The pars reticulata, located ventral to the compacta, is 
lighter. The dopaminergic nigrostriatal neurons are located in the pars compacta, whereas 
the GABAergic nigrothalamic neurons are located primarily in the pars reticulate. 
The efferent connections of the pars compacta pass primarily to the striatum (with a 
smaller contingents to the subthalamic nucleus and some other nuclei). This is the largest 
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dopaminergic pathway in the brain, and nigra is the largest collection of dopamine 
containing neurons. Pars reticulata send GABAergic fibers to the thalamus (VA, MD). 
The afferent fiber connections of the nigra arise in numerous cell groups, but 
quantitatively the most important input comes from the striatum. Even though most 
striatonigral fibers terminate in the pars reticulata, cells in the compacta can also be 
influenced because their long dendrites extend into the reticulata. GABA is the transmitter 
for the striatonigral fibers, exerting inhibitory effects on the cells in the nigra. Excitatory 
afferents to the nigra arise in the subthalamic nucleus (Brodal, 2010). 
 
2.2.4 Medium spiny neurons 
The medium spiny neurons (MSN) are the target of the dopamine innervation of the 
striatum, and comprise more than 90% of striatal neurons. These MSNs are, as their name 
suggests, of medium size and have radially projecting dendrites that are densely studded 
with dendritic spines. These projection neurons of the striatum use GABA as a transmitter, 
with two different peptide transmitters being co-localized to define two sets of MSNs. The 
first of these groups of MSNs project directly to the substantia nigra (SN), express the 
tachykinin peptide substance P, and express the D1 dopamine receptor. The other group of 
MSNs projects to the globus pallidus (neurons of which in turn project to the SN and motor 
thalamus), express the peptide leu-enkephalin as a co-transmitter with GABA, and express 
and are regulated by the D2 dopamine receptor (Deutch et al., 2007; Smith and Bolam, 
1990; Gerfen, 1992b). 
2.2.5 Striatal interneurons: cholinergic and GABAergic 
The striatum has a complex intrinsic organization, even though the majority of neurons are 
“simple” projection neurons. For example, the axons of the medium spiny neurons give off 
recurrent collaterals in the striatum (Fig. 6A). Further, a number of different interneurons 
exist (i.e., their axonal arborizations remain within the striatum). One conspicuous kind of 
interneuron, which constitutes about 1% of all striatal neurons, has a large cell body and 
smooth dendrites and contains acetylcholine (Fig. 6A). These interneurons receive 
excitatory synaptic influences from the cerebral cortex and the intralaminar thalamic nuclei 
(glutamatergic), as well as inhibitory influences by the recurrent collaterals from 
GABAergic projection neurons. Acetylcholine acts via muscarinic receptors on striatal 
projection neurons with slow, modulatory effects. The overall effect of acetylcholine on 
the projection neurons is to ensure that they react with bursts of action potentials to 
excitatory inputs from the cerebral cortex: that is, the efficiency of signal transmission is 
enhanced. The cholinergic interneurons contribute in a yet unknown way to the symptoms 
in Parkinson’s disease, since since muscarinic antagonists can improve the symptoms. 
(Brodal, 2010; Gerfen, 1992b).  
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Figure 6: Three important kinds of neuron in the striatum, and the termination of dopaminergic fibers. A: The 
striatal projection neurons are relatively small and their dendrites have many spines (medium spiny neurons). 
All striatal projection neurons are GABAergic but  two kinds can be distinguished based on their content of 
neuropeptides (substance P and enkephalin). Note the large, cholinergic interneurons. GABAergic 
interneurons are not shown. B: Dopaminergic synapses are often situated on spines that are contacted by 
glutamatergic nerve terminals from the cortex. Therefore, dopamine presumably acts via both specific 
synapses and volume transmission (Brodal, 2010). 
Slika 6: Tri pomembne vrste nevronov v striatumu ter zaključki dopaminergičnih vlaken. A: Projekcije 
striatuma so majhne in njihovi dendriti imajo trnje. Vsi striatalni projekcijski nevroni so GABAergični in se 
lahko razlikujejo po vsebini nevropeptidov (snov P in enkefalin). Pozor na velike, holinergične internevrone. 
GABAergični internevroni niso prikazani. B: Dopaminergične sinapse se pogosto nahajajo na trnjih, ki so v 
stiku z glutamatergičnimi nevroni iz skorje. Torej, dopamin verjetno deluje preko specifičnih sinaps  in 
volumskega prenosa (Brodal, 2010). 
 
2.3 DOPAMINE 
Dopamine serves as an important neurotransmitter in distinct CNS neurons. Dopamine 
signaling controls many physiological functions ranging from locomotion to hormone 
secretion and plays a critical role in addiction (De Mei et al., 2009). Because dopamine is 
involved in a variety of critical functions, it is not surprising that multiple human disorders 
have been related to dopaminergic dysfunctions. The most recognized dopamine-related 
disorder is Parkinson’s disease (PD), which originates from a loss of striatal dopaminergic 
innervations in the brain (Fahn, 2005; Katzenschlager and Lees, 2002). The fact that 
almost all of the clinically effective antipsychotics block D2 dopamine receptors (Kapur 
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and Mamo, 2003), has provided a basis for the dopaminergic hypothesis of schizophrenia 
(Fudge and Emiliano, 2003; Beaulieu and Gainetdinov, 2011). 
 
2.3.1 Biogenic amines 
The biogenic amines constitute a subgroup of the small molecule transmitters. The group 
includes the monoamines norepinephrine, epinephrine, dopamine, and serotonin (one 
amine group) as well as histamine (two amine groups). 
Norepinephrine, epinephrine, and dopamine are catecholamines. (Catecholamines: 
compounds consisting of a catechol group (benzene ring with two hydroxyl groups) with 
an attached amine group). Neurons that contain the monoamines norepinephrine, 
dopamine, serotonin, and histamine are said to be noradrenergic, dopaminergic, 
serotonergic, and histaminergic, respectively (the same terminology is used for the 
receptors corresponding to these transmitters). A common feature of the biogenic amines is 
that they are synthesized only in a small number of neurons, which, however, have widely 
branching axons. In this way, these few neurons ensure that the transmitters can act in most 
parts of the CNS. Like acetylcholine, the biogenic amines are to a large extent released 
from varicosities without typical synaptic contacts (Fig. 8); therefore, their effects are 
presumably mainly mediated by volume transmission and binding to extrasynaptic 
receptors. 
Norepinephrine (noradrenaline), epinephrine (adrenaline), and dopamine are all 
synthesized from the amino acid tyrosine (Fig.7). Tyrosine is taken up from the 
bloodstream by active transport mechanisms and concentrated in the nervous tissue. The 
synthesis of catecholamines goes through several enzymatic steps. The first is the 
conversion of tyrosine to dihydroxyphenylalanine (DOPA) by the enzyme tyrosine 
hydroxylase (Fig.7) (Nagatsua and Sawadab, 2009; Kostrzewa et al., 2005), which appears 
to be the rate limiting for the synthesis of catecholamines under most conditions. The 
activity of tyrosine-hydroxylase is regulated by negative feedback from released 
catecholamines activating the presynaptic autoreceptors (other factors also influence the 
activity, however). DOPA is converted to dopamine by the enzyme aromatic amino acid 
decarboxylase (DOPA decarboxylase). The reaction is so rapid that very little DOPA can 
be detected in the brain normally. Therefore, the synthesis of dopamine can be increased 
by artificial supply of DOPA (in the form of levodopa), as done in Parkinson’s disease in 
which parts of the brain have very low levels of dopamine. Dopamine itself does not pass 
the blood–brain barrier and therefore cannot be used therapeutically (Brodal, 2010). 
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Figure 7: The catecholamines dopamine and the key enzymes in its synthesis (Brodal, 2010). 
Slike 7: Kateholanini dopamin in ključni encimi njegove sinteze (Brodal, 2010). 
 
Synthesized dopamine is finally sequestered into storage vesicles by vesicular monoamine 
transporter 2 (VMAT2). The vesicles play a dual role: they maintain a ready supply of 
dopamine at the nerve terminal that is available for release, and they mediate the process of 
release. When an action potential reaches the nerve terminal Ca
2+
 channels open, allowing 
an influx of the cation into the terminal; increased intracellular Ca
2+ 
promotes the fusion of 
vesicles with neuronal membrane. The vesicles then discharge their soluble contents into 
extraneuronal space. Once in the synapse, dopamine binds to and activates dopamine 
receptors, which can be located either on postsynaptic target cells or on the membrane of 
the presynaptic dopamine-releasing cell itself (i.e. D2 short autoreceptors). After an action 
potential, the dopamine molecules quickly become unbound from their receptors (Brodal, 
2010). 
Transporter proteins in the membrane of nerve terminals end the transmitter action and 
control the extracellular concentration of monoamines. There are specific transporters for 
norepinephrine, dopamine, and serotonin - all belonging to the same protein family (called 
NAT, DAT, and SERT/5-HTT, respectively). The two catecholamine transporters have 
low selectivity, however, so that, for example, the dopamine transporter also can take up 
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norepinephrine, if it is present in the vicinity. After uptake into nerve terminals, the 
monoamines are partly transported back into vesicles, partly broken down by the enzyme 
monoamine oxidase (MAO) (Kuhar et al., 2006). 
 
2.3.2 Release of neurotransmitters 
Signal is conveyed from one neuron to the next by release of a neurotransmitter 
(transmitter). “Conventional” or “classical” neurotransmitters are small molecules, such as 
amino acids and amines. Another important group of signal substances, released at 
synapses, are peptide molecules, called neuropeptides. Although the “classical” transmitter 
is released and acts at receptors in a synapse, many transmitter receptors are found 
extrasynaptically, that is, without connection to a synapse (Fig 8). Indeed, many 
transmitters act both at synapses and extrasynaptically. The latter action is called volume 
transmission, and is obviously less precise than synaptic transmission. Many receptors are 
located presynaptically on nerve terminals. Some of them are autoreceptors (binding the 
transmitter released from the terminal) and others are heteroreceptors (binding other 
transmitters released from neurons in the vicinity). Many nerves terminals contain more 
than one transmitter; often a classical transmitter is colocalized with one or more 
neuropeptides (Brodal, 2010; Carlsson and Carlsson, 2006). 
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Figure 8:  Extrasynaptic receptors and transmitter release outside synapses.  Extrasynaptic  receptors are 
localized both at the nerve terminals and on the somatic and dendritic surfaces of the neuron. Autoreceptors 
bind the transmitter released by the neuron itself. Note the release of transmitter from varicosities that do not 
form typical synaptic contacts ( Brodal, 2010). 
Slika 8: Zunajsinaptični receptorji in sproščanjeprenašalcev iz sinapse. Zunajsinaptični receptorji se nahajajo 
na končičiha in na telesu nevronov ter na površini. Na avtoreceptor se veže prenašalec, ki se sprosti iz 
samega nevrona. Sproščanje prenašalcev iz varikoz ne tvorijo tipične sinaptične stike (Brodal, 2010). 
 
2.3.3 Receptors 
The receptors are not static, immutable elements of the nervous system. We will discuss 
how changes in receptor density and activity may mediate synaptic plasticity. Drugs that 
interfere with transmitter actions often induce changes in the receptors (Brodal, 2010). 
Receptor is most often used term to describe the target molecules through which soluble 
physiological mediators - hormones, neurotransmitters, inflammatory mediators, etc. - 
produce their effects (Rang, 2008). The tendency of a drug to bind to the receptors is 
governed by its affinity, whereas the tendency for it, once bound, to activate the receptor is 
denoted by its efficacy. Some compounds (known as full agonists) can produce a maximal 
response (the largest response that the tissue is capable of giving), whereas others (partial 
agonists) can produce only a submaximal response. The difference between full and partial 
agonists lies in the relationship between receptor occupancy and response (Rang, 2008). 
Intrinsic activity or efficacy refers to the relative ability of a drug – receptor complex to 
produce a maximum functional response. 
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2.3.4 Sensitization and desensitization 
Chronic exposure to antagonists often results in increased responsiveness (i.e. greater than 
normal). This phenomenon commonly referred to as supersensitivity or sensitization. 
Dopamine receptor supersensitivity, as reflected by an enhanced response, sometimes 
accompanies receptor proliferation. However, dopamine receptor supersensitivity may 
occur in the absence of a change in the number of dopamine receptors (Kostrzewa, 1995). 
Dopamine receptor supersensitivity (DARSS) often is invoked as a mechanism possibly 
underlying in psychiatric disorders. Dopamine (DA) receptors, experimentally, are prone 
to become supersensitive and to thus elicit abnormal behaviors when coupled with DA or a 
receptor agonist (Kostrzewa et al., 2011). 
Heterologous sensitization 
Whereas acute activation of Gαi/Gαo-coupled D2 receptors inhibits adenylate cyclase, 
prolonged activation leads to enhanced adenylate cyclase activity coupled D1 receptors 
(i.e. heterologous sensitization) (Watts and Neve, 2005). 
Denervation supersensitivity of central dopamine receptors following destruction of 
dopamine neurons or dopamine depletion, is well known phenomenon (Hu et al., 1990). 
Chronic exposure to agonists often results in diminished responsiveness. This phenomenon 
commonly referred to as desensitization. Redistribution (internalization) of protein 
receptors are occurred i.e. their separation of membrane. 
 
2.3.5 Dopamine receptors 
Dopamine exerts their main actions on metabotropic receptors. Metabotropic receptors 
are coupled indirectly (via intracellular second messengers) to ion channels. Their effects 
are therefore slower to start and longer lasting than effects mediated by ionotropic 
receptors. We also use the term modulatory of the synaptic effects of metabotropic 
receptors, because they adjust the excitability of the postsynaptic neuron so that it responds 
more or less vigorously to the precise effects of ionotropic receptors (Brodal, 2010). 
 
2.3.6 Introduction 
Dopamine receptors belong to the large family of heptahelical transmembrane spanning G 
protein-coupled receptors (GPCRs). Five dopamine receptor subtypes have been identified 
and are classified into two major groups, the D1-like (D1 and D5) and D2-like (D2, D3, 
D4) like receptors (Fig.9). 
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Figure 9: Dopamine receptor structure. Structural features of D1-like and D2-like receptors are              
represented. D2-like receptors are characterized by a shorter COOH-terminal tail and by a bigger 3rd 
intracellular loop. Residues involved in dopamine binding are highlighted in transmembrane domains. 
Potential phosphorylation sites are represented on 3rd intracellular loop (I3) and on COOH terminus. 
Potential glycosylation sites are represented on NH2 terminal. E1-E3, extracellular loops; 1–7, 
transmembrane domains; I2-I3, intracellular loops  ( Missale et al., 1998). 
Slika 9: Struktura dopaminskih receptorjev. Strukturne značilnosti D1 in D2 receptorjev so prikazane na sliki. 
D2 receptori imajo krajši -COOH rep in večjo terciarno znotrajcelično zanko. Aminokislinski ostanki 
vključeni v vezavo dopamina so poudarjeni v transmembranskih domenah. Morebitna mesta fosforilacije so 
zastopana na terciarni znotrajcelični zanki (I3) in na -COOH koncu. Morebitna glikozilacijska mesta so 
zastopana na -NH2 koncu. E1-E-3, izvencelična zanka; 1-7, transmembranske domene; I2-I3, znotrajcelična 
zanka (Missale et al., 1998). 
 
2.3.7 Expression 
Dopamine receptor subtypes are expressed differentially throughout the brain. D1 
receptors are the most abundant, with mRNA transcripts found in the neostriatum, nucleus 
accumbens, and olfactory tubercle. Lower levels of D1 receptor mRNA is found in the 
cerebral cortex, hypothalamus, and thalamus (Meador-Woodruff et al., 1991). D2 receptors 
are the most abundant, with mRNA transcripts found in the neostriatum, nucleus 
accumbens, and olfactory tubercle, as well as the midbrain, including the substantia nigra 
and ventral tegmental area (Meador-Woodruff et al., 1991). D2 mRNA transcripts also are 
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found in the pituitary (Chronwall et al., 1994). Khan and colleagues (1998), using specific 
antibodies directed against the D2 splice variants, report that D2S is located predominantly 
in cell bodies and axons of dopaminergic neurons of the primate midbrain, whereas D2L is 
more strongly expressed by neurons of the striatum and nucleus accumbens that are 
targeted by dopaminergic neurons (Khan et al., 1998). Accordingly, in the primate brain, 
D2S and D2L are primarily localized to pre- and postsynaptic membranes, respectively.  
 
2.3.8 Dopamine D2 long and D2 short isoforms 
The two isoforms coexist in all brain tissue analyzed; however, the expression ratio of D2L 
versus D2S varies considerably from region to region (Neve et al., 1991). The differences 
in protein structure, expression pattern, and interaction with intracellular effectors suggest 
that the two D2 isoforms may have differential functions. In addition, the etiology of motor 
deficits and psychoses involves different brain regions, and the expression ratio of D2 
isoforms differs in these regions. Thus, there is a possibility that D2L and D2S may play 
differential roles in defining the therapeutic ratio of antipsychotic and/or antiparkinsonian 
drugs (Wang et al., 2000). Analysis of mRNA of the two isoforms has shown that D2L is 
the most abundantly expressed (Vallone et al., 2000; Wang et al., 2000; Xu et al., 2002).  
The lack of an isoform-selective pharmacological agent has hampered the progress toward 
understanding the specific function of D2L and D2S in the mammalian CNS (Wang et al., 
2000). 
Due to the lack of isoform-selective pharmacological agents, studies of differential roles of 
D2L and D2S in the brain currently rely mainly on genetic manipulation (Hranilovic et al., 
2008). To contribute to understanding of functional roles of the two D2R isoforms in the 
mammalian brain, they have generated D2L receptor-deficient mice (D2L−/−) which only 
express functional D2S receptors at the level similar to that of the total D2R in wild-type 
(WT) mice (Wang et al., 2000). D2L−/− mice, in comparison to WT mice, displayed 
reduced level of locomotion in an open field, lower basal motor activity in their home 
cages, increased and enhanced stereotyped behavior (Wang et al., 2000; Fetsko et al., 
2003). Moreover, mice lacking D2L were less sensitive to typical antipsychotics (Wang et 
al., 2000; Xu et al., 2002; Hranilovic et al., 2008). D2L−/− mice still express functional 
D2S isoform on the cell surface at a level similar to that of total D2R in WT mice, due to a 
compensatory increase in D2S expression in the mutants.  
Buckland (1993) shows that mRNA levels of both isoforms of the D2 receptor are up-
regulated by 32 day long administration of haloperidol (Buckland et al., 1993) 
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Figure 10: Pre- and postsynaptic signaling mediated by D2L and D2S (De Mei et al., 2009). 
Slika 10: Pre- in post-sinaptično signaliziranje posredovano z D2L in D2S (DeMei in sod., 2009). 
 
2.3.9 Dopamine receptor coupling to G proteins 
Dopamine receptor signaling is mediated chiefly through heterotrimeric G proteins, which 
are comprised of an α, β, and γ subunit complex (McCudden et al., 2005). The G protein α 
subunit (Gα) binds guanine nucleotides and cycles between an inactive GDP-bound state 
and an active GTP-bound state (Oldham and Hamm, 2008). Upon agonist binding, 
receptors undergo a conformation change that activates Gα through the exchange of GDP 
for GTP, resulting in the dissociation of the constitutive dimeric G protein β and γ subunits 
(Gβγ). Gα-GTP and Gβγ directly modulate downstream targets of dopamine receptors, 
including second messengers and ion channels (Neve et al., 2004).  
A distinguishing feature of D1-like and D2-like receptors is their differential coupling to 
heterotrimeric G proteins. D1-like receptors couple to Gαs and Gαolf, which activates 
adenylate cyclase (Brown and Makman, 1972; Kebabian et al., 1972). In the rodent 
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neostriatum, where expression of Gαolf is abundant and Gαs is relatively low, D1 receptor 
activation of adenylate cyclase is mediated by Gαolf (Zhuang et al., 2000; Corvol et al., 
2001). In contrast, D2-like receptors couple to Gαi or Gαo, which inhibit adenylate cyclase 
(Ohara et al., 1988). Dopamine receptors couple to G proteins that modulate alternative 
effectors. For example, D1-like and D2-like receptor coupling to Gαq, which stimulates 
phospholipases and the consequent hydrolysis of phosphoinositides (Neve et al., 2004).  
D1-like receptor stimulation of Gαs or Gαolf induces the activation of adenylate cyclase, 
an enzyme that catalyzes the conversion of ATP to cyclic AMP, and consequently the 
disinhibition of the catalytic subunit of cyclic AMP-dependent protein kinase (PKA). PKA 
in turn phosphorylates multiple downstream targets, including the cyclic AMP regulatory 
element-binding protein (CREB), the dopamine and cyclic AMP-regulated phosphoprotein, 
32 kDa (DARPP-32), and various ion channels. 
D1-like receptor-mediated phosphorylation of CREB by PKA leads to the translocation of 
CREB to the nucleus and CREB-dependent transcription of numerous genes, including the 
immediate early gene c-fos (Konradi et al., 1994). CREB-induced gene transcription is 
associated with synaptic plasticity and memory formation (Josselyn and Nguyen, 2005).  
 
2.3.10 D2-like receptor regulation of adenylate cyclase 
D2-like receptors inhibit adenylate cyclase through coupling to the Gαi and Gαo, thereby 
decreasing or preventing stimulation of cyclic AMP production (De Camilli et al., 1979; 
Stoof and Kebabian, 1981). Accordingly, D2-like receptors act oppositely to D1-like 
receptors in the regulation of substrates downstream of cyclic AMP, including PKA and 
DARPP-32. D2 receptor stimulation decreases DARPP-32 phosphorylation, inhibiting this 
phosphoprotein (Nishi et al., 2000). It would be expected that D2-like receptor stimulation 
also decreases CREB phosphorylation. However, in sagittal brain slices (including the 
neocortex, neostriatum, hippocampus, thalamus, and substantia nigra) the D2- like agonist 
quinpirole stimulates CREB phosphorylation, presumably through a cyclic AMP-
independent mechanism (Yan et al., 1999). 
D2S and D2L receptors are also thought to couple differently to G proteins, since the 
alternatively spliced exon lies in a region that mediates G protein interactions. 
Furthermore, D2S receptors more potently inhibit adenylate cyclase than D2L receptors 
(Montmayeur and Borrelli, 1991; Hayes et al., 1992). Taken together, D2S receptors may 
be more efficiently coupled to or interact with distinct subtypes of G proteins. 
D1 and D2 receptor stimulate PLC and induce the release of calcium from intracellular 
stores through Gαq coupling (Rashid et al., 2007). 
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2.3.11 Arrestin-dependent signaling 
Originally identified as a protein involved in receptor desensitization (Lohse et al., 1990) 
and then resensitization (Zhang et al., 1997), there is increasing evidence for a role of 
arrestin in GPCR signaling (Lefkowitz and Shenoy, 2005; Defea, 2008). 
Arrestin-dependent signaling may involve the spatial redistribution of dopamine receptors 
from the plasma membrane into endosomal vesicles, facilitating the interaction of receptors 
with distinct cytosolic signaling proteins not available at the cell surface (Romanelli and 
Wood, 2008).  
The dopamine D2 receptor signals by two independent pathways, the classical G-protein 
coupling (cAMP turnover) and the β-arrestin-mediated pathway. Previously, β-arrestins 
were thought to be involved only in desensitization and trafficking, but they also play an 
important role in signalling, and there is evidence that there could be bias in choosing 
either of these pathways by agonists thus leading to differences in their therapeutic or side-
effect profile (Natesan et al., 2011). 
 
2.3.12 D1/D2 receptor cooperativity – synergism 
D1- and D2-like receptors act synergistically, to modulate dopamine-mediated behaviors, 
including psychiatric and motor disorders (Strange, 2001). Behaviorally, the requirement 
for activation of both receptors is reflected in the observation that administration of either 
D1 or D2 antagonists can prevent many dopamine-dependent responses. Depending on the 
efficacy of the agonist and the endogenous dopamine tone, coadministration of D1- and 
D2-like agonists may be required for the full development of some responses (Hu et al., 
1990; LaHoste and Marshall, 1992; Ikemoto et al., 1997; Missale et al., 1998).    
Therefore, functional synergism between D1 and D2 receptors is necessary for maintaining 
some normal physiological functions, and once the functional linkage between the two 
receptors is broken, disorders, such as schizophrenia, may develop (Yang et al., 2007). 
 
2.3.13 Autoreceptors 
Distinct pre-synaptic dopamine receptor subtypes, termed autoreceptors, regulate the tone 
of dopamine neurotransmission. Autoreceptors are expressed on the cell body and 
dendrites of dopaminergic midbrain neurons and modulate the rate of cell firing and 
impulse activity (Aghajanian and Bunney, 1977). It is well established that autoreceptors 
are D2-like receptors, as both agonists and antagonists that are selective for D2-like 
receptors act on dopamine neurons to cause inhibition and block dopamine-induced 
inhibition, respectively (Pinnock, 1983). Autoreceptors are also located on dopaminergic 
nerve terminals where they decrease dopamine synthesis, through inhibition of the rate-
limiting enzyme tyrosine hydroxylase, and dopamine release (Kehr et al., 1972). D2-like 
autoreceptors also decrease dopaminergic activity by enhancing dopamine reuptake via the 
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dopamine transporter (Meiergerd et al., 1993; Wu et al., 2002). It is more accurate to 
interpret these data as demonstrating that the D2S receptor has the capability to function as 
the D2 autoreceptor (Carlsson and Carlsson, 2006). 
 
2.3.14 Most drugs influence synaptic function 
Most drugs acting on the nervous system do so by influencing synaptic transmission 
directly or indirectly, regardless of whether their aim is to alleviate disorders of mood, 
cognition, movements, memory, or behavior. The drugs may interfere presynaptically in 
the synthesis, release, degradation, or reuptake of transmitters or postsynaptically in the 
activity, numbers, or localization of receptors. Another important point is that storage, 
release, and uptake of transmitters, as well as the expression of receptors, is dynamic 
processes. 
Finally, we should keep in mind that alteration of one transmitter’s activity as a rule leads 
to alterations of other transmitters as well (Brodal, 2010). 
 
2.4 SCHIZOPHRENIA 
 
Schizophrenia is a most disabling psychiatric disorder characterized by a myriad of 
symptoms (Givovart and Kapur, 2010). Symptoms usually begin in late adolescence or 
early adulthood and are typically classified  as positive symptoms with exaggeration of 
normal function, such as hallucinations, delusions, disorganized speech, and disorganized 
behavior. The negative symptoms comprise a diminution in mental functions, such as 
blunting, avolition, alogia, and anhedonia, and a deficit in social interaction (Yeganeh-
Doost et al., 2011). Cognitive symptoms (disorganized thoughts, deficits in attention, 
working and verbal memory, social cognition, and executive function). 
The course of schizophrenia is characterized by periods of symptom exacerbation (i.e. 
relapse) alternating with periods of relative remission, with a different pattern of 
exacerbation/remission episodes between the three psychopathology dimensions and 
between different individuals. Such findings have led several researchers to theorize that 
positive, negative, and cognitive symptoms reflect separate pathophysiological processes, 
though that still remains to be proven beyond doubt (Givovart and Kapur, 2010). 
Schizophrenic patients exhibit positive, negative and cognitive symptoms which arise from 
an imbalance between the brain dopamine (DA) pathways mediating D2 and D1 receptor 
signaling (Yeganeh-Doost et al., 2011; Lewis and Lieberman, 2000). Subcortical increase 
of DA, leading to hyperstimulation of D2 receptors, would give rise to the positive 
symptoms, while a concomitant cortical deficit of DA, leading to hypostimulation of D1 
receptors, would give rise to the negative and cognitive symptoms. There is indeed robust 
evidence that DA hypofunction and altered D1 receptor signaling within the prefrontal 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
24 
cortex (PFC) play a central role in the induction of working memory deficits, suggesting 
that a reduced D1 receptor neurotransmission might cause cognitive impairments in 
schizophrenia (Perrault et al., 1997). Both hypofunctioning and hyperfunctioning DA 
systems thus likely coexist in schizophrenia, albeit in different brain regions (Wang et al., 
2000).  
The mesolimbic dopamine pathways are thought to have an important role in emotional 
behaviors, especially auditory hallucinations but also delusions and thought disorder 
(Fig.2). For more than 25 years, it has been observed that diseases or drugs that increase 
dopamine will enhance or produce positive psychotic symptoms, whereas drugs that 
decrease dopamine will decrease or block positive symptoms (Stahl, 2013). 
The mesocortical dopamine pathway (Fig.2) projects to areas of the cerebral cortex, 
especially the limbic cortex. The role of the mesocortical dopamine pathway in mediating 
negative and/or cognitive symptoms of schizophrenia (Stahl, 2013). 
The nigrostrial dopamine pathway (Fig.2) is a part of the extrapyramidal nervous system 
and controls motor movements. Deficiencies in dopamine in this pathway cause movement 
disorders, including Parkinson's disease, which is characterized by rigidity, akinesia or 
bradykinesia (i.e. lack of movement or slowing of movement), and tremor. Dopamine 
deficiency in the basal ganglia also can produce akathisia (a type of restlessness) and 
dystonia (twisting movements, especially of the face and neck) (Stahl 2013). 
 
2.4.1 The Dopamine hypothesis 
 
The “classical” dopamine hypothesis of schizophrenia proposed that subcortical 
hyperactivity of dopamine transmission in the brain is responsible for the positive 
symptoms of the illness (van Rossum, 1966; Fudge and Emiliano, 2003; Heinz and 
Schlagenhauf, 2010). This hypothesis was initially based on several lines of indirect 
evidence. First, exposure to dopamine enhancing drugs, such as amphetamine, induces 
psychosis in normal individuals and worsens psychotic symptoms in schizophrenia 
patients. Second, drugs alleviating psychotic symptoms of schizophrenia were suspected to 
act through blockade of central dopamine receptors (Kapur and Mamo, 2003; Lidow and 
Goldman-Rakic, 1997). Patients with schizophrenia, whether treated or untreated, are 
known to be supersensitive to dopamine-like compounds (Seeman, 2011; Kostrzewa et al., 
2011). 
 
2.5 CLASSIFICATION OF ANTIPSYCHOTIC DRUGS 
Antipsychotic drugs exhibit possibly the most complex  pharmacologic mechanisms of any 
drug class within the field of clinical psychopharmacology. The different antipsychotic 
agents, based upon their interactions with different neurotransmitter systems, such 
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interactions can often explain both the therapeutic actions and the side effects of various 
antipsychotic medications.  
        
2.5.1 Typical Antipsychotics 
 
Antipsychotic medications are the cornerstone treatments for reducing psychotic symptoms 
and relapse rates in schizophrenia. The first antipsychotic drug used for schizophrenia, 
chlorpromazine, was introduced in 1952 and, in the late 1950s, several other antipsychotics 
were subsequently introduced, including haloperidol, thioridazine, trifluoperazine, and 
loxapine. These first-generation antipsychotics, termed typical or conventional 
antipsychotics, are effective against the positive symptoms but have limited efficacy and 
may even exacerbate the negative and cognitive symptoms of schizophrenia. The 
therapeutic action of conventional antipsychotic drugs is due to blockade of D2 receptors 
specifically in the mesolimbic dopamine pathway (Fig.2). This has the effect of reducing 
the hyperactivity in this pathway that is postulated to cause the positive symptoms of 
psychosis. All conventional antipsychotics reduced positive psychotic symptoms if they 
are dosed to block a substantial number of D2 receptors there (Stahl, 2013). Moreover, 
some 30% of patients with schizophrenia show little or no response of their positive 
symptoms to typical antipsychotic therapy (Hellewell, 1999). Unfortunately, in order to 
block adequate numbers of D2 receptors in mesolimbic dopamine pathway to quell 
positive symptoms, one must simultaneously block the same number of D2 receptors 
throughout the brain, and this causes undesirable side effects (Stahl, 2013). Because of 
this, typical drugs are associated with a wide spectrum of side effects, including sedation, 
acute extrapyramidal symptoms (EPS), hyperprolactinemia and, although rarely, the 
neuromalignant syndrome. Acute EPS are dose-dependent and manifest as dystonia, 
akathisia, and pseudoparkinsonism (Levinson et al., 1990). The most worrisome form of 
EPS, tardive dyskinesia (TD), develops on long-term utilization with an incidence of about 
5% a year and can be irreversible (Lieberman et al., 2005). These side effects are often 
severe and disabling and are a leading cause of patient noncompliance (Casey, 2006; Naber 
and Karow, 2001) which, in turn, leads to relapse (Dossenbach et al., 2005). Efforts to 
minimize EPS have revealed that lowering the dose indeed decreases side effects and still 
achieves therapeutic efficacy in many patients with schizophrenia (Geddes et al., 2000). 
However, lower doses also carry additional risk of relapse as the doses required for 
efficacy are only slightly lower than the doses that cause side effects (Dixon et al., 1995; 
Oosthuizen et al., 2001). Despite their clear benefits for the treatment of schizophrenia, the 
limited tolerability and narrow therapeutic index of typical antipsychotic (Fig. 11) drugs 
pointed out the need for better treatment options. 
D2 receptors in the mesolimbic dopamine system are postulated to mediate not only the 
positive symptoms of  schizophrenia, but also the normal reward system of the brain, and 
nucleus accumbens is widely considered to be the ''pleasure center'' of the brain. Thus, if 
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D2 receptors in the mesolimbic system are blocked, this may not only reduce positive 
symptoms of schizophrenia, but also block reward mechanisms, leaving patients apathic, 
anhedonic, lacking motivation, interest and joy from social interactions, a state very similar 
to that of negative symptoms of schizophrenia (Stahl, 2013).  
Antipsychotics also block D2 receptors in the mesocortical dopamine pathway, where 
dopamine may already be deficient in schizophrenia. This can cause or worsen negative 
and cognitive symptoms even though there is only a low density of D2 receptors in cortex 
(Stahl, 2013). 
 
 
Figure 11: Hypothetical thresholds for conventional antipsychotic drug effect (Stahl, 2013). 
Slika 11: Hipotetične mejne vrednosti učinkovitosti konvencionalnih antipsihotikov (Stahl, 2013). 
 
When a substantial number of D2 receptors are blocked in the nigrostriatal DA pathway, 
this will produce various disorders of movement that can appear very much like those in 
Parkinson's disease. Since is nigrostrital pathway is part of the extrapyramidal nervous 
system, these motor side effects associated with blocking D2 receptors in this part of the 
brain are also called exprapyramidal symptoms or EPS.  
Worse yet, if these D2 receptors in the nigrostriatal DA pathway are blocked chronically, 
they can produce a hyperkinetic movement disorder known as tardive dyskinesia. This 
movement disorder causes facial and tongue movements such as constant chewing, tong 
protrusions, facial grimacing, and also limb movements that can be quick, jerky or 
choreiform (dancing). Tardive dyskinesia is thus caused by long term administration of 
conventional antipsychotics and is thought to be mediated by changes, sometimes 
irreversible, in the D2 receptors of the nigrostriatal DA pathway. Specifically, these 
receptors are hypothesized to become supersensitive or to up-regulate (i.e. increase in 
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number), perhaps in a futile attempt to overcome drug-induced blockade of D2 receptors in 
striatum (Stahl, 2013). According to the CATIE report, the risk of TD may be correlated 
with a patient's age, duration of exposure to antipsychotics, exposure to conventional 
antipsychotics, use of anticholinergic medications, substance abuse, presence of EPS, and 
akathisia (Stip and Tourjman, 2010). 
The use of conventional antipsychotic drugs presents a powerful dilemma. That is, there is 
no doubt that conventional antipsychotic medications exert dramatic therapeutic action 
upon positive symptoms of schizophrenia by blocking hyperactive dopamine neurons in 
the mesolimbic dopamine pathway, whereas blocking dopamine receptors in the remaining 
pathways may be harmful (Stahl, 2013).  
 
2.5.2 Atypical Antipsychotics 
Research to enhance the therapeutic benefits of antipsychotics while diminishing their side 
effects has led to the development of a new class of antipsychotic agents, the atypical 
antipsychotics. Clozapine was introduced in Europe in 1975 and marked a turning point in 
schizophrenia therapy. Clozapine appeared to be effective with a minimal incidence of 
EPS, thus challenging the dogma that antipsychotic efficacy required high levels of EPS 
(Hippius, 1999). Interestingly, this drug demonstrated benefits in cases of patient’s 
refractory to typical antipsychotics and was found to be somewhat more effective against 
the negative and cognitive symptoms (Buchanan, 1995).  
Atypical antipsychotics have the clinical profile of equal positive symptom antipsychotic 
action, but low extrapyramidal symptoms and less hyperprolactinemia compared to 
conventional antipsychotics. Thus, they are ''atypical'' from what is expected from 
classical, conventional, first-generation antipsychotics (Stahl, 2013). 
Although atypical drugs improve positive symptoms with a similar efficacy (Rosenheck et 
al., 2003; Conley and Mahmoud, 2001), they differ from typical ones by their lower 
incidence of EPS and TD (Glick and Marder, 2005; Correll et al., 2004). 
Rather than their efficacy against the positive symptoms, it is thus their side effect profile 
and efficacy against the negative and cognitive symptoms that are generally considered to 
differentiate typical and atypical antipsychotics. Clearly though, the newer atypical agents 
have emerged as a good long-term treatment option because of their wide therapeutic index 
and improved control of motor side effects (Fig.12). 
While typical antipsychotic are usually preferential for D2-like receptors, atypical 
antipsychotic usually bind to a larger spectrum of receptor types. Clinical evidence also 
supports the importance of 5-HT2A receptor blockade in the treatment of positive symptoms 
(Barnes et al., 2012). From a pharmacological perspective, the current atypical 
antipsychotic as a class are defined as serotonin-dopamine antagonists, with simultaneous 
serotonin 5-HT2A receptor antagonism that accompanies D2 antagonism (Stahl, 2013).  
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Figure 12: Hypothetical thresholds for atypical antipsychotic drug effect (Stahl, 2013). 
Slika 12: Hipotetične mejne vrednosti učinkovitosti atipičnih antipsihotikov (Stahl, 2013). 
 
All 5-HT2A receptors are postsynaptic and located in many brain regions. 5-HT2A receptors 
regulate dopamine release from nigrostriatal dopamine neurons. Serotonin neurons may 
innervate nigrostriatal dopamine neurons at the level of the dopamine neuronal cell bodies 
in the supstantia nigra and at the dopamine neuronal axon terminals in the striatum. This 
innervation may be either via a direct connection between the serotonin neuron and the 
dopamine neuron, or via an indirect connection with a GABA interneuron. 5-HT2A receptor 
stimulation by serotonin blocks dopamine release in the striatum. On the other hand, 5-
HT2A receptor antagonism by an atypical antipsychotic at the same site stimulates 
downstream dopamine release in the striatum. Such release of dopamine in the striatum 
should mitigate EPS, which is why antipsychotic with 5-HT2A antagonist properties are 
atypical (Stahl, 2013). The result of this increased dopamine release is that dopamine 
competes with D2 receptor antagonists in the striatum, and reduces the D2 receptor binding 
there below 80% to more like 60%, enough to eliminate extrapyramidal symptoms. 
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Figure 13:Serotonine and dopamine interactions in the nigrostriatal DA pathway (Stahl, 2013).                
Slika 13: Serotoninsko in dopaminsko medsebojno delovanje v nigrostriatni DA poti (Stahl, 2013). 
 
One of the most striking and consistent consequences of chronic antipsychotic exposure is 
an increase in striatal D2 receptor density (Sirinathsinghji et al., 1994; Laruelle et al., 1992; 
Tarazi et al., 1997; Buckland et al., 1993; Hu et al., 1990; Meshul and Casey, 1989). This 
D2 receptor up-regulation is thought to be responsible for loss of efficacy of antipsychotics 
and provokes unwanted extrapyramidal syndrome (EPS) (Strange, 2001; Xu et al., 2002; 
Ginovart et al., 2009; Lewis and Lieberman, 2000; Hess et al., 1986; Jorgensen et al., 
1994).), characterized by parkinsonism, akathisia, catalepsy, and, after long-term 
treatment, tardive diskinesia (Kapur and Remington, 2001; Strange, 2001). Tardive 
dyskinesias are typically seen after several years of antipsychotic medication. Rarely, 
tardive diskinesia may supervene after only a few months of treatment. Tardive dyskinesia 
(TD) is a syndrome of involuntary movements that predominantly involve muscles in the 
tongue and face (Jorgensen et al., 1994). Due to long-term treatment arises supersensitivity 
D2 receptor (increase responsiveness of D2 receptors) (Meshul and Casey, 1989; 
Kostrzewa, 1995; Samaha et al., 2007). Moreover, even though most patients with 
schizophrenia are supersensitive to dopamine (Seeman, 2011).   
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Figure 14:Serotonine and dopamine interactions in the nigrostriatal DA pathway (Stahl, 2013).                
Slika 14: Serotoninsko in dopaminsko medsebojno delovanje v nigrostriatni DA poti (Stahl, 2013). 
 
Aripriprazole is a new atypical antipsychotic with a pharmacological mechanism that 
distinguishes it from currently available antipsychotic agents. It acts as a potent partial 
dopamine D2 receptor agonist, a partial serotonin 5-HT1A agonist and 5-HT2A receptor 
antagonist. Partial D2 receptor agonism is believed to help stabilize dopaminergic 
neurotransmission in schizophrenia in the mesocortical and mesolimbic pathways. Partial 
agonist activity at the 5-HT1A receptor may confer efficacy against negative and affective 
symptoms of schizophrenia, while antagonism at the 5-HT2A receptor may contribute to 
efficacy against negative symptoms as well as reducing EPS liability.  
These new atypical antipsychotics also have side effects which, due to the markedly 
different pharmacological profiles, range from weight gain, impaired glucose tolerance, 
hyperprolactinaemia with potential associated sexual dysfunction, to cardiotoxicity (Naber 
and Lambert, 2004).  
Based on the clinical evidence, including data from short-term (4–8 weeks) and long-term 
(26–52 weeks) randomized, double-blind clinical trials, aripiprazole has been associated 
with improvements in positive, negative, cognitive, and affective symptoms of 
schizophrenia and schizoaffective disorder (Stip and Tourjman, 2010). 
D1 and D2 receptors have important functional interactions. However, these interactions 
were abnormal in over half of the postmortem striata from schizophrenic patients, 
suggesting an impaired functional linkage between D1 and D2 receptors in schizophrenic 
patients (Goldman-Rakic et al., 2004). Therefore, the restoration of normal, functional 
linkage between D1 and D2 receptors may be an effective strategy for the treatment of 
schizophrenia. Before atypical antipsychotic were discovered, clinical doses of the 
available antipsychotic drugs primarily blocked D2 receptors (Seeman et al., 1984), but 
unfortunately they were less effective at PFC D1 receptors. As a result, a large proportion 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
31 
of schizophrenic patients did not show adequate relief from their negative symptoms (Saha 
et al., 2005). However, even with the development of atypical antipsychotic, most of them 
display only very small D1 agonistic effects on the PFC D1 receptor. Therefore, there is an 
urgent need to develop an agent that exerts both D1 agonistic and D2 antagonistic effects, 
which should more effectively restore synergism between D1 and D2 receptors and 
alleviate both the negative and positive symptoms of schizophrenia. LEK-8829 possesses 
these characteristics and may serve as a novel, promising agent for schizophrenia 
therapeutics (Yang et al., 2007).  
LEK-8829 acts through D1 receptors to increase adenylyl cyclase activity; subsequent 
signaling pathways regulated by adenylyl cyclase might be responsible for the 
physiological responses. By contrast, LEK-8829 inhibits both D2 autoreceptor-mediated 
feedback inhibition of dopamine containing neurons and D2 receptor-mediated effects on 
target non-dopamine-containing neurons (Jin et al., 2002). 
 
2.6 ANIMAL MODELS OF SCHIZOPHRENIA 
2.6.1 Preclinical evidence for an antipsychotic action at the D2 receptors 
A number of animal models have been used to explore antipsychotic action and to 
investigate the mechanisms underlying the differences between the actions of typical and 
atypical drugs. Some models are used to predict antipsychotic efficacy (i.e. inhibition of 
amphetamine-induced hyperactivity, disruption of conditioned avoidance responding, and 
induction of c-fos expression in the shell region of the NAcc), while others are used to 
predict their motor side effect liability (i.e. induction of catalepsy, blockade of 
apomorphine-induced sniffing, and induction of c-fos expression in the dorsolateral 
striatum). 
 
2.6.2 Antipsychotic effect on indirect DA agonist-induced behavior 
Reversal of amphetamine-induced hyperactivity in rodents is one classical animal model 
used to screen antipsychotic drugs. Indirect DA agonists such as amphetamine or 
methylphenidate induce a strong increase in locomotor activity when injected into rodents. 
There is evidence that this increased locomotor activity is due to an increased DAergic 
activity in the mesolimbic system, mainly within the NAcc (Ginovart and Kapur, 2010). 
While lacking in face validity, blockade of amphetamine-induced hyperactivity is 
considered as one of the better preclinical predictors of antipsychotic activity. Accordingly, 
both typical and atypical antipsychotic drugs reduce the hyperactivity produced by 
amphetamine and this effect has been linked to D2 receptor blockade (Ellenbroek, 1993). 
Here again, the potency of antipsychotics to antagonize amphetamine-induced 
hyperlocomotion correlated with their affinity at D2 receptors (Bardin et al., 2007). The 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
32 
similar action of typical and atypical antipsychotics in the amphetamine model is 
consistent with their similar blockade of D2 receptors and their similar antipsychotic effect 
in schizophrenia patients. 
These models thus demonstrate in vivo antagonist activity of all antipsychotics at D2 
receptors and suggest that a lower D2 action of atypical drugs in the nigrostriatal system 
may explain their lower propensity to cause EPS when compared to typical (Ginovart and 
Kapur, 2010). 
 
2.6.3 Antipsychotic effect on catalepsy 
The catalepsy test is a common and widely used preclinical screening test for the 
propensity of an antipsychotic drug to induce EPS in humans (Wadenberg, 1996). 
Antipsychotics such as haloperidol and risperidone, which have a dose-dependent 
propensity to induce EPS in humans, induce catalepsy in animals in a dose-dependent 
manner. In contrast, atypical drugs such as clozapine and aripiprazole, which significantly 
less produce EPS in humans do not produce catalepsy in animals (Natesan et al., 2006; 
Tang et al., 1997). The cataleptic behavior seems primarily to involve D2 antagonism in 
the DA nigrostriatal pathway that mediate extrapyramidal motor function and a direct 
relationship has been established between the blockade of striatal D2 receptors and 
catalepsy (Wadenberg et al., 2000). 
 
2.7 PARKINSON'S DISEASE 
Parkinson’s disease (PD) is an age-related movement disorder characterized by decreased 
levels of the neurotransmitter dopamine (DA) in the striatum of the brain, due to selective 
degeneration of the nigro-striatal DA neurons. In most instances PD appears to be 
sporadic, without any family history. While the etiology of PD has not been unequivocally 
determined, speculation has centered around complex mechanisms such as toxic 
environmental factors superimposed on susceptibility genes, oxidative stress caused by 
mitochondrial dysfunction, dysfunction of the ubiquitin proteasome system with resultant 
accumulation of misfolded proteins and endoplasmic reticulum stress, and formation of 
activated microglia accompanying an inflammatory process. These changes may lead to 
the programmed cell death (apoptosis or autophagy) of DA neurons (Nagatsua and 
Sawadab, 2009). 
Dopamine loss in the striatum in Parkinson’s disease, the degeneration of dopaminergic 
SNc neurons and their projections to the striatum is a slowly evolving process that may 
take decades to develop. SNc projections to the putamen degenerate earlier than 
projections to associative or limbic portions of the striatum. Corresponding to this time 
course of degeneration, the motor symptoms and signs of Parkinson’s disease develop 
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before the non-motor signs. Recognizable motor or non-motor signs appear only after 
substantial degeneration of the nigrostriatal neurons (affecting at least 70 %, e.g. 
Bernheimer et al., 1973), testament to the remarkable compensatory capacity within the 
dopaminergic system, or in the circuits it modulates (Galvan and Wichmann, 2008). 
The primary features of this disease include resting tremor, rigidity, bradykinesia or 
akinesia, postural instability and non-motor symptoms (sleep disturbances, depression, 
neuropsychiatric and cognitive deficits)  (Ferguson, 2007; Gurevich and Gurevich, 2010). 
In Parkinson’s disease, the degeneration of nigrostriatal dopaminergic neurons reduces the 
dopaminergic modulation through reduced striatal dopamine levels. Reduced striatal 
dopamine results in less activation of striatal D1 receptors and D2 receptors affecting the 
direct and indirect pathways, respectively (Fig.11). Through decreased activation of D2 
receptors, striatal inhibitory projections to the GPe become more active through reduced 
suppression. There is increased striatal inhibition of the GPe, subsequent disinhibition of 
the STN and therefore STN hyperactivity within the indirect pathway. Simultaneously, 
striatal projections to the GPi and SNpr become less active through decreased D1 receptors 
activation (Alexander and Crutcher, 1990). As a result of increased STN excitation and 
reduced striatal inhibition, there is increased activity of the GPi and SNr, and a subsequent 
increase in tonic inhibition of the thalamocortical projection neurons. Therefore, with PD, 
maladaptive modulation of tonic inhibition of the thalamus through the separate striatal 
neuron subpopulations and subsequent basal ganglia pathways (Albin et al., 1989) has a 
crucial impact on motor impulse control (MacDonald and Byblow, 2015). 
Dopamine loss in the basal ganglia triggers prominent secondary morphological changes. 
One change that may have pathophysiologic significance is the reduction of the density of 
dendritic spines on MSNs, particularly in the putamen (Ingham et al., 1989; Zaja-Milatovic 
et al., 2005), which may greatly alter corticostriatal transmission. Recent studies have 
suggested that MSNs with D2 receptors (belonging to the indirect pathway) may be 
preferentially affected by the spine loss, and that the loss of spines may involve the 
dysregulation of calcium channels (Day et al., 2006). 
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Figure 15: Simplified diagram demonstrating the anatomical connections within the basal ganglia circuitry, 
and changes in the activity of basal ganglia nuclei associated with development of parkinsonism ( Siegel et 
al., 2006). 
Slika 15: Poenostavljen diagram, ki predstavlja anatomske povezave znotraj povezav bazalnih ganglijev, ter 
spremembe v dejavnosti jedra bazalnih ganglijev v povezavi z razvojem parkinsonizma (Siegel in sod., 
2006). 
  
Dopamine depletion also triggers changes in the density and sensitivity of dopamine 
receptors. The mRNA expression for dopamine D2 receptors and binding sites in the 
striatum is increased in patients with Parkinson’s disease and Parkinsonian animals 
(Aubert et al., 2005; Bezard et al., 2001; Bokobza et al., 1984; Creese et al., 1977; Guigoni 
et al., 2005). Changes (increases or decreases) in striatal D1-receptor binding were also 
reported in some studies (Buonamici et al., 1986; Marshall et al., 1989), but were not seen 
by other authors (Aubert et al., 2005; Bezard et al., 2001; Guigoni et al., 2005). Gerfen 
(1990) demonstrated that the expression of D1 receptor mRNA was specifically down-
regulated in direct pathway MSNs, and that the expression of D2 receptor mRNA was up-
regulated in indirect pathway MSNs (Gerfen et al., 1990; Galvan and Wichmann, 2008). 
One of the most important implications of the enabling relationship between D1 and D2, 
DA receptors is its potential relevance for the treatment of Parkinson’s disease (Hu et al., 
1990). 
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2.7.1 Current treatment approaches 
Drug therapy at correcting the neurochemical imbalances in the basal ganglia is the 
cornerstone of treatment for PD patients. However, to date, all therapies are symptomatic 
in nature; no drug has yet been discovered which impedes or reverse PD progression. In 
addition, all current drugs have a limit to their effectiveness; patients eventually become 
tolerant to their benefit and suffer from numerous debilitating side effects. Current drug   
therapies can be divided into several drug classes: levodopa (L-DOPA)/carbidopa, 
dopamine agonists, monoamine oxidase-B inhibitors, muscarinic antagonist s(Slusher, 
1996). 
2.7.2 Levodopa (L-DOPA)  
PD being characterized by dopamine depletion, the first curative treatments were based on 
exogenous dopamine supply to restore dopaminergic transmission at striatal synapses. 
However, trials with oral dopamine failed because dopamine cannot cross the blood–brain 
barrier, leading to severe peripheral adverse events. Levodopa is a natural dopamine 
precursor that can cross the blood–brain barrier to reach the brain where it is converted into 
dopamine by peripheral decarboxylase and stored in vesicles in order to be progressively 
released onto postsynaptic receptors (Goole and Amighi, 2009). 
The duration and dosage of levodopa therapy being known to be the major risk factors in 
the appearance of motor complications, numerous strategies are now used to prevent 
dyskinesia and the “on-off” effect: (1) delay of the need for levodopa, (2) reduction of the 
cumulative dose of levodopa, (3) avoidance of the pulsatile stimulation of dopamine 
receptors, and (4) neuroprotection to slow down disease progression (Goole and Amighi, 
2009). The problems arising with long-term levodopa therapy are the dyskinesias that 
develop with treatment over months or years, presumably resulting from priming or 
supersensitization of D2 receptors (Kostrzewa et al., 2011). 
With the progression of the disease, patients become very sensitive to rapid fluctuations in 
plasma levodopa concentrations. Dopaminergic terminals continue to degenerate and are 
no longer able to buffer the exogenous levodopa adequately. As a result, patients 
experience one or more periods during the day when the dose of levodopa wears off.  
Dopamine receptors are thus stimulated in a frequent abnormal and intermittent fashion, 
thereby developing an oscillating clinical response during chronic treatment of PD (Goole 
and Amighi, 2009). 
Indeed, repeated dosing of levodopa leads to pulsatile stimulation of D1 and D2 receptors 
and subsequent sensitization, which is known to induce dyskinesia. These abnormal 
involuntary movements occur in 75 % of patients after about 6 years of levodopa therapy. 
In addition, nigrostriatal degeneration is also presumed to be an essential condition for the 
appearance of dyskinesia under levodopa medication. Therefore, motor fluctuations appear 
to be an all or nothing process, independent of the administrated dose. Among these motor 
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disturbances are choreatic movements, which are an expression of involuntary rhythmic 
contractions of the skeletal muscles, rigidity, which is an enhancement of the tonic stretch 
reflex and akinesia and bradykinesia, which are lack of movement and slowness of 
movement,  respectively (Goole and Amighi, 2009). 
Besides dyskinesias, the sudden return of parkinsonian symptoms during asymptomatic 
episodes can be observed in the latest stages of the treatment. As PD evolves, the brain 
loses its ability to regulate dopamine function as both storage and release become 
impaired. Consequently, a long duration response to a single levodopa dose is gradually 
replaced by a shortening interval of effect and a need for more drugs. This “on–off” effect 
comprises an “on” state when the patient has a good response from levodopa and an “off” 
period characterized by a sudden loss of benefit when the plasma level of the drug falls. 
Usually, a wearing off phenomenon can be defined to be present when an adequate dosage 
of levodopa does not last at least 4 h. However, in the late stages of the disease, the 
duration of the “on” response becomes shorter (Goole and Amighi, 2009). 
Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the 
control of parkinsonism. Putative therapies to reduce the problem of dyskinesias could 
focus on the glutamatergic, GABAergic, α2 adrenergic, serotonergic (5HT1A, 5HT2A), 
opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid 
CB1 receptors systems. The only currently available drug with an evidence based 
recommendation on efficacy for dyskinesia is amantadine (Fabbrini et al., 2007).  
 
 
 
Figure 16: A lassic model of basal ganglia in a normal condition, and in Parkinsonian and dyskinetic 
conditions (Olanow et al., 2001). 
Slika 16: Klasični model bazalnih ganglijev v normalnih pogojih, pri parkisonovi bolezni in diskineziji 
(Olanow in sod., 2001). 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
37 
2.7.3 Non-DA neurons (e.g. 5-HT neurons)  
It is significant that 5-HT neurons and other types of neurons can accumulate L-DOPA. If 
this occurs, L-DOPA will be converted via DOPA decarboxylase to DA and thereby 
become a ‘false transmitter’ in the 5-HT or other type of neuron. Exogenously 
administered L-DOPA is shown to enter 5-HT neurons to undergo conversion to DA which 
will be stored in vesicles in 5-HT neurons. This is so, because the VMAT in vesicles in 5-
HT nerves is identical to the VMAT in vesicles in DA nerves. Accordingly, DA will 
displace some 5-HT, as indicated by reduced 5-HT content of striatal tissue following 
levodopa treatment of an animal model of PD (Kostrzewa et al., 2000).   
In phenotypically different neurons in which DA is unable to be stored, DA might simply 
diffuse out of the nerve, independent of nerve activity. 
Levodopa remains the most effective antiparkinsonian agent available to date. The major 
practical limitation to the use of L-DOPA is the risk of developing motor complications 
and considerable evidence suggests that these problems may be prevented or attenuated 
with the use of low doses and/or continuous delivery (Olanow, 2015).  
Pharmacologically, dopamine agonists and levodopa differ in the spectrum of effects that 
they produce and clinically of course, levodopa is superior to dopamine agonists in 
efficacy (Jenner, 2008). 
 
2.7.4 Dopamine receptor agonists 
Dopamine agonists are drugs that directly stimulate dopamine receptors. It has long been 
known that these drugs have antiparkinsonian efficacy (Koller, 2002). These drugs have 
theoretical advantages over levodopa in terms of not requiring enzymatic activation, 
having longer duration of actions and causing fewer adverse effects since they offer 
receptor selectivity unlike levodopa. These drugs are useful as the initial choice for 
dopaminergic therapy as they delay the need for levodopa therapy and are associated with 
lower incidence of motor fluctuations and dyskinesias. They are also useful as an add on 
therapy to levodopa in patients who develop motor complications and allow for a reduction 
in levodopa doses. Adverse effect profile of dopamine receptor agonists includes 
hallucinations, confusion, nausea, postural hypotension, somnolence and an increased 
incidence of impulse control disorders including pathological gambling, shopping, eating 
and hypersexuality (Kakkar and Dahiya, 2015; Wolters et al., 1995; Olanow, 2002; 
Katzenschlager and Lees, 2002; Lipski et al., 2011; Schwartz and Sabetay, 2012; Calabresi 
et al., 2010; Olanow et al., 2006).  
Dopamine agonists used in the treatments of PD have a longer half-life than levodopa. 
Assuming that plasma concentration predicts what occurs in the striatum, it is reasonable 
then to consider that a dopamine-like agent with a long plasma half-life will induce more 
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continuous stimulation of striatal dopamine receptors than a dopamine like agent with short 
plasma half-life. This might prevent adaptive changes that lead to the development of 
motor complications (Olanow et al., 2006).  
All dopamine agonists have proven successful in the early stages of Parkinson’s disease, 
but they are contraindicated in patients with cognitive impairment and psychiatric 
manifestations due to increased psychotoxicity (Schwartz and Sabetay, 2012).  
Agonists are currently in use: D2 receptor agonist alone or in combination with levodopa. 
Bromocriptine became the first approved oral dopamine agonist and adjuvant therapy with 
levodopa. The duration of efficacy of bromocriptine combined with levodopa is 
approximately 2 years.  The nonselective dopamine agonist apomorphine is also used in 
the management of resistant off periods. Dihydexidine was first reported in 1990 as a 
selective D1 agonist (Brewster et al., 1990; Lovenberg et al., 1989) and was subsequently 
shown to alleviate the symptoms of MPTP-induced parkinsonism in monkeys (Taylor et 
al., 1991). Although dihydrexidine has some affinity at D2 receptors (Ki=120 nM), its 
antiparkinsonian activity is not reversed when combined with D2 antagonist, suggesting 
that this effect is due to its D1 (Ki=12nM) receptor activity. Abbot also synthesized a 
selective D1 agonist A77636 which reverses PD symptoms in Parkinsonian marmosets 
(Kebabian et al., 1992). Blanchet (1993) compared the efficacy of D1 and D2 agonists in 
alleviating PD symptoms in MPTP – treated monkeys and reported that D1 agonists were 
as effective as D2 agonists and had fewer propensities to cause dyskinesias. These data 
support the hypothesis that the D1 receptor could play a crucial role in the treatment of PD. 
Rotigotine, mirapexine and ropinirol are in use.  
 
2.7.5 The other drugs 
The drugs also in use are selective monoamine oxidase B (MAO-B) retards the breakdown 
of dopamine in the striatum, thereby benefitting the PD patients, methyltransferase 
(COMT) inhibitors block peripheral degradation of levodopa leading to its increased half 
life and enhanced central bioavailability (Kakkar and Dahiya, 2015). With regard to non-
dopaminergic systems, some therapeutic approaches are still at the developmental level 
while others are in different stages of clinical trials; these include adenosine A2A 
antagonists (Shah and Hodgson, 2010), serotonin receptor agonists, and others (Schwartz 
and Sabetay, 2012). To support this is a fact that putative therapies to reduce the problem 
of dyskinesias could focus on the glutamatergic, GABAergic, α2 adrenergic, serotonergic 
(5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport 
or cannabinoid CB1 receptors systems (Fabbrini et al., 2007).  
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2.8 ANIMAL MODELS OF PARKINSON'S DISEASE 
Animal models are an essential tool to study human diseases, not only to enable a thorough 
investigation into the mechanisms involved in the pathogenesis of a disease but also to help 
in the development of therapeutic strategies. The discovery of profound dopamine 
depletion of basal ganglia in patients with Parkinson's disease and the development of 
antiparkinsonian drug therapy were largely based on animal models (Kaakkola and 
Teravainen, 1990).  
 
2.8.1  The reserpine model 
Systemic administration of reserpine depletes dopamine at the nerve terminals and induces 
a hypokinetic state in rodents. These movement deficits are due to loss of dopamine 
storage capacity in intracellular vesicles. Reserpine induced temporary changes and striatal 
reserpine administration does not induce morphologic changes in the dopamine neurons in 
supstantia nigra. Also, reserpine administration induces the release of other 
neurotransmitters that may not be directly implicated in PD. Nevertheless, this model has 
been used successfully to investigate the therapeutic effects of striatal dopamine 
replacement agents including L-DOPA and dopamine receptor agonists (Gossel et al., 
1995). The predictive value of symptomatic drug testing in the reserpine model is 
imperfect, however, since some drugs that reverse reserpine-induced. 
 
2.8.2  The 6-OHDA model 
6-Hydroxydopamine (6-OHDA) represents one of the most common neurotoxins used in 
degeneration models of central catecholaminergic projections, including the nigrostriatal 
system. Inside neurons, 6-OHDA accumulates in the cytosol and induces cell death without 
apoptotic characteristics (Schober, 2004). Systemically administered 6-OHDA is unable to 
cross the blood-brain barrier. Thus, 6-OHDA has to be injected stereotactically into the 
substantia nigra. Following 6-OHDA injections, dopaminergic neurons start degenerating 
within 24 hours, and striatal dopamine is depleted 2 to 3 days later. The magnitude of the 
lesion is dependent on the amount of 6-OHDA injected, the site of injection and inherent 
differences in sensitivity between animal species. Usually 6-OHDA is injected in one 
hemisphere while the other hemisphere serves as an internal control. This unilateral          
6-OHDA model is also known as the hemiparkinson model. 
 
2.9 ALTERNATIVE SPLICING 
Alternative splicing is highly abundant in brain relative to other, where it can influence 
neurophysiology through spatial and temporal alterations in proteins that comprise ion 
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channels and membrane bound receptors and are involved in neurotransmitter storage and 
release. In the nervous system, regulated alternative splicing allows the cell to ‘‘fine-tune’’ 
its protein composition in order to respond and adapt to different stimuli (Grabowski and 
Black, 2001; Licatalosi and Darnell, 2006).  
Alternative splicing generates much of the enormous diversity needed in the proteins 
involved in forming specific synaptic connections and mediating synaptic transmission 
(Grabowski and Black, 2001). Importantly, an alternative splicing event may be regulated 
differently in a cell type and developmental stage specific manner (Licatalosi and Darnell, 
2006). Disruption of normal splicing or splicing misregulation has been observed in a large 
number of diseases (Licatalosi and Darnell, 2006). 
Pre-mRNA splicing is necessitated by the split nature of eukaryotic genes, in which the 
exons that will make up the mRNA product are interrupted by non-coding introns in the 
DNA and in the initial pre-mRNA transcript. Intron removal, and the concomitant joining 
of exons, is orchestrated by the spliceosome — a macromolecular ribonucleoprotein 
complex that assembles on the pre-mRNA in a series of complexes (E, A, B and C). 
Complex assembly is guided by consensus sequences at the ends of the introns. Conserved 
alternative exons are often flanked by more conserved intronic sequences than constitutive 
exons, and this has been used as an independent predictor of alternative splicing (Matlin et 
al., 2005). Certain exons are present in all messenger RNAs transcribed from a specific 
gene (constitutive exons). Other exons are only present in a subset of messenger RNAs 
transcribed from a specific gene (alternative exons). Alternative exons often have 
suboptimal splice sites and/or a suboptimal length when compared with constitutive exons 
(Caceres and Kornblihtt, 2002). 
RNA splicing requires recognition of the nucleotide sequences at the boundaries of 
transcribed exons and introns (splice junctions). The nucleotides at the ends of introns are 
highly conserved: the vast majority of introns start with a GT (becoming GU in intronic 
RNA) and end with an AG (the GT-AG rule). 
Although the conserved GT and AG dinucleotides are crucial for splicing, they are not 
sufficient to mark the limits of an intron. The nucleotide sequences that are immediately 
adjacent to them are also quite highly conserved, constituting splice junction consensus 
sequences (splice donor site on GT and splice acceptor site on AG). A third conserved 
intronic sequence that is also important in splicing  is known as the branch site and is 
typically located no more than 40 nucleotides upstream of the introns 5’ terminal AG. 
Other exonic and intronic sequences can promote splicing (splice enhancer sequences) or 
inhibit it (splice silencer sequences), and mutation in these sequences can cause disease 
(Strachan and Read, 2011).  
Pre-mRNA splicing takes place within the spliceosome, a large molecular complex 
composed of four small nuclear ribonucleoproteins (U1, U2, U4/U6 and U5 snRNPs) and 
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approximately 100 non snRNP splicing factors (Chen and Manley, 2009; Xiao and Lee, 
2010; Graveley, 2001).  
Five small nuclear RNAs form the core of the spliceosome. During processing, the pre-
mRNA has extensive, specific interaction via base pairing with five small nuclear RNAs 
(U1, U2, U4, U5, and U6). Early in spliceosome assembly, U1 forms a base-pairing 
interaction with the 5′-splice site and U2 similarly base-pairs with the branch-point. Then a 
tri-snRNP complex containing U4, U5 and U6 associates with the forming spliceosome 
and U4 is removed from the complex. This allows U6 to replace U1 at the 5′ splice site and 
leads to a U6–U2 interaction that brings the 5′-splice site and the branch point close 
together, allowing for a transesterification step. By forming noncanonical interactions, U5 
brings the two exons into close proximity and allows for the second step of splicing, when 
the two exons are joints. This shows that small RNAs play a crucial role in splicing and 
there is increasing evidence that some of the RNAs also play a role in catalysis of the 
splicing reaction (Tazi et al., 2009). 
Proteins assembling on the pre-mRNA allow exon recognition by interaction with the core 
spliceosome. Since the information in splice sites is not sufficient for regulation, 
ribonuclear–protein complexes (RNPs) forming on the pre-mRNA help in the recognition 
of exons. The majority of splicing regulatory proteins in these complexes belongs to two 
major classes: hnRNPs and SR-proteins. HnRNPs are operationally defined as proteins 
binding to RNA. SR-proteins are characterized by serine and arginine-rich protein 
domain. These proteins contain RNA-binding and protein interaction domains. They bind 
with low specificity to accessible, mostly single-stranded parts of the pre-mRNA. To 
overcome the low RNA binding specificity, splicing regulatory proteins use their protein 
interaction domains to bind to each other. Another frequent strategy to overcome the low 
affinity between splicing factors and their recognition sequence is a repetitive arrangement 
of regulatory sequences (Tazi et al., 2009). 
As already said, splicing is carried out by the spliceosome, a massive structure in which 
five small nuclear ribonucleoprotein particles (snRNPs) and a large number of auxiliary 
proteins cooperate to accurately recognize the splice sites and catalyse the two steps of the 
splicing reaction. Spliceosome assembly begins with the recognition of the 5′ splice site by 
the snRNP U1 and the binding of splicing factor 1 (SF1) to the branch point and of the U2 
auxiliary factor (U2AF) heterodimer to the polypyrimidine tract and 3′ terminal AG 
(Fig.11). This assembly is ATP independent and results in the formation of the E complex, 
which is converted into the ATP-dependent, pre-spliceosomal A complex after the 
replacement of SF1 by the U2 snRNP at the branch point. Further recruitment of the 
U4/U6–U5 tri-snRNP complex leads to the formation of the B complex, which is 
converted into the catalytically active C complex after extensive conformational changes 
and remodeling i.e. U1 and U4 leave spliceosome. Splicing activators and repressors 
commonly function by influencing the formation of the E and A complexes early in 
spliceosome assembly (Matlin et al., 2005). 
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Figure 17:  Spliceosome and steps of alternative splicing  (Bessonov et al., 2008). 
Slika 17: Spajalno telasce in koraki alternativnega zlepljanja (Bessonov in sod., 2008). 
 
The spliceosome assembles onto each intron from a set of five small nuclear 
ribonucleoproteins (snRNPs U1, U2, U4–U6) and numerous accessory proteins that bind 
specifically to locations at or within the vicinity of the splice sites, and catalyzes the 
excision of the intron. While the 5’ (donor) and 3’ (acceptor) splice sites have well 
characterized consensus sequences that are recognized to play a major role in splicing, an 
increasing body of evidence reveals that previously unknown RNA elements located 
outside the splice signals, in exons and introns, contribute to the exon’s inclusion or 
exclusion in the mature mRNA, in a network of interactions that appear to be centered on 
exons, rather than introns. These cis-regulatory elements can promote (splicing enhancers) 
or repress (splicing silencers) the inclusion of the exon in the mRNA through the activity 
of the bound regulatory proteins, and can be located in the exons -exonic splicing 
enhancers (ESEs) and silencers (ESS), or introns-intronic splicing enhancers (ISE) and 
silencers (ISS). They can act from both within the proximity of the exon, or from  300–
1000 bp away. It is becoming increasingly evident that many exons, constitutive or 
alternative, and their surrounding introns harbor both silencing and enhancing elements, 
and that the exon’s inclusion/exclusion is the result of competition between the two effects 
(Florea, 2006). 
 
2.9.1 Mechanisms of splicing activation  
Exonic enhancers are the binding sites of splicing activator proteins, the most studied 
activators being the SR (Ser/Arg) factors. The SR proteins are characterized by the 
presence of 1–2 RNA recognition motifs (RRM), and a C-terminal RS-domain enriched in 
arginine and serine residues (Arg/Ser). An RS-domain independent mechanism has also 
been hypothesized, in which the splicing factor binds to an ESE to antagonize the effect of 
a neighboring silencer (Florea, 2006). 
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Figure 18:  Elementary alternative splicing events and regulatory elements.  In addition to the splice-site 
consensus sequences, a number of auxiliary elements can influence alternative splicing. These are 
categorized by their location and activity as exon splicing enhancers and silencers (ESEs and ESSs) and 
intron splicing enhancers and silencers (ISEs and ISSs). Enhancers can activate adjacent splice sites or 
antagonize silencers, whereas silencers can repress splice sites or enhancers. Exon inclusion or skipping is 
determined by the balance of these competing influences, which in turn might be determined by relative 
concentrations of the cognate RNA-binding activator and repressor proteins (Matlin  et al., 2005). 
Slika 18: Elementi alternativnega izrezovanja in njihova regulacija. Poleg osnovnih izrezovalnih zaporedij na 
alternativno izrezovanje vplivajo številna pomožna zaporedja. Ta se delijo glede na položaj in aktivnost kot 
eksonski ojačevalci (ESE) in utiševalci izrezovanja (ESS) ter intronski ojačevalci (ISE) in utiševalci 
izrezovanja (ISS). Ojačevalci lahko aktivirajo sosednja skupna izrezovalna mesta ali delujejo antagonistično 
na utiševalce, medtem ko lahko utiševalci zavirajo skupna izrezovalna mesta ali ojačevalce. Vključitev ali 
izključitev eksona je odvisna od ravnotežja med temi tekmujočimi si vplivi, ki so lahko določeni tudi z 
relativnimi koncentracijami aktivatorskih in represorskih RNA-vezivnih proteinov (Matlin in sod., 2005). 
 
2.9.2 Mechanisms of splicing repression 
Splicing silencers are thought to be binding sites of splicing repressor proteins. Splicing 
repression is effected largely through the activity of the hnRNP protein families. Of these, 
hnRNP I, also known as PTB, members of the hnRNP A/B families, are among the best 
characterized. Several mechanisms have been proposed for hnRNP-mediated silencing by 
interfering with the spliceosome assembly through cooperative binding of several 
inhibitory elements, by blocking neighboring ESEs, or by binding to duplicate intronic 
sequences on both sides of the exon to form a loop that renders the exon inaccessible to the 
spliceosome. Experimentally identified or validated ISS sequences were reviewed in 
(Florea, 2006). 
Alternative splicing is important for generating functional diversity in the molecules 
controlling neuronal activity. Alternative splicing is also central to the development of the 
nervous system, the differentiation of neurons and the formation of their connection 
patterns. Molecules important for neural development whose activity is controlled in this 
way include transcription factors, cell adhesion molecules, exon guidance receptors and 
proteins involved in programmed cell death. Alternative splicing mechanisms are 
extremely well suited to produce large numbers of subtly different protein functions.  
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2.10 NOVA 1 
Nova 1 is an important regulator of alternative splicing in the mammalian brain (Dredge et 
al., 2005). Nova 1 target genes are highly related in function. They were associated with 
the function of inhibitory synapses, postsynaptic and presynaptic structures, as well as 
signaling and protein synthesis, suggesting that a single splicing factor regulates isoform 
expression of different genes in inhibitory neurons. It is likely that other cell-type-specific 
splicing factors also control biologically coherent functions. Nova autoregulate its own 
expression by acting as a splicing repressor (Dredge et al., 2005).  
The dopamine D2 receptor (D2R) is present in vivo in two isoforms, D2L and D2S, 
generated from the same gene by alternative pre-mRNA splicing. Each isoform has a 
specific role in vivo, underlining the importance of a strict control of its synthesis, yet the 
molecular mechanism modulating alternative D2R pre-mRNA splicing has not been 
completely elucidated (Park et al., 2011). By a mechanism of alternative splicing, the D2 
receptor gene (DRD2) encodes two molecularly distinct isoforms, D2S and D2L. D2L 
differs from D2S by an additional 29 amino acids encoded by exon 6, inserted within the 
third cytoplasmic loop of the receptor, the region interacting with G proteins. This 
insertion likely accounts for a differential interaction of D2L and D2S with G proteins, 
activation of distinct downstream signaling pathways and function (Park et al., 2011). D2L 
acts mainly at postsynaptic sites and D2S serves presynaptic autoreceptor functions (Khan 
et al., 1998). The D2S isoform appears to be involved in regulation of prefronto-striatal 
synaptic plasticity associated with long-term potentiation, centrally implicated in the 
physiology of memory (Polydorides et al., 2000). 
Alternative D2R pre-mRNA splicing is controlled by two splicing regulators, hnRNPM 
and neuro-oncological ventral antigen-1 (Nova 1). hnRNPM recognizes specific elements 
within D2R exon 6, and it enhances exon 6 excision during alternative pre-mRNA splicing. 
In contrast, Nova 1 antagonizes this effect via direct binding to both exons 6 and hnRNP M 
(Fig.14). 
The identification and characterization of the factors binding to the cis-acting regulatory 
elements are important in unraveling mechanisms that modulate gene expression by 
affecting alternative pre-mRNA splicing. hnRNPM is  a member of a family of RNA-
binding proteins; it contains three RNA recognition motifs (RRMs). hnRNPs are known to 
be negative splicing regulators by directly antagonizing the recognition of splice sites or 
interfering with the binding of splicing regulators to splicing enhancer sequences (Park et 
al., 2011). 
HnRNPM directly binds to D2R exon 6 and inhibits its inclusion, thus favoring D2S 
mRNA production in a dose dependent manner. This observation is consistent with 
previous studies implicating hnRNP M as a negative regulator of alternative pre-mRNA 
splicing.  
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Figure 19:  Schematic model of the molecular regulatory mechanisms for the alternative pre-mRNA splicing 
of D2R by Nova 1 and hnRNP M. Nova 1 and hnRNPM regulate alternative D2R pre-mRNA splicing 
antagonistically. Both Nova-1 and hnRNP M specifically interact with D2R exon 6, but hnRNP M inhibits 
the binding of Nova 1 to D2R exon 6. Nova 1 antagonizes the exon 6 exclusion activity of hnRNP M and 
enhances exon 6 inclusion ( Park et al., 2011). 
Slika 19: Shematski model molekularno regulatornih mehanizmov alternativnega izrezovanja D2R z Nova 1 
in hnRNP M. Nova 1 in hnRNP M regulirata alternativno izrezovanje D2R pre-mRNA antagonistično. Nova 
1 in hnRNP M specifično interagirata z D2R eksonom 6, pri čemer hnRNP M zavira vezavo Nova 1 za D2R 
ekson 6. Nova 1 deluje antagonistično na  izključevanje eksona 6 posredovanega s hnRNP M ter tako 
povečuje vključevanje eksona 6 (Park in sod., 2011). 
 
Although hnRNP M enhances D2S mRNA production, D2L mRNA is dominant in most 
brain regions. Thus, positive splicing regulators certainly exist that enhance D2R exon 6 
inclusion during the D2R pre-mRNA splicing process. Recently, it was reported that 
PTBP1 (polypyrimidine tract-binding protein 1) enhances exon 6 inclusion (Sasabe et al., 
2011), but there is no evidence that it binds to pre-mRNA of D2R directly. 
Nova 1 directly binds to UCAU sequences within D2R exon 6 RNA (Fig. 13). Nova 1 is 
known as a splicing factor that regulates the inclusion or exclusion of exons depending on 
the position of Nova binding relative to splice sites (Ule et al., 2006). When Nova binds to 
the 3’-region of the cassette exon, it promotes inclusion of this exon (Ule et al., 2006). 
Consistent with this, overexpression of Nova 1 dose-dependently increases D2R exon 6 
inclusion likely by blocking hnRNPM function (Fig.13). The antagonistic action of Nova 1 
is very likely mediated by its binding to D2R exon 6. Thus two splicing proteins were 
identified that, by interacting with each other, contribute to the regulation of alternative 
D2R pre-mRNA splicing. 
Several possible mechanisms might be evoked to explain how D2R pre-mRNA splicing 
can be regulated by an antagonistic interaction between hnRNPM and Nova 1 (Park et al., 
2011), suggesting that hnRNP M and Nova 1 may bind to adjacent sequence within exon 6, 
rather than competing for the same site. 
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They favor the possibility that, by binding to exon 6, Nova 1 blocks the binding of hnRNP 
M to it. Indeed, disruption of Nova 1 binding to exon 6 decreases the inhibitory effect on 
hnRNPM activity during D2R pre-mRNA splicing. Nova 1 protein abolishes hnRNP M 
function and enhances D2L mRNA expression via RNA independent interaction with 
hnRNP M and/or specific binding to D2R RNA 
Studies performed in vitro and most importantly on genetically engineered animals have 
shown that D2L and D2S signaling differentially affects physiological responses, and 
therefore, these isoforms do not have redundant functions. An altered D2S/D2L ratio has 
recently been found in schizophrenic patients (Bertolino et al., 2009) and importantly, most 
antipsychotics have D2R as a major target. Thus, control of alternative D2R pre-mRNA 
splicing might have major consequences on dopamine-mediated responses. However, the 
molecular regulatory mechanism of alternative D2R pre-mRNA splicing is not fully 
elucidated. 
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3 MATERIALS AND METHODS 
 
3.1  ANIMALS 
A total of 150 adult male Wistar rats of 270-300 g initial body weight were used in all 
experiments. The Wistar rats were obtained from the Medical Experimental Center (MEC, 
Ljubljana). The animals were allowed two weeks of adaptation to laboratory conditions 
before being used in experiments. The rats were housed four per cage under constant 
temperature and humidity, under 12 h light/dark cycles (on 8 am - off 8 pm). Food and 
water were continuously available ad libitum in home cages. The experiments were 
performed between 8 am and 2 pm.   
The animals were handled according to the NIH Guide for the Care and Use of Laboratory 
Animals. All experimental procedures were approved by the Veterinary Administration of 
the Republic of Slovenia (34401-53/2012/7). 
 
3.2  THE MOST IMPORTANT CHEMICALS AND THEIR SOLUTIONS 
  
3.2.1 Chemicals used in behavioral experiments 
 
 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8β-aminomethylergoline 
bimaleate – dopamine D2 receptor antagonist and dopamine D1 agonist (LEK-8829; 
LEK, Ljubljana, Slovenia), was calculated as the free base and dissolved in 0.9 % 
saline.  
 haloperidol – dopamine D2 receptor antagonist (Haldol ampoules, 5 mg/ml; Krka-
Jenssen, Novo Mesto, Slovenia) was dissolved in 0.9% saline.  
 R-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-
benzazepine hydrochloride – dopamine D1 receptor antagonist (SCH-23390; RBI, 
Natick, MA, USA) was dissolved in 0.9 % saline.  
 2-Br-α-ergocryptine mesylate – dopamine D2 receptor agonist (bromoergocriptine; 
LEK, Ljubljana, Slovenia), was dissolved in dimethyl sulfoxide (DMSO) (Sigma 
Aldrich, Germany), with the final solution being made up with 0.9 % saline and DMSO 
(2:1).  
 3,4,5-trimethoxybenzoyl methyl reserpate – dopamine depletion (reserpine RBI, 
Natick, MA, USA) was dissolved in DMSO(Sigma Aldrich, Germany) and propylene 
glycol (1:1) (Kertus ABEE, Greece).  
 d-amphetamine sulphate – indirect dopamine receptors agonist (amphetamine RBI, 
Natick, MA, USA) was dissolved in 0.9 % saline.     
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3.3 PREPARATION AND ADMINISTRATION OF THE SUBSTANCE 
Solutions of the test compounds were prepared immediately before behavioral 
experiments. All the solutions were stored in dark bottles because some solutions are photo 
labile. Volume of the solution of the test compound has been 2 ml/kg body weight due to 
greater accuracy of injection. All the test compounds were administered subcutaneously 
(s.c.) in the dorsal area of the neck.  These doses are deemed to substance with an additive 
salts with the exception of LEK-8829 which indicated doses apply to a free base. 
 
3.4 BEHAVIORAL TEST PROCEDURES 
 
3.4.1 Catalepsy test 
Catalepsy test was performed using the method described by Krisch (Krisch et al., 1994). 
Catalepsy was assessed by the placement of the front limbs of the rats over a horizontal bar 
(a bar is elevated 11cm above the floor). Catalepsy was scored every 20 min for 260 min. 
The scoring started 20 min after the s.c. injection of the test compounds (LEK-8829 and 
haloperidol, 2 mg/kg and 0.2mg/kg respectively). The score was assigned on the basis of 
the duration of the cataleptic posture (until one forepaw touched the floor or the hind legs 
left the floor to climb onto the bar) as follows: score 1 - between 15 and 29 sec; score 2 -
between 30 and 59 sec; and score 30 - 60 sec or more.  
 
3.4.2 Spontaneous locomotor activity 
Locomotor activity was measured in individual boxes 60cm x 40cm. Spontaneous 
locomotor activity was measured as distance moved for 20 min immediately after rats were 
placed in the boxes. These conditions produce high base-line levels of activity. Locomotor 
activity for individual rats was measured as distance moved in 20 min period using the 
video tracking system for automation of behavior experiments Noldus Ethovision Pro 
Version 3.0. 
 
3.4.3 Amphetamine-induced locomotor activity 
Rats were given s.c. injections of saline. After 20 min (spontaneous locomotor activity) 
they were given an injection of amphetamine (2 mg/kg). Locomotor activity for individual 
rats was measured as distance moved in the 120 min period using video tracking system 
for automation of behavior experiments Noldus Ethovision Pro Version 3.0.  
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3.4.4 Inhibition of amphetamine - induced locomotion with test compounds 
Rats were given s.c. injections of test compounds (LEK-8829 and haloperidol 2 mg/kg and 
0.2 mg/kg, respectively). After 20 min (spontaneous locomotor activity) they were given 
an injection of amphetamine (2 mg/kg). Locomotor activity for individual rats was 
measured as distance moved in the 120 min period using video tracking system for 
automation of behavior experiments Noldus Ethovision Pro Version 3.0. 
 
3.4.5 Locomotor activity of reserpinized rats  
Animals were treated three times, once in three days, with reserpine and every day twice a 
day (on 8 am and on 8 pm) with test compounds. The animals were recorded for 120 min 
after morning injections for nine days. 
 
3.5 RECORDING WALKING TRIALS WITH VIDEO TRACKING SYSTEM 
 
3.5.1 Noldus EthoVision 
Noldus Ethovision Pro Version 3.0 (Noldus Information Technology, Wageningen, 
Netherlands)  is an automated video tracking, motion analysis and behavior recognition 
system. It offers a wide range of video tracking options, extensive analysis of locomotory 
tracks and automatic behavior recognition.  
An automated system in which a computer processes data originating from a video camera 
or a digital video file is referred to as a computer vision or imaging system. The technique 
by which an analog video image is translated into digital information, from which features 
are extracted and parameters are derived is called digital image processing. A video 
tracking system is special kind of computer vision system, designed to process moving 
video images.  
 
3.5.2 Recording of walking trials     
A video camera was deployed above individual boxes (60cm x 40cm) and four boxes were 
in the field of vision. The image from the video camera was recorded by VCR and later the 
images from the VCR were sent to the frame grabber in computer. The frame grabber is 
plug-in computer board, also called a digitizer or acquisition card, which forms the heart of 
a digital image processing system.   
One video image from VCR is called a frame. The number of frames scanned in each 
second is called the frame rate. The frame rate differs according to which TV standard 
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camera uses. The American standard is 30 frames per second and the European standard is 
25 frames per second. Sample rate is the sampling of a digitized video image or digital 
video file by an application program. The sample rate is the number of video images that is 
sampled per unit of time. I used the sample rate of 5 samples per second which was also 
recommended for rats in Noldus EthoVision manual.  
I defined arenas which were the individual boxes 60cm x 40cm. An arena is an area within 
which one independent set of observations takes place. When arena module starts for the 
first time, EthoVision takes the image it gets from a camera or video recorder at the 
moment as the background image. The background is defined as everything in a scene 
which is not part of the object being tracked. After arenas were defined I did the calibration 
method because EthoVision measures the distance between two points in pixels. To 
convert these in real values (meters, inches) EthoVision must be calibrated.  
The second thing that EthoVision has to do is to distinguish between the object being 
tracked and the background. Object size – the number of pixels composing the object. The 
object must be at least three pixels wide so that Ethovision can distinguish it from system 
noise. My objects were ten pixels wide. Object position – the x, y coordinates of the point 
mathematically in the center of the object (referred to as its center of gravity).   
EthoVision prompts you to put the animals in the arenas and when you click OK the trial 
starts. Trial is one run of experimental data. During the trial each of the arenas being 
measured are recorded as a separate track file. The track file is one independent data set 
recorded from one arena during one trial. The data are from a series of tracks, each track 
being the x, y coordinates and the surface area of one object. 
 
3.6 ANALYZING DATA 
Each video frame of my moving animals converts into a series of numbers representing the 
x, y coordinates and the size of the animal. In order to make sense of this raw data 
EthoVison produces a series of parameters describing the behavior of the animal. These 
include simple calculations such as the speed, distance moved and direction of the object 
track, more complex parameters such the meander of the animal’s track, parameters 
describing the interaction of pairs of objects and manually score behaviors like sniffing, 
aggression, sleeping, rearing. EthoVision produces an analysis report.  
 
3.7 CATALEPSY TEST 
3.7.1 Experiment 1 
Six groups of eight animals were used. The animals (n= 48) were treated once daily for 21 
days. First group were treated with 0.9 % saline. Second and third groups were treated with 
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LEK-8829 2 mg/kg and 0.2 mg/kg respectively. Fourth group were treated with 0.9 % 
saline. Fifth and sixth group were treated with haloperidol 2mg/kg and 0.2 mg/kg 
respectively. The catalepsy response of second, third, fifth and sixth group were measured 
on day 1 and day 21 of the experiment. On all other days the animals were put back into 
home cages after drug injection.  
All animals were without test compounds, seven days after the last injection and catalepsy 
test. On 29
th
 day of experiment the first group was divided and n= 4 injected saline; n= 4 
injected LEK-8829 2 mg/kg. The second group was divided n= 4 injected saline; n= 4 
injected LEK-8829 2 mg/kg. The third group was divided n= 4 injected saline; n= 4 
injected LEK-8829 0.2 mg/kg. The fourth group was divided n= 4 injected saline; n= 4 
injected haloperidol 2 mg/kg. The fifth group was divided n= 4 injected saline; n= 4 
injected haloperidol 2 mg/kg. The sixth group was divided n= 4 injected saline; n= 4 
injected haloperidol 0.2 mg/kg. Animals were euthanized 45 min after injection.  
 
Table 1: Test compounds and doses according to groups. Treatment protocol. 
Preglednica 1: Testne spojine in odmerki po skupinah. Protokol obravnavanja. 
Saline LEK-8829 Saline haloperidol 
 2 mg/kg 0.2 mg/kg  2 mg/kg 0.2 mg/kg 
n=8 n=8 n=8 n=8 n=8 n=8 
1st group 2nd group 3rd group 4th group 5th group 6th group 
29th day of experiment. All groups were shared (n=4) and given the injections. 
saline 
LEK 
2mg/kg 
Saline  
LEK 
2mg/kg 
Saline 
LEK 
0.2mg/kg 
Saline 
hal 
2mg/kg 
Saline 
hal 
2mg/kg 
Saline 
hal 
0.2mg/kg 
Euthanized 45 min after injection. 
 
3.7.2 Experiment 2 
Three groups of six animals were used. The animals (n= 18) were treated once daily for 21 
days. First group were treated with 0.9 % saline. Second group were treated with LEK-
8829 2 mg/kg. Third group were treated with haloperidol 0.2 mg/kg. The catalepsy 
responses were tested on day 1 and day 28 of the experiment. Seven days after the last 
injection we did the catalepsy test so between day 21 and day 28 the rats no received drug 
treatment. On all other days the animals were put back into home cages after drug 
injection. On 28
th
 day after injection of test compounds I performed the catalepsy test and 
animals were euthanized 8 h after the injection of test compounds.  
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Table 2: Test compounds and doses according to groups. 
Preglednica 2: Testne spojine in odmerki po skupinah. 
Saline LEK-8829 haloperidol 
 2 mg/kg 0.2 mg/kg 
n=6 n=6 n=6 
1st group 2nd group 3rd group 
 
3.8 STATISTICAL ANAYSIS 
Data were analyzed using the SPSS computer program (SPSS 19.0 for Windows, Chicago, 
Illinois, USA).  
The statistical significance between catalepsy scores was compared by using non-
parametric statistical analysis. The Mann-Whitney U Test was used to test for the 
differences between LEK-8829 2mg/kg and haloperidol 0.2mg/kg on the first day.  The 
Wilcoxon Signed Rank Test was used to test LEK-8829 2mg/kg and haloperidol 2 mg/kg, 
0.2 mg/kg on the first and on the last day of the treatment.  
 
3.9 AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY 
 
3.9.1 Experiment 3 
Six groups of eight animals were used. The animals (n= 48) were treated once daily for 21 
days. First group were treated with 0.9 % saline. Second and third group were treated with 
LEK-8829 2 mg/kg and 0.2 mg/kg respectively. Fourth group were treated with 0.9 % 
saline. Fifth and sixth group were treated with haloperidol 2mg/kg and 0.2 mg/kg 
respectively. 
On the first day of the experiment, the catalepsy test was performed 2 h following the 
injection of the test compounds. That was the 1
st
 test. Two days after 1
st
 test I performed 
the amphetamine-induced locomotion test (4
th
 day of experiment). That was the 2
nd
 test. 
Two days after 2
nd
 test I performed another test, inhibition of amphetamine - induced 
locomotion with test compounds (7
th
 day of experiment). That was the 3
rd
 test. 
The day after 3
rd
 test a 21-day long treatment with test compounds was started. On the last 
day of the treatment, 2 h after injection I did the catalepsy test – the 1st test (28th day of 
experimenting). Two days after 1
st
 test, I performed the amphetamine-induced locomotion 
test (31
th
 day of experiment). That was the 2
nd
 test after subchronic treatment. Two days 
after 2
nd
 test, I performed the test of inhibition of amphetamine - induced locomotion with 
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test compounds (34
th
 day of experiment). That was the 3
rd
 test after subchronic treatment. 
The animals were euthanized 8 h after injection of the test compounds.  
Table 3: Test compounds and doses according to groups. Groups were treated daily for 21 day. 
Preglednica 3: Testne spojine in odmerki po skupinah. Skupine so bile zdravljene 21 dni. 
Saline LEK-8829 Saline haloperidol 
 2 mg/kg 0.2 mg/kg  2 mg/kg 0.2 mg/kg 
n=8 n=8 n=8 n=8 n=8 n=8 
1st group 2nd group 3rd group 4th group 5th group 6th group 
 
Table 4: 1
st
 test performed before and after 21 day treatment. 
Preglednica 4: Prvi test narejen pred in po 21. dnevnem zdravljenju. 
1 TEST 
Catalepsy test, 2 h after injection 
Saline LEK-8829 Saline haloperidol 
 2 mg/kg 0.2 mg/kg  2 mg/kg 0.2 mg/kg 
1st group 2nd  group 3rd group 4th group 5th group 6th group 
 
Table 5: 2nd test performed before and after 21 day treatment. 
Preglednica 5: Drugi test narejen pred in po 21. dnevnem zdravljenju. 
2 TEST 
Amphetamine-induced locomotion 
Injection of saline. 20 minuts after that injection of ampetamine (2 mg/kg) 
1st group 2nd  group 3rd group 4th group 5th group 6th group 
 
Table 6: 3rd test performed before and after 21 day treatment.  
Preglednica 6: Tretji test narejen pred in po 21. dnevnem zdravljenju. 
 
3 TEST 
Inhibition of amphetamine - induced locomotion with test compounds 
Injection of test compounds. 20 minuts after that injection of ampetamine (2 mg/kg) 
Saline + 
amphetamine 
(2mg/kg) 
LEK-8829 
(2mg/kg) + 
amphetamine 
(2mg/kg) 
LEK-8829 
(0.2mg/kg)+ 
amphetamine 
(2mg/kg) 
Saline + 
amphetamine 
(2mg/kg) 
haloperidol 
(2mg/kg) + 
amphetamine 
(2mg/kg) 
haloperidol 
(0.2mg/kg)+ 
amphetamine 
(2mg/kg) 
1st group 2nd  group 3rd group 4th group 5th group 6th group 
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3.10 STATISTICAL ANAYSIS 
 
Data were analyzed using the SPSS computer program (SPSS 19.0 for Windows, Chicago, 
Illinois, USA).  
A paired Student t-test was used for the analysis of statistical significances between 
distance moved parameter on the first day and on the last day of the treatment for saline, 
LEK-8829 and haloperidol 2mg/kg and 0.2mg/kg. To evaluate if there was a significant 
difference in the effects of different treatments between different groups on the first day of 
the treatment was evaluated using one-way ANOVA followed with Scheffe’s multiple 
comparison test. Statistical significance was set at p≤ 0.05 in all statistical analyses. 
 
3.11 RESERPINE MODEL 
 
3.11.1 Experiment 4 
Five groups of animals were used. The animals (n= 36) were treated three times, once in 
three days day with reserpine and twice a day for 9 days with test compounds.  
First group of twelve animals (n= 12) was treated three times, once in three days, with 
reserpine 10 mg/kg (1
st
, 4
th 
and 7
th
 day of the experiment) and every day twice a day (at 8 
am and at 8 pm) with saline. After the last reserpine injection the animals were treated two 
more days with saline (8
th
 and 9
th
 day of the experiment). For nine days I was recording 
animals for 120 min after the morning injection. Next two days animals were without 
saline (10
th
 and 11
th
 day of the experiment). I performed the catalepsy test the day after 
(12
th
 day of experiment). On the 13
th
 day of the experiment I divided the first group into 
four groups of three animals (n= 3). Three animals got saline, three animals got LEK-8829 
2mg/kg, three animals got bromoergocriptine 2 mg/kg and three animals got LEK-8829 2 
mg/kg + SCH 23390 1 mg/kg. Locomotor activity for individual rats was measured as 
distance moved in a 240-min period using the video tracking system. The animals were 
euthanized 4 h after injection of the test compounds.  
Second, third, fourth, fifth and sixth group consisted of six animals (n=6). I treated them 
three times, once in three days with reserpine 10 mg/kg (1
st
, 4
th 
and 7
th
 day of the 
experiment) and every day twice a day (at 8 am and at 8 pm) with LEK-8829 2 mg/kg and 
0.2 mg/kg (2
nd
 and 3
rd
 group) bromoergocriptine 2 mg/kg (4
th 
group) and LEK-8829 2 
mg/kg + SCH 23390 1 mg/kg (5
th
 group) (injection of LEK-8829 2 mg/kg  and after 20min 
injection of SCH 23390 1 mg/kg). After the last reserpine injection the animals were 
treated for two more days with the test compounds, respectively (8
th
 and 9
th
 day of 
experiment). For nine days I was recording animals for 120 min after the morning 
injection. Next two days animals were without the test compounds (10
th
 and 11
th
 day of the 
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experiment). I performed the catalepsy test the day after (12
th
 day of the experiment). The 
13
th
 day of the experiment I divided all groups into two groups of three animals (n= 3). 
Three animals got LEK-8829 2mg/kg, three animals got bromoergocriptine 2 mg/kg 
Locomotor activity for individual rats was measured as distance moved in a 240-min 
period using the video tracking system. The animals were euthanized 4 h after injection of 
the test compounds. 
 
Table 7: Groups according to test compounds and doses. Protocol of the treatment. 
Preglednica 7: Testne spojine in odmerki po skupinah. Protokol obravnavanja. 
Saline LEK-8829 bromocriptine 
LEK-8829 + SCH 
23390 
 2 mg/kg 0.2 mg/kg 2 mg/kg 2 mg/kg 1 mg/kg 
n=12 n=6 n=6 n=6 n=6 
1st group 2nd group 3rd group 4th group 5th group 
13th day of experiment. All groups were divided (n=3) and given the injections. 
saline 
LEK 
2mg/kg 
LEK 
2mg/kg 
BrEKT          
2 
mg/kg 
LEK 
2mg/kg 
BrEKT          
2mg/kg 
LEK 
2mg/kg 
BrEKT          
2 
mg/kg 
LEK 
2mg/kg 
BrEKT          
2 mg/kg 
BrEKT          
2mg/kg 
LEK 
2mg/kg 
+SCH 
1mg/kg 
 
Euthanized 4h after injection. 
 
3.12 STATISTICAL ANAYSIS 
Data were analyzed using the SPSS computer program (SPSS 19.0 for Windows, Chicago, 
Illinois, USA).  
One-way ANOVA followed by Scheffe’s multiple-comparison test was conducted to 
evaluate if there was a significant difference in the effects of different treatments between 
different groups 1
st
 to 13
th
 day. Statistical significance was set at p≤ 0.05 in all statistical 
analyses. 
 
3.13 PREPARATION OF BRAIN SLICES 
Animals were put to sleep with CO2. The brains were rapidly removed and quickly frozen 
on dry ice. Then they were wrapped in parafilm to prevent desiccation and transferred to a 
-80°C freezer until sections could be cut in a cryostat. The brains were transferred to a 
cryostat (Leica, Biosystems) and allowed to equilibrate to -20°C before cutting. Sections 
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were cut through the striatum (the area between the 1.7 mm and -2.6 mm distance from  
bregma) and substantia nigra (the area between the -4.8 and 5.8 mm distance from  
bregma), and then thaw-mounted onto poly-L-lysine coated slices (10 µm) and thaw-
mounted onto parafilm (30µm), thoroughly air dried. Slices were prepared by soaking in 
the 0.01% poly-L-lysine (Sigma Aldrich, Germany) solution.  
 
3.14 WESTERN BLOT 
 
3.14.1 Sample preparation 
Five striatum (left and right) were sliced from parafilm with scalpel or needle (cut in a 
cryostat on -20°C) and mixed with 100 µl lysis buffer (Sigma Cellysis buffer) and 2 µl 
protease inhibitor cocktail (1:50, Sigma Aldrich, Germany). Protease inhibitors must be 
included in lysis buffers to prevent degradation of proteins following the release of 
endogenous proteases during the process of cell lysis. Samples were on ice for 30 min with 
occasionally vortexing. For 15 min on 4°C and 10.000g, samples were centrifuged. 
Supernatant was taken in another tube and heated for 5 min on 95°C.  
 
3.14.2 Determination of total protein concentration 
When comparing the amount of protein from samples run in different lanes within the 
same gel or between gels, it is very important that the lanes have been loaded with same 
total amount of protein.  
Several spectrophotometric methods are routinely used to determine the concentration of 
protein in solution. These include measurement of the intrinsic ultraviolet (UV) absorbance 
of the protein as well as methods based on a protein-dependent color changes, such as the 
classic copper-based Lowry assay, the Smith copper/bicinchoninic assay (BCA) and the 
Bradford dye assay. Although widely used, none of these procedures are particularly 
convenient.  
The Bradford dye assay (Bradford, 1976) was used which is based on the equilibrium 
between three forms of Coomassie Blue G dye. Under strongly acidic conditions, the dye is 
most stable in its double protonated form (red). Upon binding to protein, however, it is 
most stable in an unprotinated form (blue).  
BSA standard (TermoScientific, Rockford, Illinois, USA) was prepared from 1,5mg/ml – 
0,125mg/ml and blank. In 96 well I pipette 250 µl  Bradford (Sigma Aldrich, Germany) 
reagent and 5 µl standards and samples. After incubation of 10 min absorbance was read 
on 595 nm in Gene 5 program (Epoch, Biotec, Luzer, Switzerland). From the measured 
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absorbance of sample the concentration of protein was determined with extrapolating from 
calibration curve of standard (the absorbance of known concentration of BSA solutions). 
 
3.14.3 Gel electrophoresis 
XCell SureLock Mini-Cell (Invitrogen) system was used for electrophoresis by 
manufacture’s instruction. 
Electrophoresis is a commonly used method for separating proteins on the basis of size, 
shape and/or charge. Separation is based on the mobility of charged molecules in an 
electric field.  
 Sample preparation: an appropriate amount of sample, 2,5 µl NuPage LDS Sample 
Buffer (4X) (Invitrogen), 1 µl NuPage Reducing agent (10X) and supplemented with 
an appropriate amount of deionized water to 10 µl. Reducing agent breaks any inter- 
and intra—chain disulfide bonds, linearizing polypeptides and disrupting quaternary 
and tertiary protein structures. Everything was done on ice. Prepared samples were 
heated on 95°C for 10 min for disrupting of secondary protein structures. After short 
spin samples were ready for loading to gel. 
 Electrophoresis preparation: gel was placed to the electrophoresis and Running buffer 
(20X MEPS Running buffer, Invitrogen) 200 ml were added to upper chamber with 
500 µl NuPage antioxidant. Lower chamber were filled with Running buffer 600 ml.  
Gel was bought (NuPage 10% bis tris gel 1 mm, Invitrogen). Polyacrylamide gels are inert, 
crosslinked structures. The pore sizes in these gels are similar to the molecular radius of 
many proteins. Polyacrylamide is a thermostabile, transparent, strong and relatively 
chemically inert. Its versatility, however, lies in the fact that it can be prepare with a wide 
range of pore sizes. The pore size of a gel can be controlled by the user and is determined 
by the concentrations of both acrylamide monomer and bisacrylamide crosslinker. 10% bis 
tris gel in combination with MEPS Running buffer allows a greater distance between 40 
kDa and 50 kDa where it was expected bands.  
Comb was removed and wells were rinsed out with running buffer. Empty wells were 
loaded with 10 µl samples and 7 µl Spectra multicolor high range (Thermo scientific) 
molecular weight markers. Molecular weight markers are used to define the size of 
proteins run in a gel. Gel was run under 180 mV and 120 mA for 90 min.  
 
3.14.4 Transfer 
XCell Blot module (Invitrogen) was used for transfer manufacture’s instruction. Gel, 
membrane, sponge and filter paper were fully immersed in the transfer buffer (NuPage 
Transfer buffer, Invitrogen) before making a sandwich and a current was applied in the 
direction of the gel to the membrane. The sandwich consisted of two sponges, lower filter 
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paper, gel, membrane, upper filter paper, two sponges. Nitrocellulose membrane (0,45µm, 
Invitrogen) was used because I had low background. The binding capacity of a membrane 
depends primarily on the pore size. The sandwich in XCell Blot module was immersed in 
the transfer buffer and put to the electrophoresis (XCell SureLock Mini-Cell). Lower 
chambers of electrophoresis were filled with 650 ml deionized cold water. The transfer was 
run under 30V and 220 mA for 90 min.      
After electrotransfer it may be necessary to confirm that all the proteins in the gel have 
been completely eluted. This can be achieved by staining the gel. The membrane was 
washed for 5 min in deionized water after electrotransfer and rinsed for 5 min in Ponceau S 
(Sigma Aldrich, Germany) staining for verification of the protein transfer. Ponceau S was 
washed 3 times per 5 min in deionized water.  
Block the membrane in blocking solution for 45 min at the room temperature. As non-
specific binding of antibodies to the membrane is detrimental to the specificity and 
sensitivity of the assay, it is essential to "block" spaces not already occupied by proteins.  
 
3.14.5 Antibody probing 
Once protein samples are separated and transferred onto a membrane, the protein of 
interest is detected and localized using a specific antibody. Usually, Western blotting 
protocols utilize a non-labeled primary antibody directed against the target protein and a 
species-specific, labeled secondary antibody directed against the constant region of the 
primary antibody. The secondary antibody serves not only as a carrier of the label but is 
also a mechanism to amplify the emitted signals. 
Membrane was incubated with primary antibody D2 receptor made in mouse 1:500   (Santa 
Cruiz, sc 5303) and GAPHD made in rabbit 1: 5000 (Santa Cruiz, sc 25778) 1h at room 
temperature and overnight at 4°C. Wash the membrane 3 times for 5min with Antibody 
wash (Western Breeze kit, Invitrogen) and 5min with deionized water. Incubate membrane 
with secondary antibody anti-rabbit with alkaline phosphatase (AP) conjugated 
(WesternBreeze kit, Invitrogen) for 45 min. Wash the membrane 3 times for 5min with 
Antibody wash (WesternBreeze kit, Invitrogen) and 5min with deionized water. Membrane 
was put on plastic bag and it was incubate 5 min with 1 ml Chemiluminescent substrate 
and 0,052 ml Chemiluminescent substrate enhancer. Membrane was covered with another 
clean transparency plastic to prepare a membrane sandwich for luminography. Expose an 
X-ray film (CP-BU x-ray film, Agfa, HeltCare NV, Mortsel, Belgium) to the membrane 
sandwich from several second to several minutes. Films were developed with developing 
machine (Curix 60, Agfa-Gevaert, Kista, Sweden).   
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3.15  IN SITU HYBRIDIZATION 
In situ hybridization is technique used to detect mRNA, using a labeled nucleic acid probe 
of complementary sequence. In situ hybridization was performed by method develop in 
(Sirinathsinghji et al., 1994) laboratory. Synthetic oligonucleotide, 45 nucleotides long (45-
mers) probes were used. Each oligonucleotide was designed to have CG content 50-60 %. 
Oligonucleotides with large numbers of AT residues will be less stable in forming 
DNA/RNA hybrids. However, if GC content is too high (> 65 %), this may cause non-
specific binding since the thermal stability of the probes will be much greater (Wisden et 
al., 1991). 
All solutions used prior to and during the hybridization step must be sterile and free of 
contaminating ribonucleases. Solutions were sterilized by treating with 
diethylprocarbonate (DEPC) 0.01 %. Gloves were worn at all stages prior to hybridization 
to avoid contaminating samples with human ribonuclease. After the hybridization step non-
sterile conditions may be used. 
 
3.15.1 Labeling of probes 
Probes were labeled with addition of multiple residues of 5’-[α-35S]dAMP to the 3’ end of 
the molecule. In centrifuge tube it was pipetted a: 2,5 µl  tailing buffer (5x Terminal 
Transferase Buffer, Promega); 1 µl oligonucleotide DNA probe (5ng/µl); 7 µl DEPC 
treated water; 1 µl 
35S (5’-[α-35S]dAMP, 1250 Ci/mmol, Promega) 1 µl terminal 
deoxynucleotide transferase (20 U/µl, Promega). Mix gently by pipetting up and down. 
Incubate at 37°C for 1h. Reaction was stopped by adding 40 µl DEPC treated water.  
Unincorporated nucleotides were separated from labeled probe by a spin column procedure 
using Sephadex G-50. Pipette the 50 µl of probe solution to the top of the pre-spin column 
and spin at 2000 r.p.m. for 2 minute and collecting the 50 µl probes in a sterile centrifuge 
tube. To eluate were added 2 µl 1M DTT to prevent cross-linking of sulphur residues. 
Probes were ready to use.   
Scintillation solution and 2 µl of probe were transferred into scintillation vials for 
counting. Scintillation counter (LS 6500 Scintillation system, Beckman). The specific 
activities of the labeled probes ranged from 0.05-0.2 x10
6
 cpm/ µl. A labeled probe was 
used immediately or stored at 4°C. 
 
3.15.2 Fixation of slices     
Slices thaw-mounted onto poly-L-lysine (Sigma Aldrich, Germany) coated slides were 
fixed for 5 min in 4 % phosphate-buffered paraformaldehyde. After that they were rinsed 
in phosphate-buffered saline (PBS) three changes of 2 min each and dehydrated for 5 min 
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in 70 % ethanol then 30 min in 100 % ethanol. Fixed slices were used immediately or 
stored in100 % ethanol at 4 °C. 
 
3.15.3 Hybridization of labeled probes on slices 
Labeled probes were diluted in hybridization buffers. It was used 1 µl of probe (from the 
50 µl eluate from spin column) per 100 µl hybridization buffer. The probe was used at a 
concentration of 1pg/ µl. A quantity of 20µl of 1M DTT per 100 µl of hybridization buffer 
was added. Mixture was well vortex.  
Sections were removed from 100 % ethanol and air-dried for 15-30 min. Hybridization 
buffers were applied to each slide covered with strip of parafilm and incubated in 
humidified containers at 42°C overnight. 
Next day the cover slips were removed individually from the sections by immersing each 
slide in 1 x SSC. The racks of sections were transferred to a pre-warmed solution of 1 x 
SSC at 55°C in a gently agitating water bath for 1 h. After that, the racks were transferred 
through very brief (couple of seconds) series of rinse in 1xSSC, 0.1xSSC, 70 % ethanol 
and 100 % ethanol. The sections were allowed to air-dry. Dry sections were exposed to X-
ray film (Kodak BioMax MR-1, Kodak). 
 
3.15.4 Developing of x-ray film 
After completing the exposition, the x-ray films were developed in the dark room. Firstly, 
the film was immersed in developer (Kodak GBX developer, Kodak) for 5 min, then very 
briefly rinsed in water and after that it was immersed in fixer (Kodak, fixer, Kodak) for 5 
min. This was followed by another very brief rinse in water and air-drying. 
 
3.15.5 Densitometric analysis  
Films were laid on negatoscope (Northern light model B90) which transmitted diffuse 
light. Images were captured with black-with camera (CCD 72, MTI) and MCID program 
(MCID elite 6.0, Imaging Research). Individual striatum were marked with rectangle and 
then program was measured ROD. From those values were subtracted  background.    
Data were statistical analyzed (SPSS 19.0 for Windows, Chicago, Illinois, USA) with one-
way ANOVA followed by Scheffe’s multiple-comparison test with p < 0.05.  
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4 RESULTS 
 
4.1 CATALEPSY ANALYSIS  
 
4.1.1 Catalepsy test on 1st and 21st day (experiment 1) 
We had 8 animals per group (see Table 1). The animals (n= 48) were treated once daily for 
21 days. We wanted to see the consequences of the 21-day long subchronic treatment on 
the catalepsy score. The catalepsy test was performed on 1
st
 and 21
st
 day after the injection 
of the test compounds. 
Haloperidol 2 mg/kg and 0.2 mg/kg produced significant catalepsy in rats. The onset of the 
response (measured in scores) was evident 40 min after administration haloperidol 2 mg/kg 
and 80 min after administration haloperidol 0.2 mg/kg on the 1
st
 day and 40 min after 
administration haloperidol 0.2 mg/kg on the 21
st
 day.  
 
 
Figure 20:  Haloperidol 2 mg/kg, on the 1st, the 21st day. Animals (n=8) got an injection and 20 min after it 
started the measuring of catalepsy scores. The onset of the response (measured in scores) was evident 40 min 
after administration. Score 1 and everything above that was considered to be catalepsy. This was also shown 
by the catalepsy test with saline (Fig.30). 
Slika 20: Haloperidol 2 mg/kg 1. in 21. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija. Začetek odgovora (merjeno v dosežkih) je bil razviden po 40. minutah. Dosežak 1 in vse 
nad tem se obravnava kot katalepsija. To je tudi pokazal test katalepsije z fiziološko raztopino (Slika 30). 
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Figure 21:  Haloperidol 2 mg/kg, on the 1st, the 21st day. Animals (n=8) got an injection and the measuring of 
catalepsy scores started 20 min later. The onset of the response (measured in scores) was evident 40 min after 
administration. Score 1 and everything above that is considered to be catalepsy. The catalepsy test with saline 
(Fig.30) showed the same. 
Slika 21: Haloperidol 0,2 mg/kg 1. in 21. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija. Začetek odgovora (merjeno v dosežkih) je bil razviden po 40. minutah. Dosežak 1 in vse 
nad tem se obravnava kot katalepsija. To je tudi pokazal test katalepsije z fiziološko raztopino (Slika 30). 
 
Haloperidol 2 mg/kg on the 1
st
 and the 21
st
 day shows more convincing catalepsy response 
than haloperidol 0.2 mg/kg which is in accordance with literature claims that haloperidol 
induces catalepsy in a dose dependent manner (Laruelle et al., 1992) 
LEK-8829 2 mg/kg shows similar catalepsy curve as haloperidol 0.2mg/kg while LEK-
8829 0.2 mg/kg does not show significant catalepsy. The curve is similar to the saline 
curve (Fig 23). 
The onset of cataleptic effects occurred 100 min after administration LEK 8829 2 mg/kg 
on the 1
st
 day and 20 min after administration on the 21
st
 day. LEK-8829 2 mg/kg has 
maximal effect (measured in scores) on the 21
st
 day (see Fig1). 
LEK-8829 2 mg/kg shows similar catalepsy effect as haloperidol 0.2 mg/kg on the 1
st
 day 
but  LEK-8829 2 mg/kg on the 21
st
 day shows a similar curve like haloperidol 2 mg/kg (1
st
 
and  21
st
  day), probably because the LEK-8829 is still in circulation. 
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Figure 22: LEK-8829 2 mg/kg, on the 1st, the 21st day. Animals (n=8) got an injection and the measuring of 
catalepsy scores started 20 min later. The onset of the response (measured in scores) was evident 100 min 
after administration on the 1st day and 20 min after administration on the 21st day. Score 1 and everything 
above that is considered to be catalepsy. That is also shown by the catalepsy test with saline (Fig.30). 
Slika 22: LEK-8829 2 mg/kg na 1. in 21. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija. Začetek odgovora (merjeno v dosežkih) je bil razviden po 40. minutah. Dosežak 1 in vse 
nad tem se obravnava kot katalepsija. To je tudi pokazal test katalepsije z fiziološko raztopino (Slika 30). 
 
 
Figure 23: LEK-8829 0.2 mg/kg, on the 1st, the 21st day. Animals (n=8) got an injection and the measuring of 
catalepsy scores started 20 min later. This is a small dose and does not show catalepsy on the 1st day and the 
21st day. The curve is similar to the saline curve (see Fig 30). 
Slika 23: LEK-8829 0,2 mg/kg na 1. in 21. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je 
začela meriti katalepsija. Ta doza je majhna in ne pokaže katalepsije na 1. ali 21. dan. Krivulja je podobna 
krivulji z fiziološko raztopino (Slika 30).  
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Figure 24: Haloperidol 2 mg/kg on the 1st and 21st day of the treatment: catalepsy scores are not significantly 
different. A Wilcoxon Signed Rank Test revealed no statistically significant difference in the catalepsy effect 
of haloperidol 2mg/kg. p≤ 0.05 was considered to be statistically significant. 
Slika 24: Haloperidol 2 mg/kg na 1. in 21. dan: dosežki katalepsije se ne razlikujejo bistveno. Wilcoxon test 
ranga ni pokazal statistično pomembne razlike v učinku katalepsije haloperidola 2 mg/kg. p≤ 0.05 se šteje za 
statistično značilne. 
 
 
Figure 25: Haloperidol 0.2 mg/kg on the 1st and 21st day of the treatment: catalepsy scores are not 
significantly different A Wilcoxon Signed Rank Test revealed no statistically significant difference in the 
catalepsy effect of haloperidol 0.2 mg/kg. p≤ 0.05 was considered to be statistically significant. 
Slika 25: Haloperidol 0,2 mg/kg na 1. in 21. dan: dosežki katalepsije se ne razlikujejo bistveno. Wilcoxon 
test ranga ni pokazal statistično pomembne razlike v učinku katalepsije haloperidola 0.2 mg/kg. p≤ 0.05 se 
šteje za statistično značilne. 
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Figure 26: LEK-8829 2 mg/kg on the 1st and 21st day of the treatment: catalepsy scores are significantly 
different A Wilcoxon Signed Rank Test revealed a statistically significant increase of catalepsy effect on 21st 
day. p≤ 0.05 was considered to be statistically significant. 
Slika 26: LEK-8829 2 mg/kg na 1. in 21. dan: * dosežki katalepsije se bistveno razlikujejo. Wilcoxon test 
ranga je pokazal statistično pomembne razlike v učinku katalepsije 21 dan. p≤ 0.05 se šteje za statistično 
značilne. 
 
 
 
Figure 27: LEK-8829 0.2 mg/kg on the 1st and 21st day of the treatment: catalepsy scores are not significantly 
different A Wilcoxon Signed Rank Test revealed no statistically significant difference in the catalepsy effect 
of LEK-8829 0.2mg/kg the 1st and 21st day. p≤ 0.05 was considered to be statistically significant. 
Slika 27: LEK-8829 0,2 mg/kg na 1. in 21. dan: dosežki katalepsije se ne razlikujejo bistveno. Wilcoxon test 
ranga ni pokazal statistično pomembne razlike v učinku katalepsije 21 dan. p≤ 0.05 se šteje za statistično 
značilne. 
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Figure 28: LEK-8829 2 mg/kg and haloperidol 0.2 mg/kg on the 1st day of the treatment: *catalepsy scores 
are not significantly different A Mann-Whitney U Test revealed no significant difference in the catalepsy 
effect of LEK-8829 2 mg/kg and haloperidol 0.2 mg/kg on the 1st day of the treatment. p≤ 0.05 was 
considered to be statistically significant. 
Slika 28: LEK-8829 2 mg/kg in haloperidol 0,2 mg/kg na 1. in 21. dan: *dosežki katalepsije se ne razlikujejo 
bistveno. Mann-Whitney test ni pokazal statistično pomembne razlike v učinku katalepsije LEK-8829 2 
mg/kg in haloperidol 0,2 mg/kg 1 dan. p≤ 0.05 se šteje za statistično značilne. 
 
 
Figure 29: LEK-8829 2 mg/kg and haloperidol 2 mg/kg on the 21st day of the treatment: *catalepsy scores are 
not significantly different A Mann-Whitney U Test revealed no significant difference in the catalepsy effect 
of LEK-8829 2 mg/kg and haloperidol 2 mg/kg on the 21st day of the treatment. p≤ 0.05 was considered to be 
statistically significant. 
Slika 29: LEK-8829 2 mg/kg in haloperidol 2 mg/kg 21. dan: *dosežki katalepsije se ne razlikujejo bistveno. 
Mann-Whitney test ni pokazal statistično pomembne razlike v učinku katalepsije LEK-8829 2 mg/kg in 
haloperidol 2 mg/kg 21. dan. p≤ 0.05 se šteje za statistično značilne. 
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A Wilcoxon Signed Rank Test revealed no statistically significant difference in the 
catalepsy effect of haloperidol 2mg/kg (Fig.19) and haloperidol 0.2mg/kg on the first and 
on the twenty first day of the treatment (Fig.20). A Wilcoxon Signed Rank Test revealed a 
statistically significant increase of catalepsy score on twenty first day of LEK-8829 
2mg/kg (Fig.21). A Mann-Whitney U Test revealed no significant difference in the 
catalepsy effect of LEK-8829 2 mg/kg and haloperidol 0.2 mg/kg on the first day of the 
treatment (Fig.23). A Mann-Whitney U Test revealed no significant difference in the 
catalepsy effect of LEK-8829 2 mg/kg and haloperidol 2 mg/kg on the twenty first day of 
the treatment (Fig.24).  
 
4.1.2 Catalepsy test on 1st and 28th day (experiment 2) 
We had 6 animals per group ( Table 2). Animals (n= 18) have been treated once daily for 
21 days. The catalepsy responses were tested on 1
st
 and 28
th
 day of the experiment. Seven 
days after the last injection we do the catalepsy test so between day 21 and day 28 the rats 
no received drug treatment. On 28
th
 day after injection of test compounds I performed the 
catalepsy test. In this experiment we waited 7 days after last injection because we want to 
drugs disappear from circulation and then performed the catalepsy test. On this way we are 
able to see effects of 21 day treatment on dopamine receptors in striatum. It was chosen 7 
day drug free because the striatal up-regulation D2 receptors reaching the highest values 
(Vasconcelos et al., 2003). This time we include saline group because we noticed that rats 
could be learned the catalepsy in the same conditions and with saline, we wanted to include 
the basic-line of learning (Fig.33).  
We consider score 1 and everything above that as catalepsy. That also shows the catalepsy 
test with saline (Fig.30).  
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Figure 30: Saline on the 1st, the 28th day. Animals (n=6) got an injection and 20 min after were started 
measure of catalepsy scores. Score 1 and everything above that we consider like catalepsy.  
Slika 30: Fiziološka rastopina 1. in 28. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija.  Dosežek 1 in vse nad tem se obravnava kot katalepsija.  
 
Effect of haloperidol 0.2 mg/kg on the 28
th
 day was a slightly higher than on the 21
st
 day. 
The onset of the response was evident 100 min after administration on the 1
st
 day and 60 
min after administration for the 28
th
 day.  
 
 
Figure 31: Haloperidol 0.2 mg/kg, on the 1st, the 28th day. Animals (n=6) got an injection and 20 min after 
were started measure of catalepsy scores. The onset of the response (measured in scores) was evident 100 
min after administration on the 1st day and 60 min after administration on the 28th day.  
Slika 31: Haloperidol 0,2 mg/kg 1. in 28. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija. Začetek odgovora (merjeno v dosežkih) je bil razviden po 100. minutah prvega dne ter 60. 
minutah po injekciji 28. dan.  
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Figure 32: LEK-8829 2 mg/kg, on the 1st, the 28th day. Animals (n=6) got an injection and 20 min after were 
started measure of catalepsy scores. The onset of the response (measured in scores) was evident 90 min after 
administration on the 1st day and 50 min after administration on the 28th day. 
Slika 32: LEK-8829 2 mg/kg 1. in 28. dan. Živali (n=8) so prejele injekcijo, po 20. minutah pa se je začela 
meriti katalepsija. Začetek odgovora (merjeno v dosežkih) je bil razviden po 90. minutah prvega dne ter 50. 
minutah po injekciji 28. dan. 
 
 
LEK-8829 show slight decrease on the 28
th
 day from 21
st
 day in experiment 1. The onset of 
the response was evident 90 min after administration on the 1
st
 day and 50 min after 
administration on the 28
th
 day.  
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Figure 33: Saline on the 1st, the 28th day: catalepsy scores are not significantly different. A Wilcoxon Signed 
Rank Test revealed a statistically significant increase of catalepsy score on the 28 th day. p≤ 0.05 was 
considered to be statistically significant. 
Slika 33: Fiziološka rastopina 1. in 28. dan: dosežki katalepsije se ne razlikujejo bistveno. Wilcoxon test 
ranga ni pokazal statistično pomembnega povečanja v učinku katalepsije 28. dan. p ≤ 0.05 se šteje za 
statistično značilne. 
 
 
Figure 34: Haloperidol 0.2 mg/kg on the 1st and 28th day of the treatment: *catalepsy scores are  significantly 
different A Wilcoxon Signed Rank Test revealed statistically significant difference in the catalepsy effect of 
haloperidol 0.2 mg/kg. p≤ 0.05 was considered to be statistically significant.  
Slika 34: Haloperidol 0,2 mg/kg 1. in 28. dan: *dosežki katalepsije se bistveno razlikujejo. Wilcoxon test 
ranga je pokazal statistično pomembne razlike v učinku katalepsije za haloperidol 0,2 mg/kg. p≤ 0.05 se šteje 
za statistično značilne. 
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Figure 35: LEK-8829 2 mg/kg on the 1st and 28th day of the treatment: catalepsy scores are not significantly 
different A Wilcoxon Signed Rank Test revealed no statistically significant difference of catalepsy effect on 
28th day. p≤ 0.05 was considered to be statistically significant. 
Slika 35: LEK-8829 2 mg/kg 1. in 28. dan: dosežki katalepsije se ne razlikujejo bistveno. Wilcoxon test 
ranga ni pokazal statistično pomembne razlike v učinku katalepsije 28. dan. p≤ 0.05 se šteje za statistično 
značilen. 
 
A Wilcoxon Signed Rank Test revealed no statistically significant difference in the 
catalepsy effect of LEK-8829 2mg/kg on the first and on the twenty eight day of the 
treatment. A Wilcoxon Signed Rank Test revealed a statistically significant increase of 
catalepsy score on 28
th
 day of haloperidol 0.2 mg/kg and saline. 
 
4.2 ANALYSIS OF AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY 
 
4.2.1 Catalepsy analysis (1 test) 
Six groups of eight animals were used. The animals (n= 48) were treated once daily for 21 
days (Table 3). Three tests were performed before and after the 21-day treatment. The 
catalepsy test was 1
st 
test (Table 4). It was noticed that rats could be learned the catalepsy 
in the same conditions and with saline it was confirmed (Fig.30). We wanted to confirmed 
that and on the 1
st
 group (saline group) the catalepsy test was performed using the method 
described by Krisch (Krisch et al., 1994). Results were the same as for the saline group on 
1
st
 and 28
th
 day of the treatment (Fig.30). On the 4
th 
group (saline group) (Table 3) 
catalepsy test was performed 4 h and 8 h after the saline injection. Catalepsy scores were 0. 
The animals were not cataleptic. 
Previous catalepsy tests (Fig.20, 21, 22, 30, 31, 32 ) showed catalepsy for all doses of test 
compounds. Based on that and on observation that rats could learn the catalepsy in the 
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same conditions it was decided to perform a catalepsy test 2 h after of the injection of the 
test compounds. 
Before the 21-day treatment, the catalepsy scores for all other groups were around score 1, 
except for the group which received haloperidol 2 mg/kg, which had a slightly higher 
catalepsy score. After the 21-day treatment catalepsy scores for all other groups were 
around score 1, except for the group which received haloperidol 2 mg/kg and had a slightly 
higher catalepsy scores, even slightly higher on the 1
st 
test before 21 day treatment. 
 
4.2.2 Amphetamine-induced locomotion (2 test) 
Six groups of eight animals were used. The animals (n= 48) were treated once daily for 21 
days (Table 3). Three tests were performed before and after the 21-day treatment. 
Amphetamine-induced locomotion was 2
st
 (Table 5). 
Before the 21-day treatment locomotion (distance moved) induced by amphetamine was 
the same for all groups. One-way ANOVA followed by Scheffe’s multiple-comparison test 
shows that groups are not significantly different (have the same efficiency). 
After the 21-day treatment locomotion (distance moved) induced by amphetamine was the 
same for all groups. One-way ANOVA followed by Scheffe’s multiple-comparison test 
shows that groups are not significantly different (have the same efficiency). 
A Two-tailed paired Student’s t test was conducted to evaluate the impact of the 21-day 
treatment on amphetamine-induced locomotor activity. Saline, LEK-8829 0.2 mg/kg and 
haloperidol 0.2mg/kg were not significantly different in the distance moved before and 
after the treatment. LEK-8829 2 mg/kg and haloperidol 2 mg/kg were significantly 
different in the distance moved before and after the treatment. 
 
 
 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
73 
 
Fig 36: Amphetamine-induced locomotor activity with test compounds before and after the treatment.  
* Significant difference as compared 2 test before 21 day treatment vs. 2 test after the 21 day treatment. 
(Two-tailed paired Student’s t-test,  p≤ 0.05 was considered to be statistically significant). 
Slika 36: Z amfetaminom izzvana lokomotorna aktivnost z testnimi spojinami pred in po zdravljenju.  
* Značilna razlika v primerjavi drugega testa prej in po 21-dnevnom zdravljenju. (parni Student t-test p≤ 0.05 
se šteje za statistično značilen). 
 
 
4.2.3 Inhibition of the amphetamine-induced locomotion with test compounds    
(experiment 3) 
Six groups of eight animals were used. The animals (n= 48) were treated once daily for 21 
days (Table 3). Three tests were performed before and after the 21-day treatment. 
Inhibition of amphetamine - induced locomotion with test compounds was 3
rd
 test (Table 
6). 
One-way ANOVA followed by Scheffe’s multiple-comparison test showed that before 
treatment saline and LEK 0.2 mg/kg were not significantly different (had the same 
efficiency) LEK-8829 2 mg/kg, haloperidol 2 mg/kg and haloperidol 0.2 mg/kg were not 
significantly different. 
One-way ANOVA followed by Scheffe’s multiple-comparison test showed that after the 
treatment saline and LEK 0.2 mg/kg were not significantly different (had the same 
efficiency). LEK-8829 2 mg/kg, haloperidol 2 mg/kg and haloperidol 0.2 mg/kg were not 
significantly different.  
A Two-tailed paired Student’s t test was conducted to evaluate the impact of the 21-day 
treatment on amphetamine-induced locomotor activity with haloperidol 2mg/kg and 0.2 
mg/kg. There was a statistically significant increase in the distance moved from the first to 
the twenty-first day. This indicates that haloperidol 2 mg/kg and 0.2 mg/kg produces 
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behavioral supersensitivity which is in accordance with clinical observations and animal 
studies which show that a withdrawal of antipsychotic treatment reveals an increased 
psychomotor response to amphetamine (Samaha et al., 2007). 
 
 
Figure 37: Inhibition of the amphetamine-induced locomotion with test compounds.  * Significant difference 
as compared with saline group 3 test before the 21 day treatment period with the respective dose of the drug. 
# Significant difference as compared with saline group 3 test  after the 21 day treatment period with the 
respective dose of drugs (One way ANOVA with Scheffe’s post hoc analysis, n = 8, p ≤ 0.05).  $ Significant 
difference as compared 3 test before the 21 day treatment vs. 3 test after the 21 day treatment. (Two-tailed 
paired Student’s t,test,  p≤ 0.05 was considered to be statistically significant). 
Slika 37: Zaviranje z amfetaminom inducirane lokomotorne aktivnosti s testnimi spojinami.   * Značilna 
razlika v primerjavi s fiziološko skupino tretjeg testa pred in po 21-dnevnom zdravljenju z ustreznim 
odmerkom zdravila. # Značilna razlika v primerjavi s fiziološko skupino tretjeg testa pred in po 21 dnevnom 
zdravljenju z ustreznim odmerkom zdravila (enosmerna ANOVA s Scheffe’s test n = 8, p ≤ 0.05). $ Značilna 
razlika v primerjavi tretjeg testa pred in po 21 dnevnim zdravljenjem. (parni Student t-test p≤ 0.05 se šteje za 
statistično pomembne). 
  
A two-tailed paired Student’s t test was used to verify the statistical significance before and 
after the treatment. Saline, LEK-8829 2 mg/kg and LEK-8829 0.2 mg/kg were not 
significantly different in the distance moved from the first to the twenty-first day i.e. LEK-
8829 2 mg/kg and 0.2 mg/kg did not produce significant differences in the inhibition of the 
amphetamine-induced locomotion with  the test compounds before and after the twenty- 
one-day treatment. LEK-8829 in both doses did not produce behavioral supersensitivity 
(increased behavioral responsiveness) after the treatment i.e. a decreased psychomotor 
response to amphetamine.  
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4.3 ANALYSIS OF RESERPINE MODEL 
 
Five groups of animals were used. The animals (n= 36) were treated three times, once in 
three days with reserpine and twice a day for 9 days with test compounds (Table 7).   
One-way ANOVA followed by Scheffe’s multiple-comparison test was conducted to 
evaluate the impact of prolonged daily treatment with saline and test compounds from 1
st
 
to 13
th
 day. There was a statistically significant increase in the distance moved with 
prolonged daily treatment with LEK-8829 2mg/kg.  
 
 
Figure 38: Comparison of prolonged daily treatment with saline and test compounds from 1st to 13th day. * 
Significant difference as compared with saline group. One way ANOVA with Scheffe’s post hoc analysis, n 
= 6, saline n = 12, p≤ 0.05 was considered to be statistically significant. 
Slika 38: Primerjava podaljšanega dnevnega zdravljenja s fiziološko raztopino in testnima spojinama. 0d 1. 
do 13. dne. * Značilna razlika v primerjavi s fiziološko skupino. Enosmerna ANOVA s Scheffe-jevim testom 
n = 6, fiziološka n = 12, p≤ 0.05 se šteje za statistično pomembne. 
 
First group of twelve animals (n= 12) was treated three times, every three days, with 
reserpine 10 mg/kg (1
st
, 4
th 
and 7
th
 day of the experiment) and every day twice a day (at 8 
am and at 8 pm) with saline. After the last reserpine injection the animals were treated with 
saline for two more days (8
th
 and 9
th
 day of experiment). For nine days I was recording the 
animals for 120 min after the morning injection. Next two days animals were without 
saline (10
th
 and 11
th
 day of the experiment). I performed the catalepsy test the day after 
(12
th
 day of the experiment). On the 13
th
 day of the experiment, I divided the first group 
into four groups of three animals (n= 3). Three animals got saline, three animals got LEK-
8829 2mg/kg, three animals got bromoergocriptine 2 mg/kg and three animals got LEK-
8829 2 mg/kg + SCH 23390 1 mg/kg (Table 7). 
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Catalepsy tests demonstrated that all animals were cataleptic which is in accordance with 
dopamine depletion. That means that reserpinization was successful.  
 
 
Figure 39: Daily treatment with saline demonstrated a minimal locomotor activity of reserpinized rats. Acute 
test doses on 13th day with saline (n = 3)  demonstrated the same locomotor activity like before. Increase of 
locomotor activity with LEK 2mg/kg (n = 3) was observed on acute test dose on 13th day. Acute test doses 
on 13th day with BrEKT 2 mg/kg (n = 3) and LEK-8829 2mg/kg + SCH 1mg/kg (n = 3) demonstrated the 
same locomotor activity like saline on the 13th day.   
Slika 39: Dnevno zdravljenje s fiziološko raztopino kaže, minimalno lokomotorno aktivnost rezerpiniranih 
podgan. Akutni test 13. dne s fiziološko raztopino (n = 3) pokaže enako lokomotorno aktivnost kot prej. 
Povečanje lokomotorne aktivnosti z LEK 2mg/kg (n = 3) je opaženo 13. dan z akutnim odmerkom. Akutni 
test odmerek 13. dan z BrEKT 2 mg/kg (n = 3) in LEK-8829 2mg/kg + SCH 1mg/kg (n = 3) pokaže enako 
lokomotorno aktivnost kot fiziološko raztopina na 13. dan. 
 
The control group showed a minimal locomotor activity during all nine days of recording 
in accordance with the reserpine treatment. On 13
th
 day three animals got an injection of 
saline, three animals got an injection of LEK-8829 2 mg/kg, three animals got an injection 
of bromokriptine 2 mg/kg and three animals got an injection of LEK 2 mg/kg + SCH 1 
mg/kg respectively. After those injections only LEK-8829 2 mg/kg produced 
approximately a three-times increase of locomotor activity. Other test compounds 
exhibited almost the same locomotor activity as acute injection of saline, BrEKT 2 mg/kg 
and LEK-8829 2 mg/kg+SCH 1 mg/kg.  
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Figure 40: Comparison of daily treatment with LEK-8829 2mg/kg and 0.2mg/kg and acute test doses on 13th 
day. Increase of locomotor activity with LEK 2mg/kg was observed on 5th day, and day by day it was more 
intensive till 9th day when  it was observed stereotype behavior. Locomotor activity was decrease on account 
of stereotype behavior.  On 13th day (n = 3) with acute test dose of LEK 2mg/kg was observed more decrease 
locomotor activity on account of more intensified stereotype behavior. On 13th day (n = 3) with acute test 
dose of BrEKT 2mg/kg was observed the same rate of locomotor activity without stereotype behavior. 
Slightly increase of locomotor activity with LEK 0.2mg/kg was observed on 5th day, with substantial increase 
on 9th day. Stereotyped behavior was not observed. On 13th day with acute test dose of LEK 2mg/kg and 
BrEKT 2mg/kg was observed the same rate of locomotor activity. 
Slika 40: Primerjava dnevnega zdravljenja z LEK-8829 2mg/kg and 0.2mg/kg in akutni test odmerjen 13. 
dan. Povečanje lokomotorne aktivnosti z LEK-8829 2 mg/kg je opažen 5. dan in je iz dneva v dan bolj 
intenziven do 9. dneva, ko je opaženo tudi stereotipno vedenje. Lokomotorna aktivnost se zmanjšuje na račun 
stereotipnega vedenja. Akutni test odmerka LEK 2mg/kg na 13. dan (n = 3) kaže zmanjšanje lokomotorne 
aktivnosti na račun stereotipnega vedenja. Akutni test odmerka LEK 2mg/kg na 13. dan (n = 3) kaže enako 
mero lokomotorne aktivnosti brez stereotipnega vedenja. Rahlo povečanje lokomotorne aktivnosti z LEK 0,2 
mg/kg je opaženo 5. dne z znatnim povečjanjem 9. dne. Akutni test odmerka 13. dan z LEK 2mg/kg in 
BrEKT 2mg/kg kaže enako stopnjo lokomotorne aktivnosti. 
 
The group treated with LEK 2mg/kg for 9 days showed strongly alleviated akinetic state 
but from the fifth day onwards, hyperlocomotion and stereotype behavior were perceived. 
On the fifth day, they exhibited an increase in locomotor activity and it lasted to the ninth 
day. The biggest locomotor activity was on the eight day when stereotype behavior was 
observed. On 13
th
 day three animals got an injection of LEK 8829 2mg/kg, and three 
animals got injection of bromokriptine 2mg/kg. After those injections the animals 
exhibited the same locomotor activity but with different behavioral pattern. LEK-8829 
produced an increase in locomotor activity and stereotypic behavior. Bromocriptine did not 
induce stereotypic behavior, only a modest locomotor activity. On the last day of the 
treatment (9
th
 day of experiment) 6 animals out of 12 animals died. In accordance with 
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hyperlocomotion and stereotype behavior (by sniffing to the self-biting and self-mutilation) 
in half of the dead animals we concluded that 2mg/kg was an extremely high dose and may 
be toxic but should it kept in mind that our animals were in the group which was extremely 
sensitive to chronic reserpinization (Rosecrans., 1967) 
The group treated for with LEK-8829 0.2mg/kg 9 days also exhibited an increase in 
locomotor activity but on 9
th
 day the stereotypic behavior was missing. Effects were more 
moderate than in the case of a high dose and perhaps the dose was in the question. On 13
th
 
day three animals got an injection of LEK 8829 2mg/kg, and three animals got an injection 
of bromokriptine 2mg/kg. After those injections the animals exhibited the same locomotor 
activity but with different behavioral patterns. 
Independent t-test was used to verify the statistical significance between LEK-8829 2 
mg/kg and LEK-8829 0.2mg/kg. LEK-8829 2 mg/kg and LEK-8829 0.2mg/kg were 
significantly different.  
The group treated for 9 day with Bromokriptine had a similar profile as LEK-8829 
0.2mg/kg. On 13
th
 day three animals got an injection of LEK-8829 2mg/kg, and three 
animals got injections of bromokriptine 2mg/kg. After those injections LEK-8829 2mg/kg 
produced a slight increase in locomotor activity and bromokrpitine markedly reduced 
locomotion.  
The group treated for 9 day with LEK-8829 2mg/kg + SCH 1mg/kg showed the same 
profile as LEK-8829 2 mg/kg but with a decrease in values from LEK-8829 2 mg/kg 
(Fig.33) because 20 min after the injection of LEK-8829 2mg/kg, injection of SCH-23390 
1 mg/kg prevented action of  LEK-8829 2 mg /kg.  
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Figure 41: Comparison of daily treatment with bromoergocriptine (BrEKT) 2mg/kg and LEK -8829 2mg/kg 
+ SCH 1mg/kg and acute test doses on 13th day. Increase of locomotor activity with BrEKT 2mg/kg was 
observed from 8th day. On 13th day (n = 3) with acute test dose of LEK 2mg/kg was observed the same rate of 
locomotor activity. On 13th day (n = 3) with acute test dose of BrEKT 2mg/kg was observed decrease of 
locomotor activity. Increase of locomotor activity with LEK 2mg/kg + SCH 1mg/kg was observed on 5th day, 
and day by day it was more intensive till 9th day. This increase was in account of first 20min locomotor 
activity with LEK-8829 2mg/kg. On 13th day (n = 3) with acute test dose of LEK-8829 2mg/kg was observed 
increase of locomotor activity. On 13th day (n = 3) with acute test dose of BrEKT 2mg/kg was observed 
decrease of locomotor activity. 
Slika 41: Primerjava dnevnega zdravljenja z bromoergocriptine (BrEKT) 2 mg/kg in LEK -8829 2 mg/kg + 
SCH 1 mg/kg ter akutni test odmerka 13. dan. Povečjanje lokomotorne aktivnosti z BrEKT 2 mg/kg je 
opaženo od 8. dne naprej. Akutni test odmerka LEK-8829 2 mg/kg (n = 3) 13. dan, kaže isto stopnjo 
lokomotorne aktivnosti. Akutni test odmerka BrEKT 2mg/kg (n = 3) 13. dan, kaže zmanjšanje lokomotorne 
aktivnosti. Povečjanje lokomotorne aktivnosti z LEK-8829 2mg/kg + SCH 1mg/kg je opaženo 5. dne in je z 
vsakim dnem bolj intezivno do 9. dne. To povečjanje se pokaže na račun prvih 20 min lokomotorne 
aktivnosti z LEK-8829 2 mg/kg. Akutni test odmerki z LEK-8829 2 mg/kg 13. dan (n = 3) kaže povečjanje 
lokomotorne aktivnosti. Akutni test odmerki z BrEKT 2 mg/kg 13. dan (n = 3) kaže zmanjšanje lokomotorne 
aktivnosti.            
 
Dopamine depletion leads to breakdown of D1/D2 synergism and increase of D2 receptors 
(LaHoste and Marshall, 1992). The increase in D2 receptors is both necessary and 
sufficient for the production of the enhanced behavioral supersensitivity to dopamine 
agonists (Hess et al., 1986). 
It is very interesting that LEK-8829 D1 receptor agonist and D2 receptor antagonist 
demonstrate a maximum locomotor response (Fig.37). Prolonged 9-day treatment of LEK-
8829 2 mg/kg and 0.2 mg/kg demonstrate an increase of locomotor activity in comparison 
with prolonged 9-day treatment with BrEKT 2 mg/kg. Acute test doses LEK-8829 2 mg/kg 
(D1 agonist and D2 antagonist) and BrEKT 2 mg/kg (D2 agonist) on the 13
th
 day 
demonstrated higher supersensitivity with LEK-8829 2 mg/kg than BrEKT 2 mg/kg. 
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4.4 PROTEIN ANALYSIS OF D2 RECEPTORS  
 
 
 
Figure 42: D2 receptor isoforms in striatum: D2 long 52kDa, D2 short 47kDa  Housekeeping protein β-
tubulin on 50 kDa. 
Slika 42: D2 receptor izooblike: D2 dolga 52kDa, D2 kratka 47kDa. Protein β-tubulin na 50 kDa. 
 
 
We are able to see D2 long and D2 short isoforms. No up-regulation can be detected due to 
different subchronic treatment. The first four samples is saline and the next four are treated 
with haloperidol 2 mg/kg, followed by four treated with LEK 2 mg/kg and the last two are 
treated with LEK 0.2mg/kg. We expect to see up-regulation in samples treated with 
haloperidol 2 mg/kg and lower lever of up-regulation in samples treated with LEK 2mg/kg 
and 0.2 mg/kg. 
 
 
 
Figure 43: D2 receptor isoforms: D2 long and D2 short more separate. Housekeeping GAPHD on 37 kDa. 
Slika 43: D2 receptorske izooblike: D2 dolga in D2 kratka izooblika bolj ločene. Protein GAPHD na 37 kDa. 
 
Optimizing the western blot method we succeeded to separate D2 long and D2 short 
isoforms. No up-regulation can be detected due to different prolonged daily treatments. 
Samples are from the reserpine model. First four samples is reserpine treated 9 day with 
saline, the next four is reserpine treated 9 days with LEK 2 mg/kg and next four reserpine 
is treated 9 day with BrEKT 2 mg/kg. We expect to see up-regulation in all samples and 
  D2 long 
      
  D2 short 
 
 
 
 
β-tubulin 
 
D2 long 
D2 shot 
          
 
GAPHD 
  Saline Haloperidol 2mg/kg LEK 2mg/kg LEK 0.2mg/kg 
 Reserpine  + saline Reserpine + LEK 2mg/kg Reserpine +BrEKT 2mg/kg 
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according to up-regulation of first for samples (reserpine + saline) to determine level of up-
regulation of other samples. 
 
 
 
Figure 44: Nova-1 protein on 50kDa. Housekeeping GAPHD on 37 kDa. 
Slika 44: Protein Nova-1 na 50kDa. Protein GAPDH na 37 kDa. 
 
No up-regulation can be detected due to different prolonged daily treatments in the 
reserpine model. We expect if D2 long isoform of D2 receptor is up-regulated more than 
D2 short isoform also Nova 1 will be up-regulated. Samples are from the reserpine model. 
First four samples is reserpine treated 9 day with saline, the next four is reserpine treated 9 
days with LEK 2 mg/kg and next four reserpine is treated 9 day with BrEKT 2 mg/kg. We 
expect no up-regulation Nova 1 in all samples because probably up-regulation of D2 
receptor is on account of equal up-regulation of both isoforms. 
It was extraordinary that we could not detect up-regulation of D2 receptor and/or D2 
receptor isoforms; we suspected that primary mouse antibodies (D2 receptor and Nova 1) 
cross-reacted with the rats’ IgG which are on 50 kDa. Around 50 kDa we have D2 receptor 
isoforms and Nova 1 on 50 kDa. To prove our suspicions we exposed only secondary 
antibodies (anti-mouse) without primary antibodies. We got bands and we confirmed 
cross-reaction between primary mouse antibodies and IgG in rat samples. 
 
 
 
 
Figure 45: Membrane incubate only with secondary antibodies. 
Slika 45: Membrana inkubirana le s sekundarnimi protitelesi. 
 
 
 
 
 
 
 
 
 
 
 
    Nova-1 
  GAPHD 
Reserpine + saline Reserpine + LEK 2mg/kg Reserpine + BrEKT 2mg/kg 
            Reserpine + saline               Reserpine + LEK 2mg/kg Saline 
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4.5 mRNA ANAYSIS OF D2 RECEPTORS 
 
The purpose of in situ hybridization was to detect changes in mRNA expression of D2 
receptor, D2 long, D2 short isoforms and Nova 1 in striatum due to subchronic treatment 
with test compounds. Alternative D2 receptor pre-mRNA splicing is controlled by splicing 
regulator Nova 1. 
The slices from experiment 3 (p.52) were analyzed here. The analysis comprised four 
animals from each group (saline, haloperidol 2 mg/kg, LEK-8829 2 mg/kg and haloperidol 
0.2 mg/kg) and two slices per animal. One-way ANOVA followed by Scheffe’s multiple-
comparison test showed that the treated groups were not significantly different. The 
obvious tendency was noticed that prolonged daily treatment caused a higher up-regulation 
of mRNA D2 receptors in the group treated with haloperidol 2 mg/kg than in the group 
treated with LEK-8829 2 mg/kg. 
  
 
 
 
 
 
 
 
 
Figure 46: Black and white view of mRNA expression D2 receptors in the striatum. 
Slika 46: Črno beli prikaz izražanja mRNA D2 receptorjev v področju striatuma. 
 
 
Saline Haloperidol  2 mg/kg 
LEK-8829  2mg/kg Haloperidol  0.2 mg/kg 
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Figure 47: Expression of mRNA D2 receptors after prolonged daily treatment with test compounds. Groups 
are not significantly different. One way ANOVA with Scheffe’s post hoc analysis, n = 4, p≤ 0.05 was 
considered to be statistically significant. The tendency is noticed that prolonged daily treatment causes a 
higher up-regulation of mRNA D2 receptors in the group treated with haloperidol 2 mg/kg than in the group 
treated with LEK-8829 2 mg/kg. 
Slika 47: Izražanje D2 receptor mRNK po podaljšanem zdravljenju z testnimi snovmi. Enosmerna ANOVA s 
Scheffejevim testom (n = 4, p≤ 0.05) ni pokazala statističnih razlik med skupinami. Opaža se trend, da 
podaljšano zdravljenje provzroča večjo up-regulacijo mRNK D2 receptorjev, skupine tretirane z 
haloperidolom 2mg/kg, kot skupine tretirane z LEK-8829 2 mg/kg. 
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Here we analyzed slices from the 6-OHDA model. The 6-OHDA model has D2 receptor 
up-regulation and this was a preliminary analysis for verification D2 receptor and its 
isoforms. It included four animals for D2R, D2L and D2S; and two slices per animal. One-
way ANOVA followed by Scheffe’s multiple-comparison test showed that lesions and 
control D2R are significantly different and that lesion and control D2S are significantly 
different. One-way ANOVA followed by Scheffe’s multiple-comparison test showed that 
lesion D2S and lesion D2L are significantly different. 
 
 
 
 
 
 
 
 
Figure 48: Black and white view of mRNA expression D2 receptors, D2L and D2S  in striatum. 
Slika 48: Črno beli prikaz izražanja mRNA D2 receptorjev, D2L in D2S v področju striatuma. 
 
 
 
 
 
Lesion                           Control    
D2 receptor 
 D2 long  
D2 short 
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Figure 49: Expression of mRNA D2R, mRNA D2L and mRNA D2S isoforms. * Significantly different 
compare to lesion D2R. # Significantly different compare to lesion D2S. One way ANOVA with Scheffe’s 
post hoc analysis, n = 4, p≤ 0.05 was considered to be statistically significant. 
Slika 49: Izražanje mRNK D2R, mRNK D2L in mRNK D2S izooblik. * Značilna razlika v primerjavi s 
lezijo D2R. #  Značilna razlika v primerjavi s lezijo D2S. Enosmerna ANOVA s Scheffejevim testom (n = 4, 
p≤ 0.05).  
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5 DISCUSSION 
 
The dopamine D2 receptor system has been implicated in the modulation of motor activity, 
learning and memory, as well as in the pathophysiology of neuropsychiatric disorders such 
as Parkinson’s disease (PD) and schizophrenia (Hranilovic et al., 2008). 
It is already known that different periods of antipsychotics treatment and dopamine 
depletion with reserpine cause up-regulation dopamine D2 receptors. Also, reserpine 
caused a breakdown in D1/D2 synergism (Tarazi et al., 1997; LaHoste and Marshall, 
1992).  
Dopamine receptor supersensitivity (DARSS) is often invoked in long-term treatment with 
antipsychotics and the problems arising with long-term L-DOPA therapy are the 
dyskinesias presumably resulting from priming or supersensitization of dopamine D2 
receptors. Dopamine receptors, experimentally, are prone to become supersensitive and to 
thus elicit abnormal behaviors when coupled with dopamine or a receptor agonist 
(Kostrzewa et al., 2011; Ushijima et al., 1995).  
It has been already described in the literature that D2 receptor up-regulation (and 
development of behavioral supersensitivity) prevent by simultaneously stimulation of D1 
receptors (Braun et al., 1997). A similar effect of D1 agonist treatment on behavioral 
supersensitivity and D2 receptor up-regulation induced by subchronic (21 day) haloperidol 
exposure has been reported (Marin et al., 1993). 
The purpose of our experiments was to analyze whether LEK-8829 may reduce 
dopaminergic supersensitivity, determine the impact on behavioral and neurochemical 
effect of subchronic treatment of LEK-8829 and determine how D2 up-regulation 
influences D2L and D2S isoforms, and  whether D1 agonist may change expression levels 
of Nova 1. 
Effects of LEK-8829 were compared with haloperidol which is representative of the 
typical antipsychotics and on reserpine model for Parkinson's disease. LEK-8829 
demonstrated an antagonist effects on dopamine D2 receptors and on serotonin 5-HT2A and 
5-HT1A receptors and was designed as a potential atypical antipsychotic drug (Krisch et al., 
1994, 1996). Zivin (1996) determine and D1 agonist properties. LEK-8829 2 mg/kg and 
haloperidol 0.2 mg/kg are equivalent doses and we choose them based on Krisch (1994) 
paper. The present work is result of subchronic treatment with LEK-8829, so far have 
made only acute treatments with LEK-8829 (Sprah et al., 1999, Zivin et al., 1996, 
Milivojevic et al., 2004, Glavan et al., 2002).      
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5.1 CATALEPSY ANALYSIS  
Catalepsy is a complex phenomenon involving more than one neurotransmitter system and 
also dependent on the D2 receptor blockade or as a consequence of dopamine depletion. 
Catalepsy is characterized by akinesia, the maintenance of even abnormal body posture 
(Carlsson and Carlsson, 2006) and rigidity and is not a simple motor inactivation but rather 
an 'active immobility' response (Frank and Schmidt, 2003). When a normal animal is 
placed in an unusual posture, it will change its position within seconds. A cataleptic 
animal, on the other hand, will maintain this posture for a prolonged period of time (i.e. 
several minutes) (Sanberg et al., 1988). Catalepsy is an animal model for Parkinson's 
disease or for neuroleptic-induced parkinsonism in humans (Frank and Schmidt, 2003; 
Miyagi et al., 1996) and it is used as a standard preclinical test to predict antipsychotic 
activity and motor side effect liability (Xu et al., 2002; Wadenberg et al., 2001). The 
intensified catalepsy can be extinguished by repeated exposure to the test environment 
(Wadenberg et al., 2001; Schmidt and Beninger, 2006). Different results of catalepsy may 
be due to factors such as strain, behavioral conditioning, animal handling and catalepsy 
rating technique (Jorgensen et al., 1994; Vasconcelos et al., 2003) but in spite all of that 
catalepsy still remains a model for Parkinson's disease or for neuroleptic-induced 
parkinsonism in humans. A full catalepsy can be induced by blocking either D1 or D2 
receptors (Frank and Schmidt, 2003). Coadministration of the D1 and D2 antagonists has a 
synergistic effect on catalepsy. Haloperidol is D2 antagonist. LEK-8829 is D1 agonist and 
antagonist on D2, 5-HT2A and 5-HT1A receptors. 
 
5.1.1 Catalepsy test on 1st and 21st day (experiment 1) 
Haloperidol 2 mg/kg on the 1
st
 and the 21
st
 day shows more convincing catalepsy response 
than haloperidol 0.2 mg/kg which is in accordance with literature that haloperidol induce 
catalepsy on dose dependent manner (Laruelle et al., 1992; Barnes et al., 1990). 
Haloperidol in both doses demonstrates almost the same cataleptic response on the 1
st
 and 
the 21
st
 day.  In the literature is described tolerance to the cataleptic response after 
subchronic treatment (Marin et al., 1993; Ushijima et al., 1995; Ezrin-Waters and Seeman, 
1977; Asper et al., 1973; Campbell and Baldessarini, 1981; Braun et al., 1997). The lack of 
tolerance to haloperidol-induced catalepsy that we saw here has been reported by some 
researches (Gyorgy et al., 1969; Moller Nielsen et al., 1974). A review by Barnes (1990) 
concluded that dose, drug administration schedule and behavioral test conditions all 
influence the evolution of catalepsy during chronic haloperidol treatment. 
Seeman (1975, 1976) determine average dose of 0.5 mg/kg/day used for patients with 
schizophrenia (Seeman et al., 1975; Seeman et al., 1976).   
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LEK-8829 2 mg/kg shows similar catalepsy effect as haloperidol 0.2 mg/kg on the 1
st
 day 
but  LEK-8829 2 mg/kg on the 21
st
 day shows a similar curve like haloperidol 2 mg/kg (1
st
 
and  21
st
  day), probably because the LEK-8829 is still in circulation. 
LEK-8829 0.2 mg/kg does not show significant catalepsy. The curve is similar to the saline 
curve (Fig 30). 
 
5.1.2 Catalepsy test on 1st and 28th day (experiment 2) 
Better view of the issue of cataleptic response, were when we performed the catalepsy test 
seven days after the last injection because then were no drug in circulation and all effects 
were due to responsiveness of receptors. It was chosen 7 day drug free because the striatal 
up-regulation D2 receptors reaching the highest values (Vasconcelos et al., 2003). 
Haloperidol 0.2 mg/kg produced slightly increased in catalepsy response on the 28
th 
day 
than on the 21
th
 day in experiment 1. LEK-8829 2 mg/kg show decrease in catalepsy 
response on the 28
th 
day than on the 21
th
 day in experiment 1 and onset of the cataleptic 
response on the 28
th 
day is delayed. This delay is probably due to drugs are out of 
circulation. Since were no drugs in circulation and a lower dose of haloperidol 0.2 mg/kg 
still have increase in catalepsy response and therefore LEK-8829 is better antipsychotic 
than haloperidol. LEK-8829 will have least exstrapyramidal side effects than haloperidol.  
Consequently we do catalepsy test on control group to check effect of repeated exposure to 
the test environment because we do the test for 260 min every 20 min and we have shown 
that animals were learning but that still is not catalepsy (Fig.30). We wanted to confirmed 
that and on the1
st
 group (saline group) catalepsy test (Table 3) was performed by method 
described by Krisch  (1994). Results were the same like saline group 1
st
 and 28
th
 day of the 
treatment (Fig.30). On the 4
th 
group (saline group) (Table 3) catalepsy test was performed 
4h and 8h after saline injection. Catalepsy scores were 0. Animals were not cataleptic.  
Haloperidol 2 mg/kg and 0.2 mg/kg demonstrates almost the same cataleptic response 
(catalepsy scores are not significantly different) on the 1
st
 and the 21
st
 day i.e. experiment1. 
Haloperidol 0.2 mg/kg in experiment 2, produced slightly increased in catalepsy response 
(catalepsy scores are significantly different) from 1
st
 to the 28
th 
day. Due to change in D2 
receptors we have behavioral supersensitivity. 
LEK-8829 2 mg/kg demonstrates increase in cataleptic response (catalepsy scores are 
significantly different) from the 1
st
 to the 21
st
 day i.e. experiment 1 but in experiment 2 it 
demonstrates almost the same cataleptic response (catalepsy scores are not significantly 
different). Behavioral supersensitivity is no longer evident on the 28
th 
day, probably due to 
D1 agonist effect.  
Subchronic treatment of rats with haloperidol enhances sensitivity to the motor effects of 
dopamine agonists and concomitantly increases D2 receptor number. Subchronic treatment 
with haloperidol, significantly increased dopamine agonist induced stereotypy (Marin et 
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al., 1993). Marin (1993) show that the dopamine D1 receptor agonist SKF attenuated the 
haloperidol induced increase in apomorphine stereotypes and that this decrease was 
correlated with a decrease in D2 receptor up-regulation. Concurrent treatment with D2 
antagonist and D1 agonist profoundly affect the emergence of behavioral supersensitivity, 
tolerance of catalepsy and increase in D2 receptor density (Braun et al., 1997). 
5-HT2A receptor antagonism can each diminish catalepsy caused by typical antipsychotics 
such as haloperidol (Lucas et al., 1997) so LEK-8829 also has antagonist activity at 5-
HT2A receptors which may contribute to its low risk for extrapyramidal symptoms (Nakai 
et al., 2003). 
 
5.2 ANALYSIS OF AMPHETAMINE MODEL OF SCHIZOPHRENIA 
We have confirmed the already known - that haloperidol decreases amphetamine-induced 
hyperactivity behavior (Meshul and Casey, 1989; Vasconcelos et al., 2003) and 
antipsychotics often lose efficacy during chronic continuous treatment (Samaha et al., 
2007). Chronic antipsychotic treatment reveals a state of dopaminergic supersensitivity 
that is characterized by increased vulnerability to psychosis and to the psychomotor 
activating effects of dopamine agonists, respectively. In humans, this has been termed 
''neuroleptic-induced supersensitivity psychosis'' (Samaha et al., 2007). Patients with 
schizophrenia, whether treated or untreated, are known to be supersensitive to dopamine-
like compounds (Seeman, 2011). In our experiment, 2 mg/kg dose of haloperidol strongly 
blocked amphetamine-induced hyperactivity then dose 0.2 mg/kg, which is in accordance 
with the fact that haloperidol is dose dependent. After 21 days of treatment, haloperidol 
demonstrates loss of efficacy (an increase in responsiveness) but it is interesting that 
haloperidol 0.2 mg/kg causes a greater loss of efficacy (increase in responsiveness) than 
haloperidol 2 mg/kg (Fig.32). This is to be expected due to the increase density of 
dopamine D2 receptors, but two distinct types of dopamine supersensitivity exist: modest 
one associated with increased D2 density and a more profound one associated with 
breakdown in D1/D2 synergism and independent of D2 density (LaHoste and Marshall, 
1992). It is known that dopamine receptor supersensitivity (as reflected by an enhanced 
response) sometimes accompanies receptor proliferation. However, dopamine receptor 
supersensitivity may occur in the absence of a change in the number of dopamine receptors 
(Kostrzewa, 1995). Continuous antipsychotic treatment and D2 receptor blockade induces 
neuro adaptations that lead to antipsychotic failure. 
The issue is not that simple, but we confirmed with LEK-8829 the evidence that is 
important breakdown of D1/D2 synergism. LEK-8829 2 mg/kg decreases amphetamine-
induced hyperactivity much stronger than LEK-8829 0.2 mg/kg (Fig.35).  Neither one dose 
of LEK-8829 loss efficacy (increases responsiveness) after 21 days. Maybe this confirms 
the hypothesis (Braun et al., 1997) that effect of chronic D2 receptor blockade can be 
modified by concurrent stimulation of the D1 receptor.  
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
90 
When selective D2 antagonist is combined with the agonist selective for the D1 receptors, 
both D2 receptor proliferation and behavioral supersensitivity is completely blocked 
(Braun et al., 1997). We therefore speculate that in our experiments the intrinsic activity of 
LEK-8829 at dopamine D1 receptors may have prevented the up-regulation of dopamine 
D2 receptors, such as occurs after the prolonged blockade of dopamine D2 receptors with 
haloperidol.   
We therefore assume, that the decreased efficacy of haloperidol for the inhibition of 
amphetamine-induced locomotor activity indicates dopamine D2 receptor up-regulation 
that has developed during the period of prolonged treatment with haloperidol, while the 
prolonged treatment with LEK-8829 did not have such effect probably due to absence of 
up-regulation. Moreover, our results also imply that the prolonged treatment with LEK-
8829 in experimental animals does not result in the development of the functional 
breakdown of dopamine receptors.  
However, LEK-8829 has proven to be better antipsychotic than haloperidol because it has 
fewer side effects (catalepsy test) and does not show behavioral supersensitivity (reduces 
amphetamine-induced hyperactivity and after 21 day treatment). However, the D1 receptor 
may be an important target for improving negative and cognitive function in schizophrenia 
(Ginovart and Kapur, 2010).  
 
5.3 ANALYSIS OF RESERPINE MODEL OF PARKINSON'S DISEASE 
Reserpine produced a much greater effect when administered subcutaneously (Rosecrans, 
1967). Animals weighing 280-300 g were found extremely sensitive to chronic 
reserpinization but animals weighing 140-160 g tolerated reserpine the best (Rosecrans, 
1967). Systemic reserpine administration depletes dopamine at the nerve terminals and 
induces a hypokinetic state in rodents. These movement deficits are due to loss of 
dopamine storage capacity in intracellular vesicles. Reserpine-induced changes are 
temporary and striatal reserpine administration does not induce changes in the dopamine 
neurons in supstantia nigra. Also, reserpine administration induces the release of other 
neurotransmitters that may not be directly implicated in Parkinson's disease (Betarbet et 
al., 2002). Dopamine depletion leads to breakdown of D1/D2 synergism and increase of 
D2 receptors followed by supersensitisation (LaHoste and Marshall, 1992). One of the 
most important implications of the enabling relationship between D1 and D2 dopamine 
receptors it is potential relevance for the treatment of Parkinson's disease. With the 
discovery that D1 receptor stimulation is required for certain behavioral effects of D2 
agonists, it was suggested that mixed D1/D2 agonists or combinations of D1 and D2 
agonists would be more effective in alleviating Parkinsonian symptoms. The finding that 
D1 receptor stimulation is no longer necessary for D2 mediated responses in the dopamine 
denervated striatum appears to argue against the need for simultaneous stimulation of D1 
and D2 receptors in Parkinson's disease patients (Hu et al., 1990).  
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Nine days long treatments showed the following. During all nine days of recording the 
control group showed a minimal locomotor activity in accordance with reserpine treatment. 
LEK-8829 2 mg/kg, shows strongly alleviated akinetic state but from the fifth day 
onwards, hyperlocomotion and stereotype behavior were perceived. LEK-8829 0.2 mg/kg 
also exhibits an increase in locomotor activity but on 9
th
 day and stereotypic behavior was 
missing. Bromokriptine had a similar profile as a LEK-8829 0.2 mg/kg. LEK-8829            
2 mg/kg + SCH 1 mg/kg showed the same profile as LEK-8829 2 mg/kg but with decrease 
in values from LEK-8829 2 mg/kg in last 100 min (Fig.33). First 20 min show an increase 
in locomotor activity because injection of LEK-8829 2 mg/kg. After 20 min of increase 
locomotor activity injection of SCH-23390 1 mg/kg prevent action of LEK-8829 2 mg/kg. 
This confirms that an increase in locomotor activity is due to D1 receptor agonist 
properties. Catalepsy test demonstrated that all animals were cataleptic which is in 
accordance with dopamine depletion. That means that reserpinization were successful.  
Acute test doses of LEK-8829 2 mg/kg and bromorekokriptine 2 mg/kg in all treated 
groups (Table 7) demonstrate greater increase in locomotor activity with LEK-8829 2 
mg/kg than with bromorekokriptine 2 mg/kg. Bromocriptine (D2 agonist) show a smaller 
increase in locomotor activity than LEK-8829. 
Dopamine D1/D2 receptor interactions are at the behavioral, pharmacological and 
biochemical level (Clark and White, 1987; Waddington, 1989; Waddington and O'Boyle, 
1989; Niznik and Van Tol, 1992). Basically, these interactions are either antagonistic or 
synergistic. While some behaviors are predominately influenced by the activity of D1-like 
receptors, such as grooming and self-mutilation, D2 receptors predominantly influence 
locomotor activity. Synergistic actions of dopamine receptors have been observed in 
locomotion, stereotypy, grooming, electrophysiological responses, yawning and climbing 
(Niznik and Van Tol, 1992). Bromcriptine (D2 agonist) demonstrate a moderate 
locomotion with shorter duration in compare with LEK-8829. That means that 
bromocriptine (D2 agonist) just stimulates D2 receptor without repair of synergism. LEK-
8829 somehow restored synergism D1/D2 receptors (Niznik and Van Tol, 1992). 
Synergistic effects between D1 and D2 receptors, since stereotypes induced by 
administration of D1 and D2 agonists together are more intense than those produced by 
either agonist alone (Vallone et al., 2000). In accordance with this it is surprising that D1 
agonist alone have intensified stereotypes. Probably these results may be explained by 
findings White (1988) indicate that D1 agonist induced effects are not abolished, even by 
near total dopamine depletion. Their behavioral and electrophysiological studies indicate 
that D1 receptor stimulation is necessary for the expression of postsynaptic dopamine 
receptor mediated functional responses. Therefore, alterations of D1 receptor activity may 
play important roles in the Parkinson's disease and schizophrenia as well as in their 
pharmacological treatment (White et al., 1988).  
Furthermore, dihydexidine was first reported in 1990 as a selective D1 agonist and was 
subsequently shown to alleviate the symptoms of MPTP induced parkinsonism in monkeys 
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(Taylor et al., 1991). Although dihydrexidine has some affinity at D2 receptors (Ki=120 
nM), its antiparkinsonian activity is not reversed when combined with D2 antagonist, 
suggesting that this effect is due to its D1 (Ki=12nM) receptor activity. Abbot also 
synthesized a selective D1 agonist A77636 which reverses PD symptoms in parkinsonian 
marmosets (Kebabian et al., 1992). Blanchet (1993) compared the efficacy of D1 and D2 
agonists in alleviating PD symptoms in MPTP treated monkeys and reported that D1 
agonists were as effective as D2 agonists and had fewer propensities to cause dyskinesias. 
These data support the hypothesis that the D1 receptor could play a crucial role in the 
treatment of PD.  
Blanchet (1998) study for the first time the clinical effects of dihydexidine in humans. Data 
suggest that monotherapy with full dopamine D1 receptor agonist is able to provide 
antiparkinsonian efficacy, but does not improve the therapeutic window over levodopa in 
levodopa treated PD.  
Dihydexidine enters the brain readily and is fully bioavailable by parenteral administration. 
However, it has poor oral bioavailability and a relatively short half-life of 1-2 hours, which 
limits its clinical use (Salmi et al., 2004).  
All of this is shown that dopamine D1 receptor agonist properties may have great promise 
as novel therapeutic agents for treatment of Parkinson's disease and underscore the 
importance of dopamine D1 receptors in the maintenance of normal motor function. Also 
shown that development of behavioral supersensitivity (and D2 receptor up-regulation) 
prevent by simultaneously stimulation of D1 receptors (Braun et al., 1997; Marin et al., 
1993 ).  
Another one reasonable explanation exists for these results. Aripiprazole represents the 
first atypical antipsychotic that acts as a partial agonist at dopaminergic receptors. Like full 
receptor agonists, partial agonists have full receptor affinity but possess limited intrinsic 
activity. Partial agonism at dopaminergic neurons results in a decrease and an increase in 
dopaminergic mediated neurotransmission in areas of hyperdopaminegic and 
hypodopaminergic activity, respectively. Therefore, complete blockade of dopaminergic 
receptors does not occur. Instead, intrinsic activity possessed by aripiprazole maintains 
dopaminergic mediated neurotransmission, although at a less intensive magnitude (DeLeon 
et al., 2004).   
Partial agonism has been shown to occur on both the postsynaptic D2 receptor and 
presynaptic dopamine autoreceptors. Two possible results of partial agonism at the 
postsynaptic D2 receptor are a reduced tendency for receptor up-regulation and 
development of EPS by avoiding complete receptor blockade. Partial agonism at the 
dopamine autoreceptor decreases dopamine synthesis, release, and subsequent 
dopaminergic neurotransmission. Multiple studies have confirmed antagonistic and 
agonistic activity with aripiprazole, depending on the presence of a hyperdopaminergic or 
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hypodopaminergic environment, respectively (Burris et al., 2002; Matsubayashi et al., 
1999; DeLeon et al., 2004). 
Antagonism at the 5-HT2A receptor minimizes excessive dopaminergic blockade by 
increasing dopaminergic release. In the nigrostriatal and mesocortical dopamine pathways, 
this results in a lower rate of EPS and may contribute to the improvement of negative 
symptoms, respectively. In the mesolimbic pathway, antagonism at the 5-HT2A receptor 
does not cause an increase in dopamine release sufficient to prevent antipsychotic activity, 
a phenomenon possibly explained by regional differences in 5-HT2A autoreceptor density 
(DeLeon et al., 2004).   
Aripiprazole monotherapy was generally well tolerated and efficacious in the treatment of 
schizophrenia. It was associated with improvements in the positive, negative and cognitive 
aspects of these disorders with a low risk for the EPS and TD. Aripiprazole’s lack of D2 
up-regulating effects relative to agents such as haloperidol has been reported to translate 
into a low incidence of treatment emergent TD (Stip and Tourjman, 2010). 
Naber (2002) has showed that aripriprazole is markedly superior to haloperidol during long 
term therapy i.e. haloperidol loses efficacy during the prolonged treatment (Naber and 
Lambert, 2004). 
Aripiprazole barely failed to elicit catalepsy, a typical behaviour which is largely 
documented for dopamine receptor blockers such as haloperidol. Very high doses of 
aripiprazole were required in order to evoke a significant cataleptic behavior (Koener et al., 
2011).  
In rats, the liability of most antipsychotics to induce catalepsy correlates with striatal 
receptor occupation (D2 receptor antagonism). Aripiprazole, on the other hand, fails to 
induce significant motor impairments even in doses that induce up to 95% of receptor 
occupation, probably because of its ability to maintain the receptors slightly activated. 
Interestingly, the same profile is observed in humans. For most antipsychotics, the 
therapeutic window occurs between 60% and 80% of striatal occupancy. Higher levels of 
receptor occupancy by these drugs lead to extrapyramidal side effects, while aripiprazole 
has a safer profile even though it occupies more than 90% of receptors. This partial 
agonistic effect of aripiprazole led to the hypothesis that this compound may act as a 
dopamine stabilizer. At somato-dentritic receptors, where the levels of dopamine are low, 
it may exert effects similar to an agonist, whilst at postsynaptic sites, where the levels of 
this neurotransmitter are high, it may occupy the receptors and reduce (but not abolish) 
their activation. Thus, this modulatory action of aripiprazole may explain why aripiprazole 
blocked the effect of amphetamine and cocaine without induce significant motor 
impairments (Leite et al., 2008). 
Aripiprazole has an ability to stabilize the sensitivity to dopamine (Tadokoro, 2013). 
The previously shown results with LEK-8829 are the same as the results with aripriprazole. 
LEK-8829 induced lower catalepsy than haloperidol. Also, LEK-8829 inhibited the 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
94 
amphetamine induced locomotion without losing efficiency after a prolonged treatment. In 
accordance with results it is rational to assume that LEK-8829 is a D2 partial agonist.  
Dopamine depletion with reserpine LEK-8829 demonstrates a maximum locomotor 
response. That is uncommon because it was suggested that mixed D1/D2 agonists or 
combination of D1 and D2 agonists would be more effective in alleviating Parkinsonian 
symptoms. Dopamine D1/D2 receptor interactions are at the behavioral, pharmacological 
and biochemical level. Basically, these interactions are either antagonistic or synergistic. 
While some behaviors are predominately influenced by the activity of D1 like receptors, 
such as grooming and self-mutilation, D2 receptors predominantly influence locomotor 
activity. Synergistic actions of dopamine receptors have been observed in locomotion, 
stereotypy, grooming, electrophysiological responses, yawning and climbing. Bromcriptine 
(D2 agonist) demonstrate a moderate locomotion with shorter duration in compare with 
LEK-8829. That means that bromocriptine (D2 agonist) just stimulates D2 receptor 
without repair of synergism. LEK-8829 restored synergism D1/D2 receptors because it is a 
D2 partial agonist. Synergistic effects between D1 and D2 receptors, since stereotypes 
induced by administration of D1 and D2 agonists together are more intense than those 
produced by either agonist alone indicate that in absence of dopamine LEK-8829 have D2 
partial agonist properties. LEK-8829 2 mg/kg shows intensified stereotypes behaviour. 
Our data suggest that LEK-8829 is a D2 partial agonist and due to its properties has a 
lower propensity to induce EPS, inhibited the amphetamine induced locomotion without 
losing efficiency after prolonged treatment, it is more effective in alleviating Parkinsonian 
symptoms than bromocriptine (D2 agonist) and stabilize the sensitivity to dopamine. 
 
5.4 PROTEIN AND mRNA ANALYSIS OF DOPAMINE D2 RECEPTORS   
The purpose of in situ hybridization was to detect changes in mRNA expression of D2 
receptor, D2 long, D2 short isoforms and Nova 1 in striatum due to subchronic treatment 
with test compounds. Alternative D2 receptor pre-mRNA splicing is controlled by splicing 
regulator Nova 1. 
Expression of mRNA D2 receptors after prolonged daily treatment with saline, haloperidol 
2 mg/kg and 0.2 mg/kg; and LEK-8829 2 mg/kg show the obvious tendency of prolonged 
daily treatment to cause a higher up-regulation of mRNA D2 receptors in the group treated 
with haloperidol 2 mg/kg than in the group treated with LEK-8829 2 mg/kg. Haloperidol 
0.2 mg/kg causes less up-regulation than haloperidol 2mg/kg because of a smaller dose 
(Fig.47).  
We have confirmed the hypothesis that subchronic treatment of experimental rats with 
LEK-8829 causes less dopaminergic supersensitivity and up-regulation of dopamine D2 
receptors in the striatum as a chronic treatment with D2 antagonist haloperidol. 
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The 6-OHDA model has D2 receptor up-regulation and this was a preliminary analysis for 
verification D2 receptor and its isoforms (Fig.49).   
Results show up-regulation of D2 receptors (due to its internal control) and up-regulation 
of D2S isoform (due to its internal control). D2L does not show up-regulation due to its 
internal control.  
It is surprising that results show an up-regulation of D2S isoform because Khan and 
colleagues (1998), report that D2S is located predominantly in cell bodies and exons of 
dopaminergic neurons of the primate midbrain, whereas D2L is more strongly expressed 
by neurons of the striatum and nucleus accumbens that are targeted by dopaminergic 
neuron. Accordingly, in the primate brain, D2S and D2L are primarily localized to pre- and 
postsynaptic membranes, respectively. 
The dorsal striatum represents an ideal system in which to study dopaminergic 
transmission. In this region, dopamine D2 receptors are expressed both postsynaptically, 
on striatal medium spiny neurons, as well as presynaptically, on dopaminergic nerve 
terminals originating from the supstantia nigra pars compacta (Lindgren et al.,2003). In the 
6-OHDA model, dopaminergic nerve terminals originating from the supstantia nigra pars 
compacta are destroyed and it is expected to have less D2S isoform.   
Perhaps the explanation is in the specific involvement of the D2S isoform in the regulation 
of dopamine biosynthesis (Lindgren et al., 2003). Due to the deterioration of dopaminergic 
neurons from the supstantia nigra pars compacta leads to a lack of dopamine. Loss of 
dopamine less than 80% can be compensated due to increasing activity of remaining 
neurons. It is possible that this increasing activity of the remaining neurons leads to an 
increase in D2S isoform. 
We showed that up-regulation of dopamine D2 receptors in the striatum have resulted in 
changes in relative splicing forms of D2S and D2L. D2S show up-regulation. 
Further work on slices from subchronic treatment with test compounds will show an 
amount of up-regulation of dopamine D2 receptors in the striatum and changes in relative 
splicing forms of D2S and D2L. Also, on same slices we will check what it happening with 
splicing factor Nova 1. 
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6 SUMMARY  (POVZETEK) 
 
6.1 SUMMARY 
Antipsychotics often lose efficacy during chronic continuous treatment. The loss of 
antipsychotic efficacy may be linked to an increase in D2 receptor number and sensitivity, 
e.g. such as occurrs after prolonged treatment with dopamine D2 receptor antagonist 
haloperidol. Consequently, the dopaminergic hypersensitivity that develops during the 
prolonged treatment with neuroleptic drugs often leads to undesired development of 
tardive dyskinesia. 
LEK-8829 has D1 agonistic and D2 antagonistic properties in the nigrostriatal and 
mesocorticolimbic dopaminergic pathways. Here we speculate that such unusual 
pharmacological profile at dopamine receptors may confer a lower propensity for the 
development of dopaminergic hypersensitivity during prolonged treatment.  
We have determined the impact on behavioral and neurochemical effect of subchronic 
treatment of LEK-8829, and the catalepsy analysis (experiment 1; catalepsy test on the 1
st
 
and on the 21
st
 day) demonstrated that only LEK-8829 significantly increased its potential 
for the induction of catalepsy. However, when we tested the LEK-8829 treated animals 
after 7 days of drug-free period (experiment 2; catalepsy test on the 1
st
 and on the 28
th
 
day), the latency to the onset of catalepsy was decreased, but the catalepsy score reverted 
to the level induced by 0.2 mg/kg of haloperidol in drug naive animals.  
The analysis of amphetamine model of schizophrenia demonstrate, when tested in drug 
naive rats, that both LEK-8829 2 mg/kg and haloperidol 2 mg/kg almost completely 
inhibited the amphetamine-induced locomotor behavior in the open field. However, after 
prolonged treatment period with the respective drug, only LEK-8829 retained its inhibitory 
properties, while haloperidol mediated inhibition was significantly reduced. These results 
indicate that in comparison with neuroleptic haloperidol, prolonged treatment with LEK-
8829 does not lose efficacy during subchronic continuous treatment and may have a lower 
propensity for the development of tardive dyskinesia. 
In models of parkinsonism with prolonged dopamine depletion in the brain the intrinsic 
activity of LEK-8829 at dopamine D1 receptors has been revealed by the robust 
psychomotor response that seems to be unabated by the concurrent blockade of dopamine. 
Our results indicate that D1 agonist propreties reduce dopaminergic supersensitivity and 
mRNA up-regulation of dopamine D2 receptors. Haloperidol causes higher up-regulation 
of dopamine D2 receptors than LEK-8829.  
Results on the 6-OHDA model show up-regulation of D2 receptors (due to its internal 
contol) and up-regulation of D2S isoform (due to its internal contol). D2L does not show 
up-regulation due to its internal control. We showed that up-regulation of dopamine D2 
receptors in the striatum has resulted in up-regulation of D2S isoform.  
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We were not able to analyse how subchronic treatment of dopamine D1 receptors and 
inhibition of D2 receptors (i.e. LEK-8829) in the striatum affect the expression of 
alternative splicing factors Nova 1.  
In western blot analysis we were able to see D2 long and D2 short isoforms but we could 
not detect up-regulation of D2 receptor and/or D2 long and D2 short isoforms because 
cross-reaction between primary mouse antibodies and Ig G in rat samples (Fig.40). 
To our surprise results indicate that LEK-8829 is a D2 patiral agonist and due to that 
properties have an ability to stabilize the sensitivity to dopamine. LEK-8829 is a D2 partial 
agonist and due to its propertis has a lower propensity to induce EPS, inhibited the 
amphetamine induced locomotion witouh losing efficency after prolonged treatment, it is 
more effective in alleviating Parkinsonian symptoms than bromocriptine (D2 agonist) and 
stabilize the sensitivity to dopamine.  
            
6.2 POVZETEK 
Pri nastanku simptomov shizofrenije in Parkinsonove bolezni, kot tudi pri zdravljenju in 
stranskih učinkih zdravljenja naštetih bolezni, ima pomembno vlogo spremenjena 
odzivnost dopaminoceptivnih nevronov v možganih. 
Pri obeh omenjenih boleznih ima pomembno vlogo povečana aktivnost dopaminoceptivnih 
nevronov v tarčnih področjih dopaminskih nevronov. Le-ta je lahko posledica plastičnih 
sprememb, ki privedejo do povečane odzivnosti dopaminoceptivnih nevronov na endogeni 
dopamin, na primer zaradi povečanega izražanja genov dopaminskih receptorjev. Povečana 
dopaminergična odzivnost dopaminoceptivnih nevronov je najbrž vpletena v nastanek 
tardivne diskinezije, ki se lahko pojavi kot neželeni učinek pri uporabi antipsihotičnih in 
antiparkinsonskih zdravil.  
Shizofrenija je huda duševna bolezen, ki jo spremljajo pozitivni simptomi (halucinacije, 
blodnje, zaznavno izkrivljenje…) in negativni simptomi (psihomotorična upočasnjenost, 
čustvena otopelost, pomanjkanje interesov in hotenja...). Po dopaminski hipotezi so 
pozitivni znaki te bolezni posledica povečanega sinaptičnega prenosa prek aktivacije 
subkortikalnih dopaminskih receptorjev podtipa D2, saj vsa klinično uveljavljena 
antipsihotična zdravila delujejo kot zaviralci dopaminskih receptorjev D2. V 
subkortikalnih limbičnih in motoričnih dopaminoceptivnih področjih (nukleus akumbens, 
striatum), ki so pomembna za nastanek pozitivnih znakov, so dopaminski receptorji D2 
izraženi v približno enaki meri kot dopaminski receptorji D1. 
Ublažitev pozitivnih znakov shizofrenije se ne pojavi že na začetku zdravljenja z 
antipsihotiki, temveč šele po dolgotrajnejšem jemanju, kar kaže na pomen možganske 
plastičnosti pri zdravljenju shizofrenije. Po drugi strani pa so po dopaminski hipotezi 
negativni znaki shizofrenije posledica zmanjšanega mezokortikalnega dopaminergičnega 
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sinaptičnega prenosa prek dopaminskih receptorjev D1, predvsem v čelni skorji 
(hipofrontalnost), ki so v tem področju sicer izraženi v večji meri kot dopaminski receptorji 
iz farmakološke skupine D2.  
Pri Parkinsonovi bolezni, za katero je značilno postopno propadanje dopaminergičnih 
nigrostriatnih nevronov, nastane tako imenovana denervacijska dopaminergična 
hipersenzitivnost. Le-ta se pokaže kot pretiran motorični odziv na stimulacijo z 
antiparkinsonskimi zdravili (L-DOPA, apomorfin). Nastane zaradi povečanja 
dopaminergične odzivnosti dveh populacij dopaminoceptivnih nevronov v striatumu, ki 
izražajo bodisi dopaminske receptorje D1 ali D2, kot kompenzacijski odgovor na hudo in 
dolgotrajno pomanjkanje dopamina v striatumu.  
Zato velja, da imajo spremembe dopaminergične odzivnosti v možganih pomembno vlogo 
pri obeh omenjenih boleznih.  
Zdravljenje shizofrenije in parkinsonizma  
Klasične antipsihotike iz zgodnjega obdobja zdravljenja shizofrenije, ki imajo zaradi 
relativno selektivnega zaviranja subkortikalnih dopaminskih receptorjev D2 tendenco 
povzročanja katalepsije in parkinsonskega sindroma, imenujemo nevroleptiki. Učinki 
zdravljenja shizofrenije se ne pojavijo takoj, temveč šele po dalj časa trajajočem zaviranju 
dopaminskih receptorjev D2, kar kaže, da so za ublažitev pozitivnih simptomov najprej 
potrebne plastične prilagoditve nekaterih možganskih področij na dolgotrajno zaviranje 
dopaminskih receptorjev D2 z dopaminskimi antagonisti. Na žalost pa dolgotrajno jemanje 
antipsihotičnih zdravil lahko povzroči pojav tardivne diskinezije, ki se kaže z 
nenadzorovanimi in pretiranimi gibi. Nastanek tardivne diskinezije povezujejo s 
povečanim izražanjem in/ali s povečano odzivnostjo striatalnih dopaminskih receptorjev, 
kot posledice dolgotrajnega zaviranja dopaminskega prenosa pri zdravljenju shizofrenije.  
Katalepsija predstavlja živalski model za z nevroleptiki povzročen parkinsonizem pri 
ljudeh in se uporablja kot standardni predklinični preizkus za napoved antipsihotične 
aktivnosti ter odgovornosti za stranske učinke. Znano je, da antipsihotiki provzročajo 
katalepsijo pri glodalcih in imajo od odmerka odvisno nagnjenost k sprožanju EPS pri 
ljudeh. Antipsihotiki provzročajo katalepsijo zaradi zaviranja dopaminskih D2 receptorjev 
v bazalnih ganglijih. Katalepsijo se lahko sproži z zaviranjem dopaminskih D1 receptorjev 
ali dopaminskih D2 receptorjev. Sočasno dajanje dopaminskih D1 in D2 antagonistov ima 
sinergistični učinek na katalepsijo. 
Velik problem pri zdravljenju shizofrenije z antipsihotičnimi zdravili, ki so trenutno v 
klinični uporabi, je tudi ta, da z zaviranjem dopaminskega prenosa v čelni skorji ne 
ublažijo oziroma lahko celo poslabšajo negativne simptome shizofrenije. 
Zaradi omenjenih stranskih učinkov in neučinkovitosti glede zdravljenja negativnih 
simptomov razvijajo nove antipsihotične učinkovine, ki se jih je oprijelo ime atipični 
antipsihotiki. Razvoj atipičnih antipsihotikov je najprej temeljil na dopaminsko-
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serotoninski hipotezi, pri čemer naj bi bila ob hkratnem zaviranju dopaminskih receptorjev 
D2 in serotoninskih receptorjev 5-HT2A, ob enakem antipsihotičnem učinku (glede 
pozitivne simptomatike), manjša potreba po zaviranju dopaminskih receptorjev D2 kot pri 
zdravljenju z nevroleptiki. Vendar pa tudi omenjeno sočasno antagonistično delovanje 
atipičnih antipsihotikov na dopaminskih in serotoninskih receptorjih ni doprineslo k 
zdravljenju negativne simptomatike. Glede na že omenjeno prevlado dopaminskih 
receptorjev D1 v čelni skorji, ob zmanjšanem dopaminskem prenosu v tem področju pri 
bolnikih s shizofrenijo (hipofrontalnost), so nekateri raziskovalci predlagali, da bi 
spodbujanje dopaminskega prenosa v čelni skorji z dopaminskimi agonisti D1 morda lahko 
neposredno ublažilo negativne simptome. Po drugi strani pa bi dopaminski agonisti D1 s 
spodbujanjem kortiko-tegmentalnih piramidnih nevronov čelne skorje (le-ti v ventralnem 
tegmentumu sproščajo glutamat), s spodbujanjem GABAergičnih internevronov v tem 
področju, zavrli in tako ponovno uravnovesili delovanje deinhibiranih subkortikalnih 
dopaminergičnih nevronov, kar bi poleg negativnih hkrati ublažilo tudi pozitivne simptome 
shizofrenije. 
LEK-8829 je snov z nenavadnim učinkom na dopaminskih receptorjih. Ta snov namreč po 
eni strani zavira delovanje dopaminskih receptorjev D2, po drugi strani pa spodbuja 
dopaminske receptorje D1. Ker so v striatumu dopaminski receptorji D1 in D2 ločeno 
izraženi na membranah različnih fenotipov dopaminoceptivnih nevronov t.i. neposredne 
poti (D1 receptorji) in posredne poti (D2 receptorji), pri čemer endogeni dopamin spodbuja 
delovanje nevronov, ki izražajo D1 receptorje in zavira delovanje nevronov, ki izražajo D2 
receptorje, so postavili hipotezo, da v striatumu LEK-8829 spodbuja delovanje tako 
nevronov posredne kot neposredne poti. Raziskave učinkov LEK-8829 na vedenje in na 
izražanje genov v striatumu, ki so bile do sedaj opravljene na živalskih modelih za 
shizofrenijo, parkinsonizem ter na modelu sprožanja recidiva pri zasvojenosti s kokainom 
so pokazale učinke, ki se skladajo z opisano dopaminergično hipotezo glede receptorskih 
učinkov LEK-8829. Pri tem pa je potrebno omeniti, da LEK-8829 deluje zaviralno tudi na 
serotoninske receptorje 5-HT2A, na katere se veže z večjo afiniteto kot na dopaminske 
receptorje D2, zaradi česar se uvršča med tako imenovane atipične antipsihotike, z 
delovanjem, ki je bolj podobno atipičnemu antipsihotiku klozapinu kot nevroleptiku 
haloperidolu. Za atipične antipsihotike nekoliko neobičajen dopaminergični profil LEK-
8829 je bil odkrit s preučevanjem akutnih učinkov LEK-8829 na vedenje in na izražanje 
genov v striatumu poskusnih podgan z normosenzitivnimi in s hipersenzitivnimi 
dopaminskimi receptorji na modelnih poskusnih podganah za shizofrenijo, parkinsonizem, 
Huntingtonovo bolezen in za zasvojenost s psihomotoričnimi stimulansi. Kronični učinki 
LEK-8829 na vedenje živali in na izražanje genov v možganih modelnih poskusnih podgan 
pa do sedaj še niso bili raziskani. 
Iz literature je znano, da je povečano dopaminergično odzivnost na dopaminske 
antagoniste D2 mogoče ublažiti s sočasnim tretiranjem z agonisti dopaminskih receptorjev 
D1. Zato predpostavljam, da bi s sočasnim antagonističnim delovanjem na dopaminskih 
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receptorjih D2 in agonističnim delovanjem na dopaminskih receptorjih D1, ob kroničnem 
tretiranju, LEK-8829 lahko zaviral nastanek dopaminergične hipersenzitivnosti in s tem 
neželene učinke pri zdravljenju shizofrenije, parkinsonizma. V doktorski nalogi sem zato  
raziskala nekatere vedenjske in nevrokemične učinke kroničnega tretiranja poskusnih 
podgan s potencialnim antipsihotičnim zdravilom LEK-8829, ki na dopaminskih 
receptorjih deluje kot D1 agonist/D2 antagonist. Osredotočila sem se na učinek LEK-8829 
na gensko izražanje postsinaptičnih dopaminskih receptorjev D2 in njihovih spojitvenih 
oblik D2S in D2L v dorzalnem in ventralnem striatumu 
Aripiprazole predstavlja prvi atipični antipsihotik, ki deluje kot delni agonist na 
dopaminergične receptorje. Kot agonist zasedenih receptorjev ima delni agonist polno 
receptorsko afiniteto vendar kljub temu omejeno aktivnost. Delni agonizem na 
dopaminergičnih neuronih privede do zmanjšanja ali zvišanja dopaminergične 
neurotransmisije na območjih povečane ali zmanjšane dopaminergične aktivnosti. Zato se 
popolna blokada dopaminergičnih receptorjev ne zgodi. Namesto tega ima aripiprazol 
aktivnost, ki ohranja dopaminergično neurotransmisijo, vendar z manj intenzivnim 
obsegom.  
Dokazano je, da pride do delnega agonizma na postsinaptičnih D2 receptorjih in 
presinaptičnih dopaminskih avtoreceptorjih. Dva možna izhoda delnega agonizma na 
postsinaptičnih D2 receptorjih sta zmanjšana nagnjenost k povečjanju števila receptora in 
razvoj EPS z izogibanjem popolne blokade receptorjev. Delni agonizem na dopaminskih 
avtoreceptorjih zmanjšuje sintezo dopamina, njegovo sproščanje in kasnejšo 
dopaminergično neurotransmisijo. Več študij je potrdilo antagonistično in agonistično 
aktivnost aripiprazola, odvisno od količine dopamina.  
Antagonizem na 5-HT2A receptorijih zmanjšuje prekomerno dopaminergično blokado z 
večjim sproščanjem dopamina. Poteka v nigrostriatni in mesokortikalni poti in se kaže v 
nižji stopnji EPS in lahko prispeva k izboljšanju negativnih simptomov. V mesolimbični 
poti antagonizem na 5-HT2A receptorijih ne povzroča povečjanja sproščanja dopamina, kar 
preprečiantipsihotične aktivnosti, pojav, ki ga lahko razložimo z regionalnimi razlikami v 
5-HT2A avtoreceptorski gostoti.  
Zdravljenje z aripiprazolom pacienti na splošno dobro prenašajo, hkrati pa je zdravljenje 
shizofrenije s tem zdravilo učinkovito. To je povezano z izboljšanjem pozitivnih, 
negativnih in kognitivnih simptomov ter z nizkim tveganjem za EPS and TD. Aripiprazolu 
primanjkuje učinek na povečjanje števila D2 receptorjev, ki je prisoten pri haloperidolu, 
zato ima aripiprazol nizko pojavnost pri zdravljenju TD. 
Naber (2002) kaže, da je aripriprazol precej boljši kot haloperidol pri dolgotrajnem 
zdravljenju, kjer haloperidol izgublja učinkovitost.Z aripiprazolom komaj uspemo, da 
izzvati katalepsijo, tipično vedenje zaradi blokade dopaminskih receptorjev, ki je v veliki 
meri dokumentirano za haloperidol. Le zelo visoki odmerki aripiprazola izzovejo znatno 
kataleptično vedenje.  
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Aripiprazole ima sposobnost da stabilizira občutljivost na dopamin. 
Dopaminergično uravnavanje izražanja pre-mRNA in alternativnega             
zlepljanja eksonov dopaminskega receptorja D2  
Znano je, da ima uporaba antagonistov dopaminskih receptorjev pri zdravljenju 
shizofrenije, kakor tudi uporaba agonistov dopaminskih receptorjev, ob hudem 
pomanjkanju endogenega dopamina pri Parkinsonovi bolezni, lahko za posledico povečano 
izražanje obeh oblik striatalnih dopaminskih receptorjev D2, ki nastajata z alternativnim 
izrezovanjem pre-mRNA z zapisom za dopaminski receptor D2 (pa tudi številnih drugih 
genov) in s temi spremembami povezano povečano dopaminergično odzivnost striatalnih 
nevronov. Kot je že omenjeno, bi omenjene receptorske spremembe lahko imele za 
posledico nastanek tardivne diskinezije pri zdravljenju shizofrenije in/ali Parkinsonove 
bolezni, pa tudi t.i dopaminergične senzitizacije, kot imenujemo povečano vedenjsko, 
elektrofiziološko in nevrokemično odzivnost.  
V striatumu se dopaminski receptorji D2 nahajajo postsinaptično, na dendritih nevronih 
posredne poti ter na dendritih holinergičnih internevronih pa tudi kot presinaptični 
avtoreceptorji na končičih dopaminergičnih nevronov, ki v striatum projicirajo iz substance 
nigre kompakte (le-ti delujejo avtoregulatorno pri sproščanju dopamina iz dopaminergičnih 
končičev teh nevronov v striatumu). Pri tem je zanimivo, da sta v striatnih 
dopaminoceptivnih projekcijskih nevronih posredne poti, kakor tudi v dopaminergičnih 
nevronih, ki projicirajo v striatum, izraženi mRNA dveh oblik mRNA dopaminskih 
receptorjev D2, ki nastaneta z alternativnim izrezovanjem intronov pre-mRNA 
dopaminskih receptorjev D2. Vendar pa dobro znano inhibitorno delovanje dopamina na 
nevrone posredne poti povezujejo z vezavo dopamina na dopaminske receptorje D2L. 
Predel v D2L, ki ga kodira  ekson 6 pre-mRNA dopaminskega receptorja (oblika D2S je 
brez tega inserta), namreč omogoča interakcijo tretje znotrajcelične zanke receptorja D2L z 
beljakovino Gαi2, ki deluje močno zaviralno na encim adenilat-ciklazo, pri obliki D2S pa 
je ta interakcija in zaviranje cAMP šibkejše, poleg tega pa določa tudi alternativni 
znotrajcelični promet in lokalizacijo na nevrolemi, npr. presinaptično lokalizacijo oblike 
D2S na dopaminskih nevronih, kjer ta oblika deluje kot inhibitorni avtoreceptor pri 
sproščanju dopamina v striatumu. Po drugi strani pa spodbujanje receptorjev D2L na 
dendritih postinaptičnih omenjenih nevronov z dopaminskimi agonisti ali z endogenim 
dopaminom zavira delovanje encima adenilat-ciklaze, zaviranje receptorjev D2L z 
antipsihotiki pa njegovo delovanje spodbuja. 
Novejše raziskave so identificirale nekatere proteine, ki sodelujejo pri vključevanju 
oziroma izključevanju eksona 6 v mRNK D2L (Nova 1, hnRNP M, PTBP1). Tako so na 
primer pokazali, da je hnRNP M ključni dejavnik pri uravnavanju altrnativnega zlepljanja 
eksonov pre-mRNK D2 receptorjev. Njegova vezava na ekson 6 pre-mRNA dopaminskega 
receptorja D2 inhibira inkluzijo tega eksona v mRNK D2L, pri čemer dejavnik Nova 1, z 
vezavo na specifične sekvence pre-mRNA D2 receptorjev zavira delovanje hnRNP M in s 
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tem favorizira nastajanje daljše oblike tega receptorja, D2L. Nova 1 je dejavnik 
alternativnega zlepljanja eksonov, ki na splošno uravnava inkluzijo oziroma ekskluzijo 
eksonov glede na položaj vezavnega mesta Nova 1. Kadar se na primer Nova 1 veže na 
mesto 3' kasetnega eksona, to promovira inkluzijo tega kasetnega eksona. Na ta način je 
protein Nova1 v striatumu udeležen tudi pri uravnavanju alternativnega zlepljanja eksonov 
nekaterih drugih genov, ki jih tako kot dopaminske receptorje D2 izražajo 
dopaminoceptivni GABA-ergični nevroni posredne poti (GlyR-α2, K+ kanale –GIRK2), ki 
so tudi funkcionalno sklopljeni z inhibitornim delovanjem oblike dopaminskega receptorja 
D2L in dejavnik PTBP1 najbrž favorizira inkluzijo eksona 6 in s tem relativno večje 
nastajanje daljše oblike D2L. Po drugi strani pa je v literaturi glede pomena izražanja obeh 
spojitvenih oblik dopaminskega receptorja v striatalnih nevronih posredne poti, kot tudi v 
dopaminskih nigrostriatnih nevronih, še veliko neznank. Prav tako ni podatkov o 
morebitnem funkcionalnem pomenu mehanizmov uravnavanja alternativnega izrezovanja 
v patofizioloških razmerah. 
Metode raziskovanja 
V raziskavi sem uporabljala skupine odraslih poskusnih podgan (270 - 300 gr), samčkov 
linije Wistar. Vedenjski poskusi so bili: test katalepsije, spontana lokomotorna aktivnost v 
odprtem polju, z amfetaminom spodbujena lokomotorna aktivnost ter z testnimi snovmi 
zavrta z amfetaminom sprožena lokomotorna aktivnost. Živali sem posnela z Noldus Ethno 
Vision programom za spremljanje živali. 
Test katalepsije 
Test katalepsije sem naredila v dveh poskusih. Test katalepsije je izvajan z metodo po 
Krishu. Po injekciji testnih snovi vsakih 20 min je merjena katelepsija do 260 min. Na 
palico višine 11 cm nad tlemi se z prednjimi šapami dajo podgane. Ocena je podana na 
podlagi čas, v katerem podgana postavi sprednje noge na tla. Ocena 1: med 15 in 29 sec; 
ocena 2: med 30 in 59 sec; ter ocena 3: 60 sec ali več.  
1) Poskus katalepsije: test katalepsije 1 in 21 dan, to je prvi in zadnji dan subhroničnega 
tretiranja z LEK-8829 2 mg/kg in 0,2 mg/kg ter z haloperidolom 2 mg/kg in 0,2 mg/kg. 
Skupine so bile sestavljene iz 8 podgan. Hotela sem preveriti ali LEK-8829 zmanjšuje 
toleranco do katalepsije po 21 dnevnem tretiranju. Rezultati so pokazali, da haloperido l 
2 mg/kg povzroča večjo katalepsijo kot haloperidol 0,2 mg/kg, kar je v skladu z 
litetarurnimi podatki o od odmerka odvisne katalepsije (Slika 20, 21). LEK-8829 0,2 
mg/kg ne povzroča katalepsije (ocena katalepsije je pod oceno 1) (Slika 23). LEK-8829 
2 mg/kg na 1 dan testiranja provzroča enako katalepsijo kot haloperidol 0,2 mg/kg 
(merjeno v oceni), kar kaže na ekvivalentne doze (Slika 28). LEK-8829 2 mg/kg na 21 
dan provzroča enako katalepsijo kot haloperidol 2 mg/kg (krivulje 1 in 21 dan so precej 
enake) (Slika 29). To pomeni da LEK-8829 v dozi 2 mg/kg provzroča zvišanje 
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katalepsije. Pri tem sta pomembni dve stvari: doza LEK 2 mg/kg je dokaj velika in 
verjetno ni terapevtska ter testne snovi so bile še vedno v obtoku tretiranih živali. 
2) Poskus katalepsije: test katalepsije 1 in 28 dan. Tretiranje z fiziološko raztopino, z 
LEK-8829 2 mg/kg in s haloperidolom 0,2 mg/kg je potekalo od 1 do 21 dneva, 28 dan 
pa v krvnem obtoku testnih živali ni več bilo prisotnih testnih snovi. Skupine so bile 
sestavljene iz 6 podgan. Hotela sem preverit odzivnost receptorjev ko testnih snovi ni 
več v obtoku. Tokrat sem merila katalepsijo tudi fiziološki skupini in ugotovila, da se 
testne živali učijo katalepsije ter da je 28. dan ocena večja kot 1. dan, kljub temu pa sta 
obe krivulji pod oceno 1. Torej ne gre za pravo katalepsijo, kar je v saglasju z 
literaturo. Presenetljivo je,  da je haloperidol 0,2 mg/kg na testu 28. dan povzročil večjo 
katalepsijo kot na testu  21. dan (1 poskus katalepsije) in Wilcoxon neparametrični 
statistični test je pokazal, da se je učinek katalepsije zvišal od 1. do 28. dneva. Medtem 
pa LEK-8829 2 mg/kg v nasprotju z prvim poskusom katalepsije oziroma testom 
katalepsije 21. dan ni pokazal razlik med krivuljama 1. in 28. dan.  
To pomeni, da v prvem poskusu, kjer je bil LEK-8829 še vedno v krvnem obtoku, dobimo 
povečanje učinka katalepsije, medtem ko je katalepsija v drugem poskusu enaka kot na 1. 
dan, pri čemer LEK-8829 ni bil več v krvnem obtoku testnih živali. Manjša doza 
haloperidola 0,2 mg/kg, ko haloperidola ni več v obtoku, provzroča večji učinek. Zaradi 
tega sklepamo, da naj bi LEK-8829 po dolgotrajnem jamanju manj vplival na receptorje ter 
provzročil manj neželenih učinkov. 
Statistična analiza rezultatov 
Podatki so analizirani z SPSS programom (SPSS 19.0 for Windows, Chicago, Illinois, 
USA). 
Katalepsija je analizirana z neparametričnim Wilcoxon testom nivoja, ki primerja iste 
skupine prej in potem in Mann-Whitney testom, ki primeja različne skupine. 
Amfetaminski živalski model za shizofrenijo 
Amfetaminski živalski model za shizofrenijo. Injiciranje testnih snovi je trajalo 21 dni. 
Skupine so bile sestavljene iz 8 podgan. Pred začetkom iniciranja in po končanem 
iniciranju je narejen test zaviranje z testnimi snovmi – z amfetaminom sprožene 
lokomotorne aktivnosti. Test izveden pri naivnih podganah je pokazal, da LEK 2 mg/kg in 
haloperidol 2 mg/kg popolnoma zavreta z amfetaminom sproženo lokomotorno aktivnost. 
Enak test po končanem 21. dnevnem injiciranju testnih snovi je pokazal, da le LEK-88829 
obdrži zaviralni učinek na amfetamin, medtem ko se je zaviranje s haloperidolom bistveno 
zmanjšalo. 
Rezultati primerjave subkroničnega tretiranja s haloperidolom in LEK-8829 kažejo, da 
LEK-8829 po subkroničnem tretiranju ne izgublja učinek in ima predvidoma manjšo 
nagnjenost k neželjenim učinkom ter razvoju tardivne diskinezije.  
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Statistična analiza rezultatov 
Podatki so analizirani z SPSS programom (SPSS 19.0 for Windows, Chicago, Illinois, 
USA). 
Zaviranje amfetaminske lokomocije s testnimi snovi je analizirano z dvo-smernim parnim 
testom t in analizo variance (ANOVA) s Scheffejevim testom. 
Rezerpinski živalski model za Parkinsonovo bolezen 
Rezerpinski živalski model za Parkinsonovo bolezen. Rezerpin so živali prejele 3-krat vsak 
3. dan. Injiciranje testnih snovi je trajalo 9 dni, sledila sta še 2 dneva brez testnih snovi. 
Zadnji dan poskusa sem živali razdellila v skupine po 3 živali, ki so prejele  LEK-8829 2 
mg/kg ali bromoergokriptin 2 mg/kg. Skupine so bile sestavljene iz 6 podgan razen 
kontrolne skupine, ki je imela 12 živali. Testne snovi so bile: fiziološka raztopina, LEK-
88209 2 mg/kg in 0,2 mg/kg, bromoerkokriptin 2 mg/kg, LEK-8829 2 mg/kg + SCH (D1 
antagonist) 1 mg/kg.  
Rezerpin ireverzibilno preprečuje vnos in shranjevanje monoaminov (dopamine, 
noradrenalin in serotonin) v sinaptični vezikel, saj zavira delovanje vezikularnega 
monoaminskega prenašalca (VMAT). Encim monoamin-oksidaza (MAO) znotraj živčne 
celice razgradi vse proste monoamine, kar provzroči, da se izpraznijo zaloge dopamina, 
noradrenalina in serotonina. Posledica pomanjkanja dopamina v striatumu privede do 
denervacijske dopaminergične preobčutljivosti ter razklopa D1 in D2 receptorjev. Pri tem 
selektivni agonisti, bodisi D1 ali D2, sprožijo psihomotorični odgovor kot stimulacijo 
lokomotorne aktivnosti in stereotipnega vedenja tudi v primeru ko so poskusne živali 
soočasno tretirane z antagonisti drugega tipa dopaminskih receptorjev. 
Rezultati kažejo, da LEK-8829, ki deluje na izpraznjene zaloge dopamina v možganih, 
zaradi intrinzične aktivnosti na dopaminske D1 receptorje, sproži močan psihomotorni 
odgovor, ki se pojavi v nezmanjšanem obsegu sočasne blokade dopaminskih D2 
receptorjev. 
Pri podganah s prekinjenim dopaminskim prenosom, LEK-8829 v nasprotju z 
bromoergokriptinom, sproži značilno psihomotorično senzitizacijo posredovano z 
dopaminsko D1 receptorsko aktivnostjo. Ta psihomotorična senzitizacija se kaže v 
postopnem povečjanju lokomotornega in stereotipnega vedenja v odprtem polju, ki se 
lahko prepreči s SCH 23390 (dopaminski antagonist D1). 
 Sklepali smo, da podaljšano tretiranje z LEK-8829 lahko povečja stimulatorne učinke na 
vedenje posredovano z dopaminskimi receptorji D1. 
Rezultati kažejo v prid hipotezi, da ima dopaminski D1 receptor lahko ključno vlogo v 
zdravljenju Parkinsonove bolezni in koristne učinke pri zdravljenju psihoz izzvanih z 
zdravljenjem z dopaminskimi agonisti D2. 
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Statistična analiza rezultatov 
Podatki so analizirani s SPSS  programom (SPSS 19.0 for Windows, Chicago, Illinois, 
USA). 
Učinek testnih snovi na rezerpinizirane živali je analiziran z analizo varijance (ANOVA) s 
Scheffejevim testom. 
Diskusija 
Sistem dopaminskih receptorjev D2 je vpleten v spremembe gibalne aktivnosti, učenja in 
spomna, kot tudi v patofiziologijo nevropsihiatričnih motenj kot sta Parkinsonova bolezen 
(PD) in shizofrenija. 
Iz raziskav je znano že, da različna obdobja zdravljenja z antipsihotiki in praznjenje 
dopaminskih zalog z rezerpinom povzroči povečanje števila dopminskih receptorjev D2. 
Prav tako pa rezerpin povzroči razklop sinergizma D1/D2.  
Pri raziskavah preobčutljivosti dopaminskih receptorjev (DARSS) se pogosto sklicujejo na 
dolgotrajno zdravljenje z antipsihotiki. Težave, ki izhajajo iz dolgotrajnega zdravljenja z 
L-DOPA, so diskinezije, ki verjetno izvirajo iz preobčutljivosti dopaminskih receptorjev 
D2. Dopaminski receptorji poskusnih živaliso nagnjeni, da postanejo preobčutljivi, s čimer 
izzovejo nenormalno vedenje, ko jih uporabljamo skupaj z dopaminom ali z agonisti 
receptorjev.  
V litereturi je opisano, da se povečanje števila receptorjev D2 (in razvoj vedenjske 
preobčutljivosti) prepreči z istočasnim stimuliranjem receptorjev D1. Podoben učinek na 
vedenjsko preobčutljivost in regulatorno povečanje receptorjev D2 kot ga ima zdravljenje z 
agonistom D1 je povzročena z subkroničnim (21 dni) dodajanjem haloperidola. 
Namen naših poskusov je bil analizirati ali bi LEK-8829 zmanjšal dopaminergično 
preobčutljivost, ugotoviti vpliv na vedenjske in nevrokemične učinke subkroničnega 
zdravljenja z LEK-8829 ter ugotoviti kako regulatorno povečanje števila receptorjev D2 
vpliva na izražanje izooblik D2L in D2S. 
Učinek LEK-8829 je bil testiran na rezerpineskem modelu za Parkinsonovo bolezen. LEK-
8829 je pokazal antagonistični učinek na dopaminske D2  in na serotoninske receptorje 5-
HT2A in 5-HT1A. LEK-8829 2 mg/kg in haloperidol 0,2 mg/kg sta ekvivalentna odmerka, 
ki smo jih izbrali na temelju rezultatov iz literature Krisch (1994). Sedanje delo je rezultat 
subkroničnega zdravljenja z LEK-8829. Narejene so le akutne obravnave z LEK-8829.  
Test katalepsije 1. in 21. dan 
Haloperidol 2 mg/kg 1.  in 21.  dne pokaže bolj prepričljiv kataleptični odziv kot 
haloperidol 0,2 mg/kg, kar je v skladu z literaturo, da haloperidol povzroča katalepsijo 
odvisno od odmerka. Haloperidol v obeh odmerkih kaže skoraj enak kataleptični odgovor 
1. in 21. dne. V literaturi je opisana toleranca do kataleptičnega odziva po subkroničnom 
zdravljenju. O pomanjkanju tolerance s haloperidolom povzročene katalepsije, ki smo jo 
Bogićević S. Regulation of expression of alternatively spliced forms of dopamine D2 ... rat brain.  
    Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty,  2015 
  
106 
opazili pri naših poskusih, so poročali v nekaterih raziskavah. Pregled po Barnesu (1990) 
ugotavlja, da odmerek,  urnik uporabe zdravil in vedenjski poizkusni pogoji vsi vplivajo na 
razvoj katalepsije med kroničnim zdravljenjem s haloperidolom. LEK-8829 2 mg/kg kaže 
podoben učinek katalepsije kot haloperidol 0,2 mg/kg 1. dne, med tem ko  LEK-8829 2 
mg/kg 21. dne kaže podoben učinek katalepsije kot haloperidol 2 mg/kg (1. in 21. dne). 
Učinek se verjetno pojavi zato, ker je LEK-8829 še vedno prisoten v krvnem obtoku. 
LEK-8829 0,2 mg/kg ne kaže statistično značilne katalepsije. Krivulja je podobna krivulji s 
fiziološko raztopino (Slika 30). 
Test katalepsije 1. in 28. dan 
Boljši pogled o vprašanju kataleptičnega odziva smo dobili, ko smo izvedli test katalepsije 
7 dni po zadnji injekciji, saj takrat zdravilo ni bilo več prisotno v obtoku. Vse učinke tako 
lahk pripišemo odzivnosti receptorjev. Izbralismo obdobje 7 dni brez zdravil, ko povečano 
izraženje rreceptorjev D2 v striatumu doseže največje vrednosti. Haloperidol 0,2 mg/kg 
daje nekoliko povečan kataleptični odgovor 28.  dne kot 21. dne v eksperimentu 1. LEK-
8829 2 mg/kg kaže zmanjšanje v kataleptičnem odgovoru 28. dne v primerjavi z 21- 
dnevnim poskusom v eksperimentu 1. Zato ker v primeru eksperimenta 2, ko zdravila 28. 
dan ni več v obtoku, dobimo zmanjšan kataleptični odgovor kot pri haloperidolu 0,2 
mg/kg, je torej LEK-8829 bolj učinkovit antipsihotik kot haloperidol. Za LEK-8829 
pričakujemo manj neželjenih učinkov kot za haloperidol.  
Amfetaminski model za shizofrenijo 
S poskusi smo potrdili že znano - da haloperidol zmanjšuje z amfetaminom provzročeno 
hiperaktivno vedenje ter da antipsihotiki pogosto zgubljajo učinkovitost med kroničnim 
neprekinjenim zdravljenjem. Kronično zdravljenje z antipsihotiki spreminja stanje 
dopaminergične preobčutljivosti, ki se kaže s povečano preobčutljivosti za psihoze in z 
vplivom dopaminskih agonistov na psihomotorno aktivacijo. Pri ljudeh to imenujemo ''z 
nevroleptiki provzročena preobčutljivostna psihoza''. Za bolnike s shizohrenijo je znano, da 
so preobčutljivi na dopaminu podobne snovi. V našem poskusu odmerek 2 mg/kg 
haloperidola močno zavira z ampfetaminom provzročeno hiperaktivnost v primerjavi z 
odmerkom 0,2 mg/kg, kar je v skladu z dejstvom, da je učinek haloperidol odvisen od 
odmerka. Po 21. dnevu zdravljenja haloperidol začne izgubljati učinkovitost (zmanjšanje 
odzivnosti). Prav tako pa haloperidol 0,2 mg/kg povzroča še večjo izgubo učinkovitosti 
(povečanje v odzivnosti) kot haloperidol 2 mg/kg (Slika 37). To lahko razložimo  s 
povečanjem gostote dopaminskih D2 receptorjev, ki vodi v dopaminsko preobčutljivost, ki 
je  povezana z razklopom sinergizma D1/D2. Znano je, da preobčutljivost dopaminskih 
receptorjev (kar se odraža z povečanim odzivom) včasih spremlja proliferacija receptorjev.  
Vendar se preobčutljivost dopaminskih receptorjev lahko zgodi v odsotnosti sprememb v 
številu dopaminskih receptorjev. Neprekinjeno zdravljenje z antipsihotiki in zaviranje D2 
receptorjev povzroča nevroadaptacijo, ki vodijo k zmanjkani učinkovitosti antipsihotikov. 
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V poskusih smo potrdili, da je za LEK-8829 pomemben razklop sinergizma D1/D2. LEK-
8829 2 mg/kg zmanjšuje z amfetaminom povzočeno hiperlokomocijo veliko močneje kot 
LEK-8829 0,2 mg/kg (Slika 35). Niti en odmerek LEK-8829 ne izgublja učinkovitosti 
(poveča odzivnost) po 21. dnevu. To potrjuje hipotezo (Braun et al., 1997), da se učinek 
kroničnega zaviranja receptorja D2 lahko spreminja s hkratno stimulacijo receptorja D1.  
Ko je selektivni antagonist receptorjev D2 v kombinaciji z agonistom selektivnim za 
receptorje D1, je proliferacija in vedenjska preobčutljivost receptorja D2 popolnoma 
zavrta. Zato domnevamo, da je v naših poskusih intrinzična aktivnost LEK-8829 na 
dopaminskih receptorjih D1 sklopljena s povečanim izražanjem dopaminskih receptorjev 
D2, kot se dogaja po podaljšanem zaviranju dopaminskih receptorjev D2 s haloperidolom.  
Naša predpostavka je, da je zmanjšanje učinkovitosti haloperidola za inhibicijo z 
ampfetaminom provzročene lokomotorne aktivnosti posledica povečanega izražanja 
dopaminskih receptorjev D2, ki se je razvili v času dolgotrajnega zdravljenja s 
haloperidolom. Medtem pa dolgotrajno zdravljenje z LEK-8829 ni imelo takšnega učinka 
verjetno zaradi odsotnosti regulatornega povečanja receptorskih molekul.. Naši rezultati 
tudi kažejo, da dolgotrajno zdravljenje poskusnih živali z LEK-8829, ne kaže razvoja 
funkcionalnega razklopa dopaminskih receptorjev. Tako se je izkazalo, da je LEK-8829 
boljši antipsihotik kot haloperidol, saj ima manj neželjenih učinkov (test katalepsije) in ne 
kaže vedenjske preobčutljivosti (zmanjšuje z amfetaminom provzročene hiperaktivnosti in 
po 21. dnevnem zdravljenju). Sklepamo, da so receptorji D1 pomembna tarča za 
izboljšanje negativnih in kongnitivnih funkcij pri shizofreniji.  
Model za Parkinsonovo bolezen 
Prikazani rezultati z LEK-8829 so enaki kot rezultati s aripriprazolom. LEK-8829 
provzroča manjšo katalepsijo kot haloperidol. Poleg tega LEK-8829 zavira z amfetaminom 
provzročeno lokomocijo brez izgube učinkovitosti pri dolgotrajnem zdravljenju. V skladu 
z rezultati je utemeljena domneva, da je LEK-8829 delni agonist receptorjev D2.  
Pri izpraznjenih zalogah dopamina z rezerpinom LEK-8829 kaže, maksimalan lokomotorni 
odgovor. To je neobičajno, saj je bilo predlagano, da naj bi bila mešanica agonista D1/D2 
ali kombinacija agonista D1 in D2 agonista bolj učinkovita pri lajšanju simptomov 
parkinsonizma. Medsebojno delovanje podtipov dopaminskih receptorjev D1/D2 poteka na 
na vedenjski, farmakološki in biokemični ravni. V osnovi ta medsebojno delujejo bodisi 
antagonistično ali sinergistično. Medtem ko na nekatera vedenja pretežno vpliva aktivnost 
receptorjev D1 (to so vzpostavljanje stikov in samouničenje), pa receptorji D2 pretežno 
vplivajo na lokomotorno aktivnost. Sinergistično delovanje dopaminskih receptorjev se 
opaža pri lokomociji, stereotipiji, vzpostavljanju stikov, elektrofiziološkem odgovoru, 
zehanju in plazenja. Bromkriptin (agonist receptorjev D2) kaže, zmerno lokomocijo s 
krajšim trajanjem v primerjavi z LEK-8829. To pomeni, da bromokriptin (agonist D2 ) 
stimulira le receptorje D2 brez pojava sinergizma. LEK-8829 obnavlja sinergizem 
receptorjev  D1/D2, saj je delni agonist D2. Sinergistični učinki med receptorjema D1 in 
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D2, kot tudi stereotipije provzročene z dodajanjem D1 in D2 agonistov hkrati, so bolj 
intenzivni kot tisti, ki ga proizvajajo bodisi samo agonist. Kaže da ima v odsotnosti 
dopamina LEK-8829 lasnosti delnega agonista D2. LEK-8829 2 mg/kg kaže okrepljeno 
stereotipno vedenje. 
Sklepi 
LEK-8829 je bolj varen antipsihotik kot haloperidol saj povzroča manj EPS in ne kaže 
preobčutljivosti. 
Naši rezultati kažejo, da agonist D1 zmanjšuje dopaminergično preobčutljivost in 
regulatorno povečanje števila dopaminskih receptorjev D2. Haloperidol provzroča 
povečano izražanje dopaminskih receptorjev D2 medtem ko ga LEK-8829 ne povzroča. In 
situ hibridizacija na 6-OHDA modelu pokaže, da se poveča izražanje izooblike D2S 
dopaminskih receptorjev D2.  
Z metodo prenosa po Westernu nam je uspelo ločiti izoobliki D2L in D2S  dopaminskih 
receptorjev D2, ni pa nam uspelo zagotovo potrditi povečano izražanje receptorjev D2 ter 
Nova 1, saj so primarna mišja protitelesa reagirala s podganjimi IgG, katerega velikost je 
okoli 50 kDa. 
Na naše presenečenje rezultati kažejo, da je LEK-8829 delni agonist D2. Zaradi te lasnosti 
ima zmožnost, da stabilizira občutljivost na dopamin. LEK-8829 ima kot delni agonist D2 
manjšo nagnjenost za povzročanje EPS, zavira z amfetaminom provzročeno lokomocijo 
brez izgubljanja učinkovitosti po dolgotrajnem zdravljenju, je bolj učinkovit pri lajšanju 
simptomov parkinsonizma kot bromokriptin (D2 agonist) ter ima stabilnejšo občutljivost 
na dopamin.  
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